| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Accuray Incorporated$0.27
-0.02 (-5.93%)
F 19Pipeline Score MedTech · Clinical
Market Cap
47.37 M
EPS
-0.38
P/E Ratio
-1.05 $
Value Trade
453.88 K
SEC Financials
Q1 2026Dilution Risk
50%Revenue
104.84 M
R&D Expenses
8.18 M
Total Assets
447.60 M
Total Liabilities
405.89 M
Equity
41.71 M
D/E Ratio
12,345
7.68 %
Week
-27.1 %
1 Month
-44.8 %
3 Month
-67.35 %
6 Month
-93.2 %
5 Year
-98.54 %
All Time
Cash Data
Cash Position
38.07 M
Monthly Burn
3.03 M
Runway
9.9 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
1.90 M
52 Week Range
0.25 - 2.10
% held by Insiders
4.51 %
% held by Institutions
51.37 %
Enterprise Value
191.23 M
Total Shares
118.96 M
Short %
4.81 %
Float Shares
98.15 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Accuray Incorporated
671Total events
1Upcoming
94Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 1
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Debt Royalty FinancingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F19
Pipeline Score $1M
Pipeline ValueValuation Signal
1
Drugs Scored0.0x
rNPV / MCap Top 19%
Micro Cap (rank 741 of 913)
Percentile RankAccuray Incorporated has significant pipeline risk (19/100), with $29M risk-adjusted pipeline value, led by 5Fluorouracile and Mitomycin-C in Locally Advanced Anal Canal Cancer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5Fluorouracile and Mitomycin-C Small molecule | Locally Advanced Anal Canal Cancer | Phase 2 | NCT02701088 | 10% | $29M | ACTIVE NOT_RECRUITING | 71 | - | - | Dec 1, 2025 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CyberKnife System | prostate cancer | — | 2025-05-07 | 262 men over the age of 70 or with severe comorbidities; median follow-up of 39 months; 51 patients with a median follow up of 16 months Read More | Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025 Read More | |
CyberKnife System | prostate cancer | — | 2025-05-07 | 262 men over the age of 70 or with severe comorbidities; median follow-up of 39 months; 51 patients with a median follow up of 16 months Read More | Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025 Read More | |
CyberKnife System | prostate cancer | — | 2025-05-07 | 262 men over the age of 70 or with severe comorbidities; median follow-up of 39 months; 51 patients with a median follow up of 16 months Read More | Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ARAY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ARAY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ARAY▲ +23.4%on this news
Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation
Accuray Incorporated has announced a comprehensive plan to enhance its financial position and operational strategy. The plan includes agreements with TCW Asset Management for debt restructuring and additional liquidity, alongside strategic partnerships to boost innovation. The company is also focusing on differentiated technology and improving operational efficiency to drive long-term value creation.
Read more →ARAY▼ -9.9%on this news
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray Incorporated announced the granting of equity inducement awards to its newly appointed Chief Commercial Officer, Paul Miele, and Chief Legal Officer, David Shin, as part of their hiring packages. Mr. Miele received 650,000 restricted stock units and another 650,000 performance-based restricted stock units, while Mr. Shin received 375,000 restricted stock units along with 375,000 performance-based restricted stock units. The inducement awards are designed to align the executives' interests with the company's performance over the next several years.
Read more →ARAY▼ -5.2%on this news· ran to +17% by day 3
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
Accuray Incorporated and the University of Wisconsin-Madison have entered a 10-year strategic collaboration to enhance personalized cancer treatments using Accuray's adaptive radiation therapy platform. This partnership aims to advance clinical research, education, and the development of innovative therapies, building on a successful history of collaboration in radiation medicine. The agreement seeks to improve patient care by leveraging both organizations' strengths.
Read more →ARAYAccuray Reports Fiscal 2026 Third Quarter Financial Results
Accuray Incorporated reported its third quarter financial results for fiscal 2026, revealing a 7% decrease in total net revenue compared to the previous year. The company has made progress with its transformation plan, achieving $10 million in cost improvements. However, geopolitical uncertainties have led to the withdrawal of its financial guidance, impacting product shipments and service revenues. The net loss for the quarter increased to $11.8 million.
Read more →ARAY▲ +11%on this news
Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
Accuray Incorporated will announce its financial results for the third quarter of fiscal 2026 on May 6, 2026. The conference call will be hosted by company management and will include options for both live participation and replay. Accuray emphasizes its commitment to innovation in radiation therapy, aiming to enhance patient care.
Read more →ARAYAccuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
Accuray Incorporated has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele, who has extensive experience in global commercial leadership, will oversee Accuray's global commercialization strategy. His appointment is expected to enhance the company's commercial performance and drive growth in systems and services sales.
Read more →ARAYAI in Radiation Oncology: What It Takes to Deploy Responsibly
A recent course on AI in radiation oncology highlighted the importance of responsible deployment and shared frameworks for AI tools. Experts discussed the promising results of AI in thoracic radiotherapy but also raised concerns about variability in AI-generated contours and the need for human oversight. The upcoming EU AI Act emphasizes the necessity for documentation and ethical considerations in AI use in healthcare.
Read more →ARAYWRAD: Celebrating Over a Year of Global Radiotherapy Advocacy
The inaugural World Radiotherapy Awareness Day (WRAD) on September 7, 2025, successfully highlighted the importance of radiotherapy in cancer care. The event saw global participation, with significant engagement on social media and support from numerous professional societies. Looking ahead, WRAD aims to enhance patient involvement and advocate for better access to radiotherapy.
Read more →ARAY▼ -20.7%on this newsshared move
Accuray Reports Fiscal 2026 Second Quarter Financial Results
Accuray Incorporated reported its fiscal 2026 second quarter results, revealing a 12% decline in total net revenue to $102.2 million. Despite a 4% increase in service revenue, product revenue fell by 26%. The company is undergoing a transformation aimed at enhancing growth and profitability, with CEO Steve La Neve expressing confidence in the strategic changes being implemented.
Read more →ARAYMiroki: the companion robot that ensures children undergoing radiotherapy never feel alone
Miroki, a humanoid robot, has been introduced in the Montpellier Cancer Institute's pediatric radiotherapy department to support children undergoing treatment. Designed to provide emotional comfort, Miroki helps alleviate anxiety by being present during sessions. The robot's development was inspired by the need for a comforting presence during challenging treatments, and its integration has positively impacted both patients and healthcare providers.
Read more →ARAYAccuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
Accuray Incorporated will announce its financial results for the second quarter of fiscal 2026 on February 4, 2026. The results will be discussed during a conference call at 1:30 p.m. PT. Investors can access the call via dial-in numbers or a live webcast. A replay will be available for one week after the call.
Read more →ARAYAccuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth
Accuray Incorporated has announced the first phase of its strategic transformation plan, aiming to enhance operational efficiency and accountability. This initiative is projected to improve annualized operating profitability by around $25 million. The plan includes workforce reductions and restructuring costs, with full implementation expected by the end of fiscal 2026. Accuray maintains its forecasts for the fiscal year despite these changes.
Read more →ARAYGoing Live: Lessons from CyberKnife® System Installation in Melbourne
5D Clinics Melbourne has successfully integrated the CyberKnife System, beginning patient treatments on September 3, 2025. The installation was supported by Accuray and AlphaXRT, ensuring rapid onboarding and ongoing assistance. The center has treated various cancers, receiving positive patient feedback and establishing a reputation for precision radiotherapy. Continuous training and collaboration with the Perth team have been pivotal in this transition.
Read more →ARAY▼ -15.9%on this news
Accuray Reports Fiscal 2026 First Quarter Financial Results
Accuray Incorporated reported its fiscal 2026 first quarter financial results, showing a 7% decrease in total net revenue to $93.9 million. Despite a decline in product revenue, the company noted growth in service revenue and ongoing expansion of its CyberKnife and Radixact systems. The net loss widened significantly compared to the previous year, prompting the company to reaffirm its financial guidance for the year.
Read more →ARAYAccuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025
Accuray Incorporated will announce its first quarter fiscal 2026 financial results on November 5, 2025. The results will be discussed during a conference call at 1:30 p.m. PT/4:30 p.m. ET. A live webcast will also be available, along with a replay for those unable to attend the live event.
Read more →ARAYAccuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth
Accuray Incorporated has announced a significant transformation plan, appointing Steve La Neve as CEO to enhance operational performance and competitiveness. The company aims to increase margins and agility while continuing innovation in radiation therapy. The Board has also appointed Steven F. Mayer as Transformation Board Sponsor and nominated Chan W. Galbato to the Board. Preliminary financial results for Q1 2026 show mixed performance, with service revenues exceeding expectations but product revenues falling short.
Read more →ARAY▲ +7%on this news· ran to +18% by day 1
Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System
Accuray Incorporated has announced the successful treatment of the first patients in Melbourne, Australia, using the CyberKnife S7 System. This initiative, in partnership with 5D Clinics and Icon Group, aims to enhance access to advanced radiation therapy for cancer patients. The new center marks a significant step in improving cancer care and patient outcomes in the region.
Read more →ARAY▼ -8.2%on this newsshared move
Exploring the Impact of Advanced Radiosurgery on Trigeminal Neuralgia
The article discusses the effectiveness of the CyberKnife System in treating trigeminal neuralgia (TN), highlighting various studies that demonstrate its high rates of initial pain relief and low complication rates. It emphasizes the importance of individualized treatment planning, especially for patients with multiple sclerosis. The findings suggest that CyberKnife radiosurgery is a reliable first-line treatment option for TN.
Read more →ARAYAccuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care
Accuray and the University of Wisconsin-Madison have signed a memorandum of understanding to advance online adaptive radiotherapy (OART). This collaboration focuses on clinical research, education, and technology development to enhance cancer care. Both parties aim to leverage their strengths to improve treatment personalization and precision for patients.
Read more →ARAYAccuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care
Accuray has launched the Accuray Stellar solution, an advanced adaptive radiotherapy system designed to enhance cancer treatment. This innovative technology provides clinical teams with a comprehensive set of tools to tailor treatments to individual patient needs. The solution will be showcased at the upcoming ASTRO Annual Meeting, highlighting its capabilities in delivering precise and effective radiotherapy.
Read more →ARAYAccuray to Host Analyst Event at the American Society of Radiation Oncology Meeting on September 29, 2025
Accuray Incorporated will host an analyst event on September 29, 2025, during the ASTRO Annual Meeting in San Francisco. The event will feature presentations from global experts discussing adaptive radiotherapy's role in radiation medicine. Both in-person and virtual attendance options are available, with registration required by September 25, 2025.
Read more →ARAYWorld Radiotherapy Awareness Day: A Call to Action to Make Radiotherapy Understood and Accessible
World Radiotherapy Awareness Day (WRAD) is set for September 7, 2025, to promote the importance of radiotherapy in cancer treatment and improve global access. The initiative, led by a committee of professionals and advocates, aims to educate stakeholders and address disparities in treatment availability. Key objectives include raising awareness and recognizing the contributions of radiotherapy professionals.
Read more →ARAYAccuray Reports Fourth Quarter and Fiscal 2025 Financial Results Strong Service Growth; Debt Refinancing Complete; Company Issues FY26 Guidance
Accuray Incorporated reported its financial results for the fourth quarter and fiscal year 2025, revealing a net revenue decrease of 5% for Q4 compared to the previous year. Despite this, the company achieved a total net revenue increase of 3% for the fiscal year, with notable growth in adjusted EBITDA. Accuray's debt has been refinanced successfully, offering improved financial backing for future operations. The guidance for FY26 suggests continued growth expectations, with forecasts for net revenue and adjusted EBITDA up compared to FY25.
Read more →ARAYAccuray to Report Fourth Quarter Fiscal 2025 Financial Results on August 13, 2025
Accuray Incorporated plans to report its financial results for the fourth quarter of fiscal year 2025 on August 13, 2025. The results will cover the period ending June 30, 2025, and will be discussed during a conference call hosted by company management. Investors can access the call through dial-in numbers and a live webcast. A replay of the call will also be available for those unable to join live.
Read more →ARAYHighlights from the ISRS CNS Summit 2025: The CyberKnife® System’s Impact in Radiosurgery
The ISRS CNS Summit 2025 highlighted the CyberKnife System's effectiveness in treating conditions like trigeminal neuralgia, optic nerve sheath meningiomas, and benign vascular tumors. Studies presented showed lower recurrence rates and high disease stabilization, emphasizing the system's safety and versatility in radiosurgery. However, further comparative analysis is needed to refine treatment understanding.
Read more →ARAY▼ -15.1%on this news
ESTRO 2025 Research Highlights
The ESTRO 2025 congress focused on transformative innovation in radiation oncology, emphasizing collaboration among stakeholders. Accuray presented research on their CyberKnife and TomoTherapy systems, showcasing effective treatment outcomes for various cancers, including brain, spine, prostate, liver, and gynecological cancers. The event aimed to connect the radiotherapy community and highlight advancements in cancer care.
Read more →ARAY▼ -15.1%on this newsshared move
Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities
Accuray Incorporated has announced a refinancing of its existing credit facilities and a convertible notes exchange worth $82 million. The company will exchange this amount for common stock shares and pay approximately $68.6 million in cash to the note holders. Additionally, Accuray has secured a new $150 million term loan and governance measures, including the appointment of Steven F. Mayer to the board. This restructuring is aimed at improving liquidity and supporting longer-term growth strategies in radiation therapy.
Read more →ARAYAccuray to Participate in the Jefferies Global Healthcare Conference 2025
Accuray Incorporated (NASDAQ: ARAY) has announced its participation in the Jefferies Global Healthcare Conference 2025. The company's management team will engage in a fireside chat scheduled for June 4th, 2025. Investors will have the opportunity to listen via a live webcast, which will also be available for replay for 90 days after the event.
Read more →ARAYAccuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025
Accuray Incorporated presented new long-term data at the ESTRO 2025 meeting, showcasing the effectiveness of its CyberKnife System in treating men with prostate cancer. The studies revealed that the system allows for accurate and precise treatment options, including for high-risk and recurrent cases. Moreover, the data highlighted the benefits of stereotactic body radiation therapy (SBRT) with low toxicity rates. Accuray's advancements could offer significant improvements in patient care and quality of life following treatment.
Read more →ARAYAccuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System
Accuray Incorporated has successfully launched the CyberKnife System in Austria, specifically at the CyberKnife Center Salzburg, which is the first facility in the country to treat patients using this advanced technology. The CyberKnife System allows for precision-targeted radiation therapy in fewer sessions compared to conventional methods, potentially enhancing patient quality of life. However, Austria is facing a significant shortage of radiation therapy equipment compared to EU standards, which could impact patient access to necessary treatments.
Read more →ARAYAccuray Reports Fiscal 2025 Third Quarter Financial Results
Accuray Incorporated (NASDAQ: ARAY) reported its financial results for the third quarter of fiscal 2025, highlighting a 12% year-over-year increase in total net revenue, reaching $113.2 million. The company reported a significantly reduced net loss of $1.3 million, which is an improvement compared to $6.3 million in the same period last year. However, gross product orders experienced a decline, totaling $71.2 million, with the order backlog also decreasing by approximately 10%. The company reaffirmed its adjusted EBITDA guidance while adjusting its total revenue outlook for fiscal year 2025 due to recent tariff impacts.
Read more →ARAYAccuray to Report Third Quarter Fiscal 2025 Financial Results on April 30, 2025
Accuray Incorporated (NASDAQ: ARAY) is set to report its financial results for the third quarter of fiscal year 2025, which ended on March 31, 2025. The announcement will be made during a conference call on April 30, 2025, at 1:30 p.m. PT/4:30 p.m. ET. Investors can participate through a dial-in number or a live webcast, which will also be available for replay for a week after the call. This event reflects Accuray's commitment to keeping stakeholders informed.
Read more →ARAY▼ -7.1%on this news
Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting
Accuray Incorporated announced promising new data on its CyberKnife® System, presented at the 2025 Radiosurgery Society Scientific Meeting. The studies showcased the device's effectiveness in treating central nervous system tumors, with long-term efficacy for conditions such as vestibular schwannoma and spinal metastases. The CyberKnife System enhances treatment options for patients experiencing debilitating neurological conditions, demonstrating high success rates and minimal complications. This reinforces Accuray's commitment to improving patient care through advanced radiotherapy technology.
Read more →ARAYIcon Cancer Centre and 5D Clinics: A Joint Venture to Expand Access to Advanced Radiotherapy in Australia
Icon Cancer Centre has partnered with 5D Clinics to introduce the CyberKnife System to eastern Australia, enhancing access to advanced radiotherapy. This joint venture aims to reduce travel burdens for patients and improve treatment outcomes. The first center is set to open in Cremorne, Melbourne, with plans for further expansion along the east coast.
Read more →ARAYAccuray to Participate at 37th Annual Roth Conference
Accuray Incorporated (NASDAQ: ARAY) has announced its participation in the upcoming 37th Annual Roth Conference, scheduled for March 16-18, 2025, in Dana Point, California. Management will engage in a fireside chat on March 18, 2025, at 9:30 AM PT, and will be available for individual meetings with investors. The event is poised to enhance the company's visibility and foster connections with the investment community.
Read more →ARAYSBRT for Prostate Cancer: Understanding the Evidence of the PACE-B Trial
The PACE-B trial indicates that stereotactic body radiation therapy (SBRT) is a viable alternative to conventional radiotherapy for low and intermediate-risk prostate cancer patients. Conducted across multiple centers, the trial showed that SBRT has comparable efficacy with lower toxicity rates, making it a promising new standard of care. The results highlight the potential for improved patient quality of life and healthcare efficiency.
Read more →ARAY▲ +6.9%on this news
Expanding Access to Radiotherapy in Ghana: A Conversation with Rev. Dr. Kofi Adesi Kyei
Ghana faces significant challenges in providing radiotherapy, with only 23% of patients receiving necessary treatment. Rev. Dr. Kofi Adesi Kyei emphasizes the need for increased awareness and government support to address these gaps. Innovative treatment approaches and advocacy efforts are underway to improve access and outcomes for cancer patients in the country.
Read more →ARAY▲ +6.9%on this newsshared move
Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance
Accuray Incorporated reported strong financial results for the second quarter of fiscal 2025, achieving total net revenue of $116.2 million, up 8% from the prior year. The company transitioned from a net loss to a net income of $2.5 million. Adjusted EBITDA rose significantly to $9.6 million. Despite these positive developments, Accuray noted a decrease in gross product orders and a reduction in the order backlog compared to the previous year. The company has raised its revenue guidance for the fiscal year 2025, anticipating improved market conditions in the latter half of the year.
Read more →ARAYWorld Cancer Day: United by Unique – Inspiring Stories from People Affected by Cancer
On February 4th, World Cancer Day promotes equitable cancer care through the 'United by Unique' campaign. Accuray supports this initiative by showcasing advanced treatment technologies and sharing inspiring patient stories. The campaign emphasizes the importance of personalized cancer care and advocates for policies ensuring access to treatment for all individuals.
Read more →ARAYAccuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product
Accuray Incorporated has reported that Shandong Cancer Hospital and Institute has successfully completed treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System. This system, developed through a joint venture with CNNC, aims to address the growing demand for advanced cancer treatments in China, where new cancer cases are expected to rise significantly. The milestone reflects the effective integration of precision radiotherapy technology into clinical practice, supporting a broader range of cancer treatment options.
Read more →ARAYAccuray to Report Second Quarter Fiscal 2025 Financial Results on February 5, 2025
Accuray Incorporated will announce its second quarter fiscal 2025 financial results on February 5, 2025. The results will cover the quarter that ended on December 31, 2024. A conference call will be hosted by management at 1:30 p.m. PT/4:30 p.m. ET, allowing stakeholders to participate. Additionally, there will be options for a dial-in replay and a live webcast, making the information accessible to a wider audience.
Read more →ARAYLeonel Peralta to Join Accuray as Chief Operations Officer
Accuray Incorporated announced the appointment of Leonel Peralta as Chief Operations Officer, effective February 3, 2025. With over 25 years of experience, Peralta will oversee global manufacturing operations and align them with corporate objectives. His previous roles include senior positions at Siemens Healthineers and Medtronic Diabetes, where he significantly improved operational efficiency and productivity. Accuray President Suzanne Winter expressed optimism about Peralta's impact on the company's operations and business growth.
Read more →ARAYbkaplan@accuray.com Investor Contact Aman Patel, CFA Investor Relations, ICR-Westwicke +1 (443) 450-4191 aman.patel@westwicke.com
Accuray Incorporated (NASDAQ: ARAY) announced that Leonel Peralta will join as Chief Operations Officer on February 3, 2025. Peralta, with over 25 years of experience in supply chain and operations, previously served as Vice President at Siemens Healthineers. His role will focus on improving operational efficiency and customer service as Accuray strives to enhance its offerings in radiation therapy. CEO Suzanne Winter expressed confidence in Peralta's ability to drive growth and operational excellence.
Read more →ARAYOver Two Decades of AI-Powered Precision: How Synchrony has Revolutionized Real-time Adaptive Radiotherapy Delivery
Accuray's Synchrony technology has revolutionized radiation oncology by utilizing AI for real-time adaptive radiotherapy delivery. This system learns individual patient motion patterns to enhance treatment precision, reduce normal tissue exposure, and improve patient outcomes. With over two decades of development, Synchrony exemplifies the integration of AI in personalized medicine, continuously adapting to patient needs during treatment.
Read more →ARAYAccuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System
Accuray Incorporated received approval from the Chinese National Medical Products Administration for its Radixact SynC System and CyberKnife S7 System. This expansion allows medical teams in China to offer advanced radiation therapy solutions, meeting an increasing demand for treatment. The Radixact SynC System introduces real-time adaptive delivery technology, while CyberKnife S7 System enhances precision and reduces treatment time. These approvals align with Accuray's strategy to increase patient access to life-saving radiation therapy technologies.
Read more →ARAYThe Royal Marsden NHS Foundation Trust: Embracing Technological Advancements in Radiation Therapy
The Royal Marsden NHS Foundation Trust has integrated the Radixact Treatment Delivery Systems to enhance its radiation therapy capabilities. This technological advancement allows the hospital to treat approximately 6,000 patients annually with improved efficiency and precision. The successful implementation involved collaboration among various departments and comprehensive training for staff. The hospital aims to expand its treatment offerings further with the new systems.
Read more →ARAYRecord-Breaking Attendance at Accuray French-speaking Users Meeting
The Accuray French-speaking Users Meeting, held in Lille, France, achieved record attendance with over 130 participants from four countries. The event focused on advancing patient-centered radiotherapy techniques, featuring dynamic presentations and discussions on topics like breast irradiation and stereotactic radiosurgery. The success is attributed to the guidance of a dedicated scientific committee, ensuring actionable insights for clinical practices.
Read more →ARAY▼ -6.3%on this newsshared move
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat
Accuray Incorporated announced promising results from an international study indicating that the CyberKnife System is effective for treating brainstem metastases. Conducted across nine institutions and involving 136 patients, the study showcased high local control rates at one, two, and three-year marks, while maintaining a robust safety profile. The CyberKnife allows for treatment without the need for a fixed head frame, potentially improving the quality of life for patients. The findings, published in the International Journal of Cancer, highlight the system's capabilities in neurological care.
Read more →ARAY▲ +5.7%on this news
The Art of Radiotherapy: What Unusual Patients Have Taught Me
Professor Mack Roach, a radiation oncologist at UCSF, discusses the complexities of treating exceptional patients in radiotherapy. He shares insights from six unique clinical cases, emphasizing the balance between scientific rigor and the art of patient care. The symposium aims to inspire confidence and respect in the practice of radiotherapy.
Read more →ARAYSuccess at Prostate SBRT Course in Miami
The Prostate SBRT Course recently concluded, highlighting advancements in prostate cancer treatment. Over 220 attendees from 20 countries participated, discussing the efficacy and innovative techniques of SBRT. Notable presentations included data supporting SBRT as a standard treatment option and its advantages over traditional therapies. The event concluded with optimism for the future of SBRT in cancer management.
Read more →ARAYExpanding Radiotherapy Access in Pakistan: An Interview with Dr. Tariq Mahmood
Dr. Tariq Mahmood is addressing cancer care disparities in Pakistan by enhancing radiotherapy access through public-private partnerships, advanced technologies, and awareness campaigns. With only 21.4% of patients receiving necessary radiotherapy, Mahmood's efforts at Jinnah Postgraduate Medical Centre aim to provide free treatment and expand facilities. His initiatives have led to significant improvements in patient outcomes and increased public trust in radiation therapy.
Read more →ARAY▲ +5.7%on this news
Accuray Reports Fiscal 2025 First Quarter Financial Results Strong Start to Fiscal Year, Raises 2025 Guidance
Accuray Incorporated announced its financial results for the first quarter of fiscal 2025, indicating a strong start to the fiscal year and a raised guidance. The company reported total net revenue of $101.5 million, a slight decrease from the previous year's $103.9 million, alongside an increased net loss of $4 million. Despite these challenges, Accuray experienced strong demand for its products, particularly in China, and expressed optimism about its strategic growth plans for the future.
Read more →ARAYSGRT on the Radixact® System: Ways of Enhancing Radiotherapy Delivery with VitalHold™
The article discusses the integration of Surface Guided Radiotherapy (SGRT) with the Radixact® System, highlighting its benefits in enhancing radiotherapy delivery. VitalHold™ technology improves patient positioning and treatment accuracy while reducing anxiety by eliminating the need for permanent marks. The system is particularly effective for deep inspiration breath hold (DIBH) treatments, minimizing radiation exposure to the heart and lungs. Clinical examples demonstrate its successful application in breast cancer treatment.
Read more →ARAYAccuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024
Accuray Incorporated will report its first quarter financial results for fiscal year 2025 on November 6, 2024. The report will follow the quarter ending September 30, 2024, and will be discussed during a conference call at 1:30 p.m. PT. Interested parties can listen via dial-in or a live webcast, with a replay accessible for a week thereafter. This reflects the company's ongoing commitment to engage with investors and maintain transparency.
Read more →ARAYBeth Kaplan Accuray +1 (408) 789-4426 bkaplan@accuray.com Investor Contact Aman Patel, CFA Investor Relations, ICR-Westwicke +1 (443) 450-4191 aman.patel@westwicke.com
Accuray Incorporated has appointed Michael Murphy as Vice President of Corporate Controller. He will oversee the global accounting function and is expected to be appointed principal accounting officer after the upcoming quarterly report. Murphy brings over 15 years of experience in finance and accounting from various leadership roles. The company highlights his strong track record in delivering value and supporting revenue growth initiatives.
Read more →ARAYAccuray Appoints Michael Murphy as VP, Corporate Controller
Accuray Incorporated has announced the appointment of Michael Murphy as Vice President and Corporate Controller. With over 15 years of financial expertise, Murphy is set to lead the company's global accounting function, which includes corporate tax, regulatory reporting, and risk management. He is expected to be appointed as the principal accounting officer following the filing of the company's quarterly report. Murphy's previous experience includes significant roles in several organizations, and he expresses enthusiasm for Accuray's focus on innovation in cancer treatment.
Read more →ARAYNew England Journal of Medicine Study Reaffirms Five Session Radiation Treatment Provides Comparable Rates of Cancer Control, Tolerability and Sexual Functioning to Conventional Radiotherapy Treatment in Men with Localized Prostate Cancer
Accuray Incorporated announced the publication of the PACE-B trial results in the New England Journal of Medicine, demonstrating that stereotactic body radiation therapy (SBRT) offers similar cancer control and tolerability to conventional radiotherapy for localized prostate cancer, but reduces treatment time from as long as 39 days to just five. The trial involved 874 patients and showed that both SBRT and conventional therapy achieve high cancer control rates. The study's lead investigator emphasized that SBRT can substantially benefit men with prostate cancer by minimizing treatment disruption.
Read more →ARAYAccuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence
Accuray Incorporated announced that Suzanne Winter has returned from her medical leave and is assuming her responsibilities as President and CEO. During her absence, Sandeep Chalke served as interim CEO and will remain in his position as Senior Vice President and Chief Commercial Officer. The Board of Directors expressed their appreciation for Chalke's leadership and support from the Accuray team during this period.
Read more →ARAYAccuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife® S7™ System Medical Professional Training
Accuray Incorporated has launched a medical professional training program for its CyberKnife S7 System at the Genolier Innovation Hub in Switzerland. This facility aims to facilitate clinician-industry collaboration to improve patient care and feature advanced training tools. The education center at the hub is designed to provide a comprehensive learning experience, including hands-on simulations and expert instruction. The launch highlights Accuray's commitment to enhancing the capabilities of healthcare providers dealing with cancer treatments.
Read more →ARAYGifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution
Accuray Incorporated has announced that Gifu Prefectural General Medical Center is the first hospital in Japan to utilize the Radixact Radiation Delivery System and VitalHold solution for cancer treatment. This marks a significant advancement in the adoption of surface-guided radiation therapy (SGRT), which enhances precision and monitoring during treatment. The center aims to improve patient access and outcomes through these innovative technologies, following relevant regulatory approvals. Increased capabilities offered by this system support better positioning and treatment accuracy for cancer patients.
Read more →ARAYAccuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence
Accuray President and CEO Suzanne Winter has taken a temporary medical leave to address a treatable form of cancer. Sandeep Chalke, the Senior Vice President and Chief Commercial Officer, will serve as the interim CEO, supported by an Executive Committee formed by the Board of Directors. Despite this leadership change, the Board expresses confidence in the management team to continue achieving the company's strategic goals and vision in the field of radiation therapy.
Read more →ARAYAccuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix™
Accuray Incorporated has been granted CE Mark approval for its new Accuray Helix™, a CT-guided helical radiotherapy system aimed at improving cancer care access in emerging markets like India. The system addresses significant gaps in radiation therapy availability and offers features that enhance treatment speed, efficiency, and personalization. This innovation is part of the company's strategic expansion of its helical radiation therapy portfolio, aiming to support medical facilities with limited resources in delivering advanced cancer treatments.
Read more →ARAYAccuray Reports Fourth Quarter and Fiscal 2024 Financial Results 14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance
Accuray Incorporated reported its financial results for the fourth quarter and fiscal year 2024, showcasing a 14% growth in revenue for Q4 compared to the same period last year. The company posted a net income of $3.4 million, a positive shift from the previous year's loss. Despite a slight overall decline in net revenue for the fiscal year, Accuray is optimistic about fiscal year 2025, projecting total revenue between $460 million to $470 million and highlighting new product approvals and market expansion efforts. The company remains committed to improving its service offerings and controlling operational expenses.
Read more →ARAYHalifax Health in Florida is First in the U.S. to Treat Patients with Cancer Using the Accuray Radixact® Radiation Delivery System and VitalHold™ Technology
Accuray Incorporated and Halifax Health announced that the Cancer Center for Hope in Florida is the first in the U.S. to use the Accuray Radixact® System equipped with VitalHold™ technology for treating cancer patients. This innovative system enhances patient positioning and monitoring, increasing the effectiveness of radiotherapy treatments while ensuring patient comfort. The partnership signifies a commitment to advanced cancer care in Volusia County, allowing for significant improvements in treatment outcomes. With features like deep inspiration breath hold techniques, this technology aims to improve the quality of life for patients undergoing cancer therapies.
Read more →ARAYAccuray to Report Fourth Quarter Fiscal 2024 Financial Results on August 14, 2024
Accuray Incorporated is set to announce its financial results for the fourth quarter of fiscal year 2024, which concluded on June 30, 2024. The announcement will occur during a conference call on August 14, 2024, at 1:30 p.m. PT/4:30 p.m. ET. Participants can join the call via specified dial-in numbers, and a live webcast will also be available on the company's Investor Relations website. A recording of the call will be accessible for a week post-event.
Read more →ARAYWhy Motion Matters: The Advantage of Real-time Tracking
The article discusses the significance of real-time tracking in radiation therapy, particularly for lung cancer treatment. It highlights how Synchrony technology allows for accurate targeting of tumors by adapting to patient motion. This innovation minimizes side effects and enhances treatment efficacy, making it a promising advancement in cancer care.
Read more →ARAY▼ -5.8%on this news
Pioneering Advanced Radiotherapy in Kenya
Kenyatta University Teaching, Referral & Research Hospital (KUTRRH) has introduced the CyberKnife System to enhance cancer treatment in Kenya. This initiative aims to improve access to advanced radiotherapy, reduce medical tourism, and provide comprehensive care. Despite these advancements, challenges such as high treatment costs and limited awareness still affect patient access to necessary care.
Read more →ARAYBringing Together Leading Liver Cancer Experts in the 7th APAC Liver Roundtable
The 7th APAC Liver Roundtable, held in Hiroshima, Japan, focused on enhancing the role of radiation therapy (RT) in treating hepatocellular carcinoma (HCC). Experts discussed advancements in stereotactic body radiation therapy (SBRT) and its integration with immunotherapy. The roundtable has facilitated the development of clinical guidelines and evidence to improve treatment practices for liver cancer.
Read more →ARAYExperts Gather in Bangkok to Advance Precision Radiation Therapy for Breast Cancer Treatment in ASEAN Region
The 6th Breast Roundtable in Bangkok gathered experts from the ASEAN region to discuss advancements in precision radiation therapy for breast cancer. Key topics included hypofractionation and its efficacy in postoperative treatment. The event highlighted the importance of collaboration and knowledge sharing among healthcare professionals to improve patient outcomes. Future plans aim to expand the scope of discussions to include more cancer indications.
Read more →ARAYHeidelberg University Hospital in Germany Invests in Fourth Accuray Radiotherapy Device, the Radixact® System, to Improve Cancer Patient Care
Accuray Incorporated (NASDAQ: ARAY) announced that Heidelberg University Hospital in Germany has invested in its Radixact System to enhance cancer patient care. This advanced radiotherapy device, featuring innovative technologies such as ClearRT, Synchrony, and VOLO Ultra Optimizer, aims to improve treatment precision and workflow efficiency. The partnership marks a continuation of their long-term collaboration, as Heidelberg University Hospital is recognized as a global leader in oncology. The investment replaces older equipment, enabling the hospital to provide more comprehensive cancer care.
Read more →ARAY▲ +5.2%on this news
Accuray and TrueNorth Medical Physics Sign Agreement to Provide Radiation Oncology Support Intended to Advance Cancer Care for More Patients
Accuray Incorporated has signed an agreement with TrueNorth Medical Physics to enhance radiation oncology support. This partnership will provide hospitals with additional staffing resources and expertise in using Accuray's systems. TrueNorth will offer tailored services that address the unique needs of each facility, aiming to improve patient care outcomes. The collaboration reflects Accuray's commitment to innovation and addressing the operational challenges faced by healthcare providers.
Read more →ARAYAccuray Announces Approval of the Accuray Precision® Treatment Planning System by China
Accuray Incorporated announced that its Accuray Precision Treatment Planning System (TPS) has received approval from the Chinese National Medical Products Administration. This system will be utilized in conjunction with the Tomo C radiation therapy system, enhancing precision in cancer treatments. The approval allows the company to commence shipments to customers via its joint venture in China, aiming to meet the high demand for effective radiation therapy. The TPS is tailored to adapt treatment plans swiftly, potentially improving patient outcomes in various cancer indications.
Read more →ARAYISRS 2024 News
The ISRS 2024 conference in New York City brought together over 630 attendees from 53 countries to discuss advancements in stereotactic radiosurgery. Key studies highlighted the effectiveness of the CyberKnife System for treating brain metastases and recurrent glioblastoma, showcasing high survival rates and positive patient outcomes. Discussions also included the potential of artificial general intelligence in enhancing radiation oncology practices.
Read more →ARAYAccuray to Participate in the Jefferies Global Healthcare Conference 2024
Accuray Incorporated (NASDAQ: ARAY) has announced its participation in the upcoming Jefferies Global Healthcare Conference scheduled for June 5, 2024. The management team will engage in a fireside chat, providing insights into the company’s strategies and innovations. A live webcast of the discussion will be available on the company's Investor Relations website, which will also host a replay for 90 days following the event. This participation underscores the company’s commitment to investor engagement and market visibility.
Read more →ARAYESTRO 2024 NEWS
At ESTRO 2024, significant advancements in radiation therapy were highlighted, marking 30 years since the CyberKnife System's introduction. The conference emphasized the importance of equitable access to radiotherapy and showcased innovative treatment strategies for oligometastatic disease. Notable clinical trial results demonstrated effective outcomes, reinforcing the role of advanced technologies in cancer care.
Read more →ARAYAccuray Reports Fiscal 2024 Third Quarter Financial Results
Accuray Incorporated reported its financial results for the third quarter and nine months ended March 31, 2024, showing a significant decline in net revenue and an increase in net losses compared to the prior year. While gross orders saw a 21% increase, the company's net revenue was down by 14%, leading to a GAAP net loss of $6.3 million. The report highlighted the opening of a training center in Switzerland and the launch of a new product intended to improve efficiency. Despite the challenges, Accuray remains committed to its growth strategy and long-term profitability.
Read more →ARAYAccuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024
Accuray Incorporated (NASDAQ: ARAY) announced major advancements in radiation therapy solutions at ESTRO 2024, focusing on improving the patient experience. The showcased technologies, including the latest CyberKnife and Radixact platforms, aim to enhance the accuracy and effectiveness of cancer treatment. CEO Suzanne Winter emphasized the importance of personalization in cancer management, while the innovations at the conference reflect the company's long history of collaboration in the healthcare industry. Accuray continues to lead in developing state-of-the-art solutions to empower clinicians and improve patient outcomes.
Read more →ARAYAccuray Innovation & Partnership Hub
Accuray has inaugurated its Innovation & Partnership Hub in Genolier, Switzerland, emphasizing its commitment to radiotherapy and cancer treatment innovation. The facility, located within the Genolier Innovation Hub, will serve as a training center for Accuray's advanced systems, including the Radixact® and upcoming CyberKnife® Systems. The event was attended by local leaders and stakeholders, highlighting community support.
Read more →ARAYAccuray Hosts Successful Northern Europe User Meeting
Accuray hosted a successful Northern Europe User Meeting in London, marking the first in-person gathering since 2019. The event attracted over 40 participants from seven countries, facilitating knowledge exchange among clinicians and medical professionals. Presentations included advancements in adaptive radiotherapy and the Radixact System, highlighting innovative treatment protocols and collaborative efforts in the field.
Read more →ARAYSBRT Highlights from the RSS Scientific Meeting 2024
The Radiosurgery Society (RSS) highlighted advancements in stereotactic body radiation therapy (SBRT) for high-risk prostate cancer at its annual scientific meeting. Notable studies presented included the Georgetown experience with SBRT showing excellent toxicity profiles and promising biochemical recurrence-free survival rates. Other studies also support the effectiveness of combination therapies in improving patient outcomes.
Read more →ARAYAccuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
Accuray Incorporated has launched a new training center in Genolier, Switzerland, aimed at enhancing education for medical professionals in radiosurgery and radiotherapy. This center, part of Accuray's global training network, is designed to provide hands-on simulation facilities and advanced technology for training sessions. It is positioned to be the European hub for educating medical teams on the use of Accuray's CyberKnife and Radixact systems, potentially improving patient care through better training and best practices.
Read more →ARAYAccuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
Accuray Incorporated (NASDAQ: ARAY) is scheduled to report its financial results for the third quarter of fiscal year 2024, which ended on March 31, 2024. The results will be shared during a conference call on May 1, 2024, at 1:30 p.m. PT. Investors can also access a live webcast of the call through the company's Investor Relations website. A replay of the call will be available for one week following the event.
Read more →ARAYIntroducing Jeffrey Carpenter, Accuray Deputy Chief Information Security Officer
Jeffrey Carpenter, Accuray's deputy CISO, delivered the closing keynote at the Open Cyber Security Conference 2024, reflecting on 30 years of incident response. He also led a workshop aimed at enhancing communication skills for cybersecurity professionals. The event focused on future challenges in security incident management and encouraged sharing experiences among attendees.
Read more →ARAYNew Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System
Accuray Incorporated presented new data at the 2024 Radiosurgery Society Meeting, highlighting the effectiveness of its CyberKnife System in treating high-risk and recurrent prostate cancer. The studies demonstrate that the treatment can be completed in just 4-5 sessions, compared to the typical 30-40 sessions with conventional therapies, while maintaining patient quality of life. The CyberKnife's advanced motion tracking technology enhances its precision in delivering high doses of radiation safely and effectively.
Read more →ARAYAddressing the Disparities in Radiotherapy in Asia-Pacific Region: Perspectives from Dr. Imjai Chitapanarux
The Asia-Pacific region faces significant disparities in access to radiotherapy, with only 43.9% of the necessary megavoltage machines available. The Federation of Asian Radiation Oncology (FARO) was formed to address these challenges and improve cancer care. Despite progress in some countries like Thailand, barriers such as affordability, public awareness, and healthcare provider shortages persist.
Read more →ARAYAccuray Incorporated to Speak at 36th Annual Roth Conference
Accuray Incorporated announced its participation in the 36th Annual Roth Conference, where its management team will engage in a fireside chat on March 18, 2024. This event will facilitate connections between institutional investors and companies across diverse sectors. The chat will be live-streamed and available for replay on Accuray's website, emphasizing the company's commitment to investor engagement and transparency.
Read more →ARAYAccuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Accuray Incorporated will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12, 2024. The company's management team is scheduled for a fireside chat where they will discuss updates and insights related to their operations. A live webcast of the presentation will be available, along with a recorded replay for 90 days post-event. This conference aims to connect various healthcare companies with institutional investors, facilitating valuable discussions within the industry.
Read more →ARAYRadiotherapy – An Overlooked Pillar of Cancer Care: Learn how Radiotherapy UK is driving change for a better future
Radiotherapy is essential for cancer treatment, yet the UK faces significant access challenges. A report by Radiotherapy UK highlights disparities in treatment availability and calls for a National Cancer Control Plan. The charity emphasizes the need for strategic investment in workforce and technology to improve patient outcomes. Delays in treatment pose serious risks, necessitating urgent government action.
Read more →ARAYUnderstanding the Global Cancer Care Gap – World Cancer Day
World Cancer Day emphasizes the urgent need to address health equity in cancer care. The theme 'Close the Care Gap' highlights the disparities in access to treatment resources across different income levels. Notably, 30 countries lack radiotherapy centers, predominantly in Africa, leading to significant outcome disparities. The rising cancer burden, especially in low-income nations, exacerbates these issues.
Read more →ARAYQuebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System
Accuray Incorporated announced that the Montérégie Integrated Cancer Center in Quebec is the first in Canada to use its Radixact radiation therapy system for cancer treatment. This system incorporates advanced ClearRT imaging and Synchrony motion adaptation technologies, enhancing treatment precision while minimizing harm to surrounding healthy tissues. The demand for innovative cancer treatments in Quebec is underscored by statistics showing that someone is diagnosed with cancer every 8 minutes in the province. A second Radixact System is expected to be installed by mid-2024, further expanding treatment capabilities.
Read more →ARAY▲ +6.4%on this newsshared move
Driven to Make a Difference: Women of Accuray Share their Career Journeys
In celebration of International Day of Women and Girls in Science, women from Accuray share their personal journeys in STEM. They discuss their inspirations, challenges, and the importance of mentorship in encouraging girls to pursue careers in science and technology. Each story emphasizes resilience, passion, and the impact of their work in the healthcare industry.
Read more →ARAYClosing the cancer care gap: An interview with Dr. B. S. Ajaikumar
In an interview with Dr. B. S. Ajaikumar, he discusses the pressing issue of cancer care equity, particularly in India, where access remains a challenge due to geographical and cultural barriers. He highlights the role of technology, such as remote consultations and advanced treatment methods, in bridging these gaps. Dr. Ajaikumar also addresses the importance of precision medicine and changing perceptions of cancer treatment, noting improvements in early diagnosis.
Read more →ARAYAccuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Accuray Incorporated announced its participation in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, scheduled for February 13, 2024. This event is designed for prospective and existing BTIG clients, indicating Accuray's strategic engagement with investors. Investors can request one-on-one meetings with Accuray management through their BTIG representatives.
Read more →ARAYNavigating the Challenges: Bringing Advanced Radiation Therapy Solutions to the Frontline
The article discusses the challenges faced in radiation therapy, including rising patient demand, complex workflows, and accessibility barriers. Accuray aims to address these issues by providing advanced treatment solutions and comprehensive support for healthcare professionals. The focus is on evolving radiotherapy practices to enhance patient care and outcomes in a changing environment.
Read more →ARAYAccuray Reports Fiscal 2024 Second Quarter Financial Results 19% Order Growth YOY; 8% Service Revenue Expansion; Confirms FY24 Guidance
Accuray Incorporated reported its fiscal 2024 second quarter financial results, highlighting a 19% year-over-year increase in gross orders, although net revenue decreased by 7% compared to the prior year. The company experienced a GAAP net loss of $9.6 million, an increase from a loss of $1.9 million during the same period last year. Despite these challenges, Accuray confirmed its fiscal year 2024 guidance, expecting total revenue between $460 million and $470 million, signifying a projected year-over-year growth of 3 to 5%. The company noted strong performance in both the EIMEA region and the Chinese market, driven by recent product launches.
Read more →ARAYProvidence Swedish Radiosurgery Center in Seattle Invests in Second Accuray CyberKnife® System, a Robotic Delivery Device That Makes Extremely Precise Radiation Treatments Possible in 1-5 Sessions
Accuray Incorporated has announced that the Providence Swedish Radiosurgery Center in Seattle is investing in a second CyberKnife S7 system to enhance its radiation treatment capabilities. This system promises to deliver faster stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), thanks to its robotic design and AI technology, which ensure high precision. The partnership between Accuray and the center has evolved positively over more than a decade, focusing on improving patient comfort and treatment outcomes. The investment reflects confidence in Accuray's innovations in radiation therapy.
Read more →ARAYAccuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024
Accuray Incorporated (NASDAQ: ARAY) is set to report its financial results for the second quarter of fiscal year 2024, which ended on December 31, 2023. The report will be delivered during a conference call on January 31, 2024, at 1:30 PM PT/4:30 PM ET. Investors can participate through a dial-in or access a live webcast on the company's investor relations website.
Read more →ARAYAccuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System
Accuray Incorporated has launched the VitalHold solution in Japan to support surface-guided radiation therapy (SGRT) on the Radixact System, effective November 30, 2023. This new feature facilitates deep inspiration breath hold treatments primarily for breast cancers and allows for markerless patient setup. The implementation of SGRT technology aims to improve treatment accuracy and patient positioning. Accuray anticipates that the VitalHold package will enhance radiotherapy options for clinicians and potentially lower the burden on both patients and medical teams.
Read more →ARAYOvercoming AI Bias: Understanding, Identifying and Mitigating Algorithmic Bias in Healthcare
The article discusses the critical issue of AI bias in healthcare, highlighting how biases can be unintentionally integrated into AI algorithms, affecting patient outcomes. It outlines the sources of AI bias, including human biases and data generalizability issues. The piece emphasizes the importance of addressing these biases through inclusive data practices and regulatory measures to ensure equitable healthcare delivery.
Read more →ARAYAccuray Reports Fiscal 2024 First Quarter Financial Results Company Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance
Accuray Incorporated (NASDAQ: ARAY) reported financial results for the first quarter of fiscal 2024, highlighting an 8% revenue growth to $103.9 million compared to the previous year. The company also announced improved adjusted EBITDA, which rose to $6.5 million from $1.9 million. Key operational achievements include securing FDA and European regulatory approvals for their VitalHold breast cancer treatment package. Despite positive growth, Accuray did report a net loss of $3.0 million and a decline in order backlog.
Read more →ARAYAccuray to Participate in the 14th Annual Jefferies London Healthcare Conference
Accuray Incorporated announced its participation in the 14th Annual Jefferies London Healthcare Conference, set for November 15, 2023. The management team will deliver a presentation followed by a moderated Q&A session. Investors can access a live webcast on the company's Investor Relations website, with a replay available for 90 days afterward. This involvement highlights Accuray's commitment to engaging with the investment community.
Read more →ARAYAccuray to Report First Quarter Fiscal 2024 Financial Results on November 7, 2023
Accuray Incorporated will announce its financial results for the first quarter of fiscal year 2024 on November 7, 2023. The announcement will be made during a scheduled conference call at 1:30 p.m. PT/4:30 p.m. ET. Investors will have the option to join the call live or listen to a replay available for one week following the call. The company's commitment to providing updates highlights its ongoing operational activities.
Read more →ARAYThe Importance of Research in the Evolving Field of Radiation Oncology. ASTRO 2023 Highlights
The ASTRO 2023 Annual Meeting emphasized the importance of patient experience in clinical trials, highlighting its role in recruitment and reliable data collection. Key research findings included effective radiation therapy options for prostate and breast cancer, as well as advancements in minimizing neurocognitive decline in patients with brain metastases. These developments promise to enhance patient care and outcomes in radiation oncology.
Read more →ARAYAccuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China
Accuray Incorporated announced that its Tomo C Radiation Treatment Delivery System has received approval from the Chinese National Medical Products Administration. This approval marks a significant milestone for Accuray and its joint venture with CNNC, enabling greater access to radiation therapy for cancer patients in China. The Tomo C system features advanced imaging and radiation delivery capabilities, optimizing treatment precision. The collaboration aims to address the current gap between the demand for treatment and the available resources in the country.
Read more →ARAYForward-looking Statements This presentation is intended exclusively for investors. 2 Proprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary
Accuray held an investor briefing at ASTRO 2023, presenting forward-looking statements regarding its financial expectations for fiscal years 2024 to 2026. The company discussed strategic growth plans focused on innovation and improving access to cancer care. Accuray anticipates significant opportunities in the radiotherapy market while acknowledging the risks posed by the global economic environment and operational challenges. The briefing outlined initiatives aimed at closing gaps in cancer care and enhancing profitability through service expansion.
Read more →ARAYAccuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
Accuray Incorporated has announced the introduction of Cenos, an online adaptive therapy option for its Radixact System, during the ASTRO Annual Meeting. Developed in collaboration with Limbus AI, this innovative solution allows for real-time adjustments to treatment plans while patients are on the treatment table. The tool aims to enhance personalized patient care by addressing the dynamic nature of tumor characteristics during radiation therapy. However, Cenos is pending regulatory approval for availability in the U.S. market, which may delay its launch.
Read more →ARAYAccuray Opens New Global Training Center at Madison, WI Headquarters to Advance Radiotherapy Treatment Techniques Amid Growing Demand for Precision Cancer Care
Accuray Incorporated has opened a new global training center at its headquarters in Madison, Wisconsin, aimed at improving education in radiotherapy techniques. The facility, designed for modern training needs, provides both in-person and remote learning options to accommodate care providers. The center will support ongoing education related to Accuray's radiation therapy systems, enhancing healthcare practitioners' ability to deliver optimal patient care. This initiative responds to the increasing demand for precision cancer care and demonstrates Accuray's commitment to enhancing treatment outcomes.
Read more →ARAYAccuray to Host Investor Day at ASTRO on October 3, 2023
Accuray Incorporated (NASDAQ: ARAY) will host an Investor Day on October 3, 2023, during the ASTRO Annual Meeting. The event, which can be attended in person or virtually, will feature presentations from the company's leadership team discussing their vision and advancements in patient care. Additionally, insights from global thought leaders on radiation medicine technology will be shared. Attendees are required to register before September 27, 2023, and a replay of the meeting will be available on the company's website afterward.
Read more →ARAYOvercoming Barriers to Deliver Total Body Irradiation
The article discusses the challenges associated with total body irradiation (TBI) in treating blood cancers and highlights how the TomoTherapy platform addresses these issues. It emphasizes the benefits of improved treatment times and accuracy, which enhance patient comfort and outcomes. The Indo-American Hospital's experience with TBI using TomoTherapy is also detailed, showcasing its effectiveness in clinical practice.
Read more →ARAY▼ -12.2%on this news· ran to -23% by day 1
Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market
Accuray Incorporated has received FDA clearance for its VitalHold technology, which will be integrated into the Radixact System for breast cancer treatment. This innovation allows for deep inspiration breath hold (DIBH) treatments, enhancing precision in targeting tumors while reducing radiation exposure to healthy organs. The VitalHold technology will also be available in the European market, further expanding access to advanced breast cancer therapies. Clinicians will benefit from increased versatility and personalization in treatment delivery options, aiming to improve outcomes for breast cancer patients.
Read more →ARAY▼ -12.2%on this news· ran to -23% by day 1
Accuray Reports Fourth Quarter and Fiscal 2023 Financial Results 8% Q4 revenue growth; Record shipments for FY23; Company issues guidance for FY24
Accuray Incorporated reported its fourth-quarter and fiscal year 2023 results, showcasing an 8% revenue growth in Q4. The total net revenue for FY23 reached $447.6 million, though the company experienced a net loss of $9.3 million, up from $5.3 million during the previous year. Positive highlights included record shipments and successful product clearances, while challenges such as increased losses and a decrease in gross profit margins were noted. For fiscal year 2024, Accuray anticipates revenue growth of 3% to 5% and an Adjusted EBITDA range of $27 million to $30 million.
Read more →ARAYAccuray to Report Fiscal Year-End 2023 Financial Results on August 9, 2023
Accuray Incorporated (NASDAQ: ARAY) is set to report its financial results for the fourth quarter and fiscal year 2023, ending June 30, 2023, during a conference call scheduled for August 9, 2023. The call will begin at 1:30 p.m. PT/4:30 p.m. ET, and will be accessible via dial-in numbers or through a live webcast. A replay of the call will be available for one week post-conclusion.
Read more →ARAYAccuray Incorporated Announces Its Addition to the Russell 2000® Index
Accuray Incorporated (NASDAQ: ARAY) has announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of Russell stock indexes, effective immediately. This milestone is seen as an important step in enhancing the company's visibility in the investment community and expanding access to its radiation therapy technologies. Membership in the Russell 3000® Index offers further exposure as it encompasses the largest U.S.-traded stocks, thereby benefiting Accuray as a part of a widely recognized benchmark used by various investors. The company anticipates this inclusion will support its growth and innovation efforts.
Read more →ARAYAccuray Announces Suzanne Winter Selected as One of the Top 50 Healthcare Technology CEOs of 2023
Accuray Incorporated has announced that its president and CEO, Suzanne Winter, has been named one of the Top 50 Healthcare Technology CEOs of 2023 by The Healthcare Technology Report. This recognition acknowledges her significant contributions to healthcare technology and her previous roles in prominent organizations. Winter expressed her honor in being recognized alongside other distinguished executives and emphasized her commitment to enhancing patient care through innovative solutions.
Read more →ARAYAccuray CyberKnife® and TomoTherapy® Platforms Featured in More Than 55 Abstracts Presented at ESTRO 2023, Reinforcing Systems
Accuray Incorporated announced that over 55 abstracts showcasing their CyberKnife and TomoTherapy platforms were presented at the ESTRO 2023 conference, highlighting their effectiveness in delivering hypofractionated radiation treatments. The data reinforces the precision and personalized nature of these technologies in managing various cancers. Accuray also introduced the VitalHold™ breast package, aimed at enhancing treatment delivery. Despite positive developments, the company acknowledges risks surrounding market acceptance and future product development.
Read more →ARAYAccuray Reports Fiscal 2023 Third Quarter Financial Results Company delivers record quarterly revenue and unit volume in Q3; Reiterates fiscal year guidance
Accuray Incorporated reported its financial results for the third quarter of fiscal 2023, showcasing significant growth with a net revenue of $118.1 million, a 22.8% year-over-year increase. The company achieved a net income of $0.6 million, recovering from a loss during the same quarter last year. Operational highlights include setting a record with 30 system shipments and a 45% growth in global product revenue. Despite these achievements, Accuray noted a decrease in order backlog and some order cancellations.
Read more →ARAYAccuray to Report Third Quarter Fiscal 2023 Financial Results on April 26, 2023
Accuray Incorporated (NASDAQ: ARAY) will announce its financial results for the third quarter of fiscal year 2023, which ended on March 31, 2023. A conference call hosted by the company's management is scheduled for April 26, 2023, at 1:30 p.m. PT. Investors will have access to a live webcast and a replay option, promoting transparency for stakeholders.
Read more →ARAYAccuray Incorporated to Speak at 33rd Annual Oppenheimer Healthcare Conference
Accuray Incorporated announced its participation in the 33rd Annual Oppenheimer Healthcare Conference scheduled for March 13-15, 2023. The management team will engage in a fireside chat on March 14, which will be available via live webcast. Following the event, a replay will be accessible on the company’s website for approximately 90 days. The conference aims to connect institutional investors with a variety of healthcare companies from diverse sectors.
Read more →ARAYProprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking st
Accuray has shared its forward-looking statements regarding fiscal strategies at the 2023 Cowen Healthcare Investor Conference. The statements focus on expectations for revenue growth, market share, and product development in the radiation therapy sector. However, they also acknowledge several risks, including economic instability and supply chain challenges, which could affect the company's ability to meet its projections. Overall, while the company has outlined a comprehensive growth strategy, it also recognizes significant uncertainties in the market environment.
Read more →ARAYAccuray to Participate in the Cowen 43rd Annual Health Care Conference
Accuray Incorporated (NASDAQ: ARAY) has announced its participation in the Cowen 43rd Annual Health Care Conference, scheduled for March 6-8, 2023. The company will take part in a Fireside Chat on March 6 at 10:30 am PST. Investors will have the opportunity to engage with the management team during the event, with a live webcast available on the Accuray website.
Read more →ARAYTrial Data Indicates Targeted, Short Course Radiation Therapy Preserves Urinary Continence and Sexual Function Better Than Surgery in Men With Prostate Cancer
Accuray Incorporated has announced promising results from the PACE-A trial, which indicates that stereotactic body radiation therapy (SBRT) is more effective than surgery in preserving urinary continence and sexual function in men with localized prostate cancer. The study involved 123 men and showed that only 4.5% of SBRT patients required urinary pads at two years, compared to 47% of surgery patients. These findings suggest that SBRT can significantly improve the quality of life for prostate cancer patients while reducing the risk of long-term side effects associated with surgical procedures.
Read more →ARAYAccuray Reports Fiscal 2023 Second Quarter Financial Results Delivered strong Q2 performance amidst challenging macroenvironment; Reiterate fiscal year guidance
Accuray Incorporated released its financial results for the second quarter of fiscal 2023, reporting a net revenue of $114.8 million, a minor decrease from the previous year. Despite a decline in gross orders compared to the prior year, orders increased sequentially by 13.2 percent. The company also saw a notable growth in adjusted EBITDA, rising 24.1 percent year-over-year. Accuray reiterated its financial guidance for the fiscal year, anticipating revenue in the range of $447 million to $455 million.
Read more →ARAYRobert C. Kill Joins Accuray Board of Directors
Accuray Incorporated announced the appointment of Robert C. Kill to its Board of Directors, effective January 30, 2023. With over 30 years in the healthcare industry, Kill brings extensive experience, especially from his role as CEO of Parata Systems, where he significantly increased revenue. His background includes working with various healthcare-related companies and private equity funds, which complements Accuray's strategic goals. Both the company president and Kill express optimism about the future contributions he will make to the organization.
Read more →ARAYEuropean Radiosurgery Center Munich Invests in Second Accuray CyberKnife® System to Support the Demand for High-Precision Radiosurgery Treatments
Accuray Incorporated announced that the European Radiosurgery Center Munich has invested in a second CyberKnife System, the latest CyberKnife S7 model. This addition will help the center meet the high demand for precision radiosurgery treatments while enabling the treatment of a broader range of indications. The CyberKnife S7 is designed for efficient workflow and accurate tumor tracking during sessions, enhancing patient care. The center aims to leverage this technology to improve treatment accessibility for patients suffering from various tumors and neurological conditions.
Read more →ARAYAccuray to Report Second Quarter Fiscal 2023 Financial Results on February 1, 2023
Accuray Incorporated (NASDAQ: ARAY) is set to report its financial results for the second quarter of fiscal year 2023 on February 1, 2023. The results will cover the period ended December 31, 2022, with a conference call scheduled at 1:30 p.m. PT / 4:30 p.m. ET on the same day for management to review these results. The call will be accessible via dial-in numbers and a webcast that will remain available until the results for the third quarter are announced.
Read more →ARAYAccuray Announces First Patient Treatments in New Zealand With the CyberKnife® System, the World
Accuray Incorporated has announced that Auckland Radiation Oncology is the first center in New Zealand to use its latest-generation CyberKnife S7 System for patient treatments. This robotic system delivers precise stereotactic radiosurgery and body radiation therapy, allowing for rapid and non-invasive cancer treatments. The new technology is designed to enhance treatment accuracy and minimize damage to surrounding healthy tissues. The introduction of this system is expected to significantly improve access to advanced cancer treatment options for patients in New Zealand.
Read more →ARAYAccuray to Participate in the B. Riley Securities
Accuray Incorporated (NASDAQ: ARAY) has announced its participation in the B. Riley Securities' 3rd Annual Oncology Conference, scheduled for January 18-19, 2023. The company's management team will engage in a virtual Fireside Chat on January 18 at 7:00am PST/10:00am EST. The conference will feature over 30 small and mid-cap healthcare companies and discuss advancements in various oncological therapies, including immunotherapy and radiation oncology. Accuray aims to expand its innovative radiation therapy solutions to enhance patient care.
Read more →ARAYAccuray Receives IMV Award for Best In Service in Radiation Oncology for 2022
SUNNYVALE, Calif., Nov. 28, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its commitment to delivering better, faster cancer treatment technology and superior service is resulting in highly satisfied customers. According to the IMV ServiceTrak™ Rad
Read more →ARAYOscar Lambret Center in France Installs Second Accuray Radixact® System, the Hospital
Hospital Adds Accuray ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies to Both Radixact Systems, Creating the Ultimate System for Personalized Cancer Care SUNNYVALE, Calif., Nov. 16, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that
Read more →ARAYAccuray Reports Fiscal 2023 First Quarter Financial Results Strong customer demand. Navigating FX and Supply Chain Challenges. Company reiterates full year guidance.
Accuray Reports Fiscal 2023 First Quarter Financial Results Strong customer demand. Navigating FX and Supply Chain Challenges. Company reiterates full year guidance. SUNNYVALE, Calif., November 2, 2022 Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the
Read more →ARAYAccuray Announces Tomo® C Registration Submission to China
SUNNYVALE, Calif., Nov. 1, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system for the Type B market has been submitted to the Chinese National Medical Products
Read more →ARAYNew Reimbursement Approved by the Japanese Ministry of Health, Labor and Welfare for the Accuray CyberKnife® System to Treat Trigeminal Neuralgia, a Condition Often Causing Severe Facial Pain
SUNNYVALE, Calif., Oct. 26, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved reimbursement for the CyberKnife® System for the treatment of trigeminal neuralgia (TN). The system pro
Read more →ARAY▲ +7.4%on this newsshared move
GE Healthcare and Accuray Collaborate to Expand Access, Advance the Practice of Precision Radiation Therapy
Collaboration places emphasis on personalized medicine; brings together key precision diagnostic and treatment delivery tools aimed at creating shorter, more comfortable and more effective treatments for patients CHICAGO and SUNNYVALE, Calif., Oct. 21, 2022 /PRNewswire/ -- GE He
Read more →ARAYAccuray to Report First Quarter Fiscal 2023 Financial Results on November 2, 2022
SUNNYVALE, Calif., Oct. 19, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2023, ended September 30, 2022, after the market close on November 2, 2022. Management will host a conference call to review the
Read more →ARAYAccuray and C-RAD Unveil Automated Breast Cancer Treatment Package for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
SUNNYVALE, Calif., Oct. 13, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company, in partnership with C-RAD AB (NASDAQ Stockholm: CRAD B), will showcase an important new option for improving the care of people diagnosed with breast cancer during th
Read more →ARAYData Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators
Latest research published in The Lancet Oncology: suggests bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment Almost 20 years of global clinical data: shows the non-surgical Cy
Read more →ARAYAccuray to Host Meeting with Analysts and Investors at ASTRO on October 24, 2022
SUNNYVALE, Calif., Oct. 6, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a key opinion leader (KOL) discussion with analysts and investors on Monday, October 24, 2022, in conjunction with the American Society of Radiation Onco
Read more →ARAYAccuray Announces First CyberKnife® Systems in Africa, Providing a New Option and Hope for Potentially Life-Saving Radiation Treatments for More Cancer Patients
World's Only Robotic Radiation Therapy Device Delivers Extremely Precise Treatments in Just 1 to 5 Out-Patient Sessions SUNNYVALE, Calif., Sept. 30, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding its global footprint with the in
Read more →ARAYDr. Seth Blacksburg Joins Accuray as VP, Chief Medical Officer Americas Region
SUNNYVALE, Calif., Sept. 14, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Seth Blacksburg, M.D., MBA has joined the company as vice president, chief medical officer for the Americas (North and South America) region. Dr. Blacksburg will be responsi
Read more →ARAYAccuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster
Accuray Will Anchor Hub That Will Unite Companies From the MedTech, Pharma and Biosciences Sectors, Physicians and Scientists SUNNYVALE, Calif., Sept. 7, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is joining forces with Genolier Innovati
Read more →ARAY▲ +5.3%on this news· ran to +43% by day 3
Accuray Reports Fourth Quarter and Fiscal 2022 Financial Results 8.5% FY22 revenue growth; Company issues guidance for FY23
Accuray Reports Fourth Quarter and Fiscal 2022 Financial Results 8.5% FY22 revenue growth; Company issues guidance for FY23 SUNNYVALE, Calif., August 10, 2022 Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2022 ended June
Read more →ARAYAccuray to Report Fiscal Year-End 2022 Financial Results on August 10, 2022
SUNNYVALE, Calif., July 27, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and fiscal year 2022, ended June 30, 2022, after the market close on August 10, 2022. Management will host a conference call to review the res
Read more →ARAYAccuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications
SUNNYVALE, Calif., July 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new clinical studies presented at the 15th Congress of the International Stereotactic Radiosurgery Society (ISRS) in Milan, Italy reinforce the value of the company's CyberKn
Read more →ARAYactual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the COVID-19 pandemic on the
Accuray Appoints Franco N. Palomba as VP, Chief Accounting Officer & Controller SUNNYVALE, Calif., June 15, 2022 Accuray Incorporated (NASDAQ: ARAY) announced today that Franco N. Palomba has joined the company as vice president, chief accounting officer & controller. Mr. Palomb
Read more →ARAYAccuray Appoints Franco N. Palomba as VP, Chief Accounting Officer & Controller
SUNNYVALE, Calif., June 15, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Franco N. Palomba has joined the company as vice president, chief accounting officer & controller. Mr. Palomba will be responsible for the controllership function, including
Read more →ARAYAccuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
SUNNYVALE, Calif., June 6, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Sandeep Chalke, the company's new senior vice president, chief commercial officer. As a material inducement to Mr.
Read more →ARAY▲ +6.8%on this newsshared move
Accuray and Limbus AI Inc. Partner to Leverage Limbus
Partnership will Enable Accuray to Use Limbus' Technology to Streamline the Treatment Planning Process and Increase Operational Efficiency SUNNYVALE, Calif. and SASKATCHEWAN, Canada, June 2, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and Limbus AI Inc. announced to
Read more →ARAYAccuray Appoints Sandeep Chalke as SVP, Chief Commercial Officer
SUNNYVALE, Calif., May 17, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Sandeep Chalke has joined the company as senior vice president, chief commercial officer effective May 16, 2022. Mr. Chalke will have responsibility for the global commercial,
Read more →ARAY▲ +6.2%on this news
New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities
More Than 70 Abstracts Build on the Clinical Evidence Supporting the Use of These Technologies SUNNYVALE, Calif., May 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that clinical studies continue to validate the versatility of the company's CyberKni
Read more →ARAY▼ -5.9%on this newsshared move
Accuray ClearRT™ Helical Fan-Beam kVCT Imaging Wins "Best New Technology Solution for Oncology" MedTech Breakthrough Award
Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies SUNNYVALE, Calif., May 5, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its ClearRT™ helical fan-beam kVCT imaging capability for the Radixact® System
Read more →ARAYAccuray Announces Suzanne Winter, President, Promoted to President and CEO; Joshua Levine Will Retire as CEO and Board Member
Accuray Also Announces Chief Financial Officer, Ali Pervaiz SUNNYVALE, Calif., April 27, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Suzanne Winter, President, will succeed Joshua Levine as the company's Chief Executive Officer, effective July 1
Read more →ARAYAccuray Reports Fiscal 2022 Third Quarter Financial Results
Accuray Reports Fiscal 2022 Third Quarter Financial Results SUNNYVALE, Calif., April 27, 2022 Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter of fiscal 2022 ended March 31, 2022. Third Quarter Fiscal 2022 Summary Other Recent Operati
Read more →ARAYOwner of Arkansas Derby Winner Named Horse After the Life-Changing Accuray CyberKnife® Radiation Therapy Technology Used to Treat His Cancer
SUNNYVALE, Calif., April 21, 2022 /PRNewswire/ -- When Al Gold, the owner of the Arkansas Derby winner Cyberknife, received a diagnosis of prostate cancer, he was determined to find a potential cure for his disease while minimizing the impact of treatment on his daily life. Mr. G
Read more →ARAY▲ +10.6%on this news
Accuray to Report Third Quarter Fiscal 2022 Financial Results on April 27, 2022
SUNNYVALE, Calif., April 13, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2022, ended March 31, 2022, after the market close on April 27, 2022. Management will host a conference call to review the resu
Read more →ARAY10-Year Data Shows Accuray CyberKnife® System Provides Long-Lasting Relief of the Excruciating Pain Caused by Trigeminal Neuralgia
Study Abstract Recognized as Best Clinical Abstract at 2022 Radiosurgical Society Meeting SUNNYVALE, Calif., March 31, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that long-term follow-up data from a study of men and women with trigeminal neuralgia (
Read more →ARAYCARTI Selects Accuray CyberKnife® S7™ System to Increase Access to Advanced Cancer Care for Patients in Rural Communities Throughout Arkansas
SUNNYVALE, Calif., March 8, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the CARTI medical care team in Little Rock, Arkansas has treated the first patients in the state using the Accuray CyberKnife® S7™ System. The entire CyberKnife procedure is
Read more →ARAYNICE Endorses Radiosurgery Treatments for Trigeminal Neuralgia, Supporting Accuray CyberKnife® System Indications for Use
SUNNYVALE, Calif., Feb. 28, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the National Institute for Health and Care Excellence (NICE)* has endorsed the use of radiosurgery for trigeminal neuralgia (TN), strengthening the evidence for the company t
Read more →ARAYAccuray to Participate in the Cowen 42nd Annual Health Care Conference
SUNNYVALE, Calif., Feb. 24, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Cowen 42nd Annual Health Care Conference taking place March 7-9, 2022. The management team is scheduled to participate in a virtual Fireside Chat on Monda
Read more →ARAYLargest Hospital in Queensland, Australia Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies
SUNNYVALE, Calif., Feb. 14, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Royal Brisbane and Women's Hospital (RBWH), the largest medical facility in Queensland, Australia, has selected two Radixact Systems with ClearRT™ helical fan-beam kVCT imagi
Read more →ARAYAccuray TomoTherapy® Helical Radiotherapy System Helps Preserve Breast Cancer Patients
SUNNYVALE, Calif., Feb. 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a phase III, randomized controlled trial, TomoBreast, indicate post-surgery hypofractionated radiotherapy delivered with the TomoTherapy® System is superior to conv
Read more →ARAYAccuray Reports Fiscal 2022 Second Quarter Financial Results Record Revenue For Second Quarter Fiscal 2022
Accuray Reports Fiscal 2022 Second Quarter Financial Results Record Revenue For Second Quarter Fiscal 2022 SUNNYVALE, Calif., January 26, 2022 Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2022 ended December 31, 2021. Se
Read more →ARAYAccuray to Report Second Quarter Fiscal 2022 Financial Results on January 26, 2022
SUNNYVALE, Calif., Jan. 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2022, ended December 31, 2021, after the market close on Wednesday, January 26, 2022. Management will host a conference call to
Read more →ARAYAccuray CyberKnife® Robotic Radiosurgery System Receives Shonin Approval to Treat Trigeminal Neuralgia, a Chronic Pain Condition Affecting a Facial Nerve
SUNNYVALE, Calif., Dec. 15, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has received approval from the Japanese Ministry of Health, Labor and Welfare (Shonin) to market the CyberKnife® Robotic Radiosurgery System for the treatment of trigeminal neu
Read more →ARAYAccuray CyberKnife® Robotic Radiotherapy Platform Expands Range of Neurological Indications That Can Be Effectively Treated With Stereotactic Radiosurgery
SUNNYVALE, Calif., Nov. 10, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that more than two decades of globally-driven clinical data support the use of the company's CyberKnife® robotic radiotherapy platform for the delivery of stereotactic radiosurger
Read more →ARAY▲ +5.1%on this newsshared move
Accuray To Participate at Stifel 2021 Virtual Healthcare Conference
SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced its participation in Stifel's 2021 Virtual Healthcare Conference. The management team is scheduled to present on Tuesday, November 16th, 2021 at 6:20 am PACIFIC / 9:20 am EASTERN.
Read more →ARAYJoseph Diaz Beth Kaplan Managing Partner, Investor Relations, Lytham Partners, LLC Public Relations Director, Accuray +1 (602) 889-9660 +1 (408) 789-4426 jdiaz@accuray.com bkaplan@accuray.com Accuray Reports Fiscal 2022
Joseph Diaz Beth Kaplan Managing Partner, Investor Relations, Lytham Partners, LLC Public Relations Director, Accuray +1 (602) 889-9660 +1 (408) 789-4426 jdiaz@accuray.com bkaplan@accuray.com Accuray Reports Fiscal 2022 First Quarter Financial Results Record Revenue First Quart
Read more →ARAYAccuray Reports Fiscal 2022 First Quarter Financial Results
SUNNYVALE, Calif., Nov. 3, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2022 ended September 30, 2021. First Quarter Fiscal 2022 Summary Record net revenue of $107.4 million, including $25.5 million of
Read more →ARAYAccuray Transforming Patient Care Through Innovation Investor Day
1 Proprietary and Confidential Property of Accuray Accuray Overview Video Exhibit 99.1 Accuray Transforming Patient Care Through Innovation Investor Day October 25, 2021 Agenda 3 Proprietary and Confidential Property of Accuray Proprietary and Confidential Property of Accuray
Read more →ARAYAccuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients
SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial
Read more →ARAYJoe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 717-7804 +1 (408) 789-4426 jdiaz@accuray.com bkaplan@accuray.com Accuray Announces Preliminary First Quarter Fiscal 202
Joe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 717-7804 +1 (408) 789-4426 jdiaz@accuray.com bkaplan@accuray.com Accuray Announces Preliminary First Quarter Fiscal 2022 Financial Results and Raises FY22 Revenue Guidance to ra
Read more →ARAYAccuray Announces Preliminary First Quarter Fiscal 2022 Financial Results and Raises FY22 Revenue Guidance to range between $420 million to $427 million
SUNNYVALE, Calif., Oct. 21, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), today announced preliminary financial results for the first quarter of fiscal 2022 ended September 30, 2021. Accuray is currently finalizing its financial results for the first quarter of fisca
Read more →ARAYAccuray Unveils VOLO™ Ultra, the Latest Innovation for the Radixact® System, at ASTRO 2021
SUNNYVALE, Calif., Oct. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is showcasing its new VOLO™ Ultra for the Radixact® System, at ASTRO 2021. VOLO Ultra, a new way of planning with the Accuray Precision® Treatment Planning System, ena
Read more →ARAYAccuray to Report First Quarter Fiscal 2022 Financial Results on November 3, 2021
SUNNYVALE, Calif., Oct. 13, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2022, ended September 30, 2021, after the market close on Wednesday, November 3, 2021. Management will host a conference call to
Read more →ARAYAccuray to Host ASTRO Analyst & Investor Meeting on October 25, 2021
SUNNYVALE, Calif., Oct. 12, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host an Analyst & Investor Meeting on Monday, October 25, 2021, in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting. The ev
Read more →ARAYC-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities
Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated) UPPSALA, Sweden, and SUNNYVALE, Calif., Oct. 4, 2021 /PRNewswire/ -- C-RAD AB (NASDAQ Stockholm: CRAD B) and Accuray Incorporated (NASDAQ: ARAY) announced today they have signed an agreement
Read more →ARAYFrench Hospital Network Unicancer Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies
SUNNYVALE, Calif., Sept. 29, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Unicancer has selected three Radixact® Systems with the ClearRT™ helical fan-beam kVCT imaging and Synchrony® real-time delivery adaptation technologies to further their goa
Read more →ARAY▲ +6.4%on this news
Nagoya City University Hospital is First in Japan to Treat Cancer Patients Using the Accuray Radixact® System with ClearRT™ Helical Fan-Beam kVCT Imaging
SUNNYVALE, Calif., Sept. 23, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Nagoya City University Hospital in Aichi has treated the first cancer patient in Japan using the Radixact® System with ClearRT™ helical fan-beam kVCT imaging. ClearRT im
Read more →ARAYAccuray CyberKnife® Robotic Radiotherapy Platform is Superior to Conventional Linear Accelerators in Reducing Incidence of Bladder Side Effects in Prostate Cancer Patients
SUNNYVALE, Calif., Sept. 14, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from the PACE – Prostate Advances in Comparative Evidence – trial indicate the company's CyberKnife® robotic radiotherapy platform is superior to conventional linear ac
Read more →ARAY▲ +5.4%on this news
Investor Contact: Joe Diaz Investor Relations, Lytham Partners +1 (602) 889-9700 diaz@lythampartners.com Media Contact: Beth Kaplan Accuray +1 (408) 789-4426 bkaplan@accuray.com
Mika Nishimura Joins Accuray Board of Directors SUNNYVALE, Calif., August 23, 2021 - Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Mika Nishimura to the company's Board of Directors, effective as of August 17, 2021. With Ms. Nishimura's appointment, the
Read more →ARAY▲ +5.4%on this news
Mika Nishimura Joins Accuray Board of Directors
SUNNYVALE, Calif., Aug. 23, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Mika Nishimura to the company's Board of Directors, effective as of August 17, 2021. With Ms. Nishimura's appointment, the Accuray Board will consist of nine me
Read more →ARAYJoe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 717-7804 +1 (408) 789-4426 jdiaz@accuray.com bkaplan@accuray.com Accuray Reports Fourth Quarter and Fiscal 2021 Financi
Joe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 717-7804 +1 (408) 789-4426 jdiaz@accuray.com bkaplan@accuray.com Accuray Reports Fourth Quarter and Fiscal 2021 Financial Results SUNNYVALE, Calif., August 11, 2021 - Accuray In
Read more →ARAYAccuray Reports Fourth Quarter and Fiscal 2021 Financial Results
SUNNYVALE, Calif., Aug. 11, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2021. Q4 Fiscal 2021 and Recent Operating Highlights Gross orders of $112.7 million, an increase of 19 per
Read more →ARAYHong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact® System and ClearRT™ Helical Fan-Beam kVCT Imaging
SUNNYVALE, Calif., July 22, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the medical care team at Hong Kong Sanatorium & Hospital (HKSH) in Hong Kong treated the first cancer patient in Asia using the Radixact® System, the next-generation TomoTher
Read more →ARAYAccuray to Report Fiscal Year-End 2021 Financial Results on August 11, 2021
SUNNYVALE, Calif., July 14, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and fiscal year 2021, ended June 30, 2021, after the market close on Wednesday, August 11, 2021. Management will host a conference call to rev
Read more →ARAYBeloved Family Pet
SUNNYVALE, Calif., June 24, 2021 /PRNewswire/ -- The University of Wisconsin-Madison (UW-Madison) School of Veterinary Medicine team is advancing cancer care as the first to treat an animal using the Radixact® System with Synchrony®. Accuray (NASDAQ: ARAY) announced today that Ma
Read more →ARAYAccuray Announces Promotion of Suzanne Winter to President
SUNNYVALE, Calif., June 22, 2021 /PRNewswire/ -- Accuray (NASDAQ: ARAY) announced today that Suzanne Winter has been promoted to president, effective as of July 1, 2021. Ms. Winter, who previously served as the company's chief commercial officer and senior vice president of R&D a
Read more →ARAYto accelerated revenue growth, expectations related to the impact of the company's vision, and expectations related to the company's innovation pipeline and its potential effects. If any of these risks or uncertainties m
Accuray Announces Promotion of Suzanne Winter to President SUNNYVALE, Calif., June 22, 2021 - Accuray (NASDAQ: ARAY) announced today that Suzanne Winter has been promoted to president, effective as of July 1, 2021. Ms. Winter, who previously served as the company's chief commerc
Read more →ARAYAccuray Expands CyberKnife® System Versatility with Integration of RaySearch
SUNNYVALE, Calif., June 16, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the launch of RayStation* treatment planning support for the company's CyberKnife® M6™** and S7™** Robotic, Radiotherapy Systems. RayStation helps enable clinicians to create trea
Read more →ARAYAccuray Expands Commercialization of ClearRT™ Helical Fan-Beam kVCT Imaging for the Radixact® System with CE Mark Certification
SUNNYVALE, Calif., June 10, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark certification for its ClearRT™ helical fan-beam kVCT imaging capability. The Accuray-only ClearRT technology is now available to customers in the
Read more →ARAYAccuray continua a expansão global do Sistema Radixact® para mais centros de tratamento de câncer
SUNNYVALE, Califórnia, 11 de maio de 2021 /PRNewswire/ -- A Accuray Incorporated (NASDAQ: ARAY) anunciou hoje que o Hospital das Clínicas em La Paz, Bolívia, é o primeiro no país a tratar pacientes com câncer usando o Sistema de Tratamento Radixact®, a nova geração da plataforma
Read more →ARAYAccuray continúa la expansión global del sistema Radixact® a más centros de tratamiento de cáncer
SUNNYVALE, California, 11 de mayo de 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) anunció hoy que el Hospital de Clínicas de La Paz, Bolivia, es el primero en el país en tratar a pacientes con cáncer a través del sistema de entrega de tratamiento Radixact®, la platafo
Read more →ARAYAccuray Announces New $120 Million Credit Facility
SUNNYVALE, Calif., May 6, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced it has entered into a new five-year $80 million term loan and $40 million revolving credit facility with Silicon Valley Bank and a syndicate of banks (the "New Credit Facility"). Th
Read more →ARAYAccuray Announces Convertible Notes Exchange and Subscription
Accuray Announces Convertible Notes Exchange and Subscription SUNNYVALE, Calif., May 6, 2021 Accuray Incorporated (NASDAQ: ARAY) today announced that it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2022 (th
Read more →ARAYGeisinger becomes first in U.S. to treat cancer patients with Accuray Synchrony® technology on the Radixact® and CyberKnife® S7™ Systems to better target radiation treatments
Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated) WILKES-BARRE, Pa. and SUNNYVALE, Calif., May 3, 2021 /PRNewswire/ -- Geisinger continues to bring advanced cancer care closer to home as it is the first hospital system in the U.S. to offer
Read more →ARAYAccuray Customers Achieve Top Scores in AAPM MArkerless Lung Target Tracking CHallenge (MATCH) Using Synchrony® Technology on the Radixact® and CyberKnife® Systems
SUNNYVALE, Calif., April 29, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Accuray customers took the top two positions in the MArkerless Lung Target Tracking CHallenge (MATCH) experimental branch using the Accuray Synchrony Lung Tracking with Resp
Read more →ARAYJoe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 717-7804 +1 (408) 789-4426 jdiaz@accuray.com bkaplan@accuray.com Accuray Reports Third Quarter Fiscal 2021 Financial Re
Joe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 717-7804 +1 (408) 789-4426 jdiaz@accuray.com bkaplan@accuray.com Accuray Reports Third Quarter Fiscal 2021 Financial Results SUNNYVALE, Calif., April 27, 2021 - Accuray Incorpor
Read more →ARAYAccuray Reports Third Quarter Fiscal 2021 Financial Results
SUNNYVALE, Calif., April 27, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the third quarter of fiscal 2021 ended March 31, 2021. Third Quarter Fiscal 2021 Summary Net revenue of $102.6 million including $24.9 million of syste
Read more →ARAYAccuray Appoints Jean-Philippe Pignol, M.D., Ph.D. as Chief Medical & Technology Officer
SUNNYVALE, Calif., April 26, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Jean-Philippe Pignol, M.D., Ph.D. as its chief medical & technology officer, effective as of April 15, 2021. In this new role, Dr. Pignol will lead the company
Read more →ARAYAccuray Receives Shonin Approval for ClearRT™ Helical kVCT Imaging, CE Mark Expected by End of June; Expands Commercial Launch
SUNNYVALE, Calif., April 22, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the innovative ClearRT™ helical fan-beam kVCT imaging* capability has now been in clinical use for over two months, and is on track to expand into other markets. ClearRT on
Read more →ARAYAccuray to Report Third Quarter Fiscal 2021 Financial Results on April 27, 2021
SUNNYVALE, Calif., April 13, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2021, ended March 31, 2021, after the market close on Tuesday April 27, 2021. Management will host a conference call to review
Read more →ARAYAccuray to Participate in the Cowen 41st Annual Health Care Conference
SUNNYVALE, Calif., Feb. 23, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced its participation in the Cowen Annual Health Care Conference. The management team is scheduled to participate in a virtual Fireside Chat on Tuesday, March 2nd at 11:50 am PACIFIC
Read more →ARAYAccuray Appoints Healthcare Executive and Physician Byron C. Scott to Board of Directors
SUNNYVALE, Calif., Feb. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Byron C. Scott, M.D., MBA to the company's Board of Directors, effective as of February 12, 2021. Dr. Scott brings significant experience as a physician executi
Read more →ARAYJoe Diaz Investor Relations - Accuray Tel: +1 (602) 717-7804 E-mail: jdiaz@accuray.com
Accuray Appoints Healthcare Executive and Physician Byron C. Scott to SUNNYVALE, Calif., February 19, 2021 - Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Byron C. Scott, M.D., MBA to the company's Board of Directors, effective as of February 12, 2021. D
Read more →ARAYAccuray to Participate in BTIG
SUNNYVALE, Calif., Feb. 5, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced its participation in BTIG's Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference. The management team is scheduled to participate in a Fireside Chat on Thu
Read more →ARAYAccuray Reports Second Quarter Fiscal 2021 Financial Results
SUNNYVALE, Calif., Jan. 27, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the second quarter of fiscal 2021 ended December 31, 2020. Second Quarter Fiscal 2021 Summary Net revenue of $97.5 million including $21.3 million of sy
Read more →ARAYJoe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 889-9700 +1 (408) 789-4426 diaz@lythampartners.com bkaplan@accuray.com Accuray Reports Second Quarter Fiscal 2021 Finan
Joe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 889-9700 +1 (408) 789-4426 diaz@lythampartners.com bkaplan@accuray.com Accuray Reports Second Quarter Fiscal 2021 Financial Results SUNNYVALE, Calif., January 27, 2021 - Accuray
Read more →ARAYSeven-year Data Shows Accuray TomoTherapy® System Provides Excellent Long-Term Control of Low-Risk Breast Cancer
SUNNYVALE, Calif., Jan. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelera
Read more →ARAYSafe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" pro
Accuray Innovation Driven Growth Strategy 2021 J.P. Morgan Healthcare Conference January 14, 2021 Exhibit 99.1 Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-lookin
Read more →ARAYAccuray to Report Second Quarter Fiscal 2021 Financial Results on January 27, 2021
SUNNYVALE, Calif., Jan. 8, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2021, ended December 31, 2020, after the market close on Wednesday January 27, 2021. Management will host a conference call to r
Read more →ARAYAccuray To Participate at J.P. Morgan
SUNNYVALE, Calif., Jan. 6, 2021 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced its participation in the 39th J.P. Morgan Annual Healthcare Conference. Josh Levine, President and CEO, is scheduled to present on Thursday, January 14, 2021 at 11:00 am PACIFIC /
Read more →ARAYAccuray Receives 510(k) FDA Clearance for ClearRT™ Helical kVCT Imaging for the Radixact® Treatment Delivery System
SUNNYVALE, Calif., Jan. 5, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ClearRT™ Helical kVCT Imaging* for the Radixact® System, the next generation
Read more →ARAYAccuray and DHL Supply Chain establish global service logistics platform to support delivery of advanced cancer treatment technology
Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated) SUNNYVALE, Calif. and WESTERVILLE, Ohio, Nov. 18, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and DHL Supply Chain announced today they have entered into a global service parts
Read more →ARAYAccuray Appoints Renowned Medical Device Industry Executive Jim Dennison as Senior Vice President of Global Quality and Regulatory Affairs
SUNNYVALE, Calif., Nov. 12, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed Jim Dennison as its senior vice president of global quality and regulatory affairs, effective immediately. Mr. Dennison is an accomplished quality assurance and r
Read more →ARAYAccuray Showcases Radiation Therapy Innovations Designed to Enable Better Outcomes with Less Damage, Less Time, and Less Cost, at ASTRO 2020
SUNNYVALE, Calif., Nov. 10, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that innovations in hardware and software solutions and clinical data presented at this year's ASTRO (American Society for Radiation Oncology) Annual Meeting continue to support t
Read more →ARAYAccuray Reports First Quarter Fiscal 2021 Financial Results
SUNNYVALE, Calif., Oct. 29, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2021 ended September 30, 2020. First Quarter Fiscal 2021 Summary Net revenue of $85.3 million, operating income of $5.5 mill
Read more →ARAYJoe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 889-9700 +1 (408) 789-4426 diaz@lythampartners.com bkaplan@accuray.com Accuray Reports First Quarter Fiscal 2021 Financ
Joe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 889-9700 +1 (408) 789-4426 diaz@lythampartners.com bkaplan@accuray.com Accuray Reports First Quarter Fiscal 2021 Financial Results SUNNYVALE, Calif., October 29, 2020 - Accuray
Read more →ARAYAccuray Announces Agreement with Brainlab to Expand CyberKnife® Platform Treatment Capabilities for the Neuro-Radiosurgery Market
SUNNYVALE, Calif., Oct. 28, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a pioneer in the robotic stereotactic radiosurgery (SRS) field announced today a collaboration with Brainlab, a Munich, Germany based market leader in digital surgery and precision radiotherapy
Read more →ARAYAccuray Appoints Mike Leischer Vice President and General Manager, Americas Region
SUNNYVALE, Calif., Oct. 19, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed Mike Leischer as its vice president and general manager, Americas (AMS) region, effective immediately. In this role, he will provide leadership of the AMS region
Read more →ARAYAccuray To Report First Quarter Fiscal 2021 Financial Results on October 29, 2020
SUNNYVALE, Calif., Oct. 15, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2021, ended September 30, 2020, after the market close on Thursday, October 29, 2020. Management will host a conference call to
Read more →ARAYAccuray to Host ASTRO Analyst & Investor Meeting on October 26, 2020
SUNNYVALE, Calif., Oct. 13, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will host an Analyst & Investor Meeting on Monday, October 26th, 2020 in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting. Prese
Read more →ARAYAccuray Radixact® System with Synchrony® Technology Delivers Advanced Cancer Treatments at Multiple Hospitals in Japan
SUNNYVALE, Calif., Sept. 17, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that leading hospitals in Japan are using the Radixact® System with the Synchrony® Automatic, Real-time Motion Synchronization Technology1 to provide advanced cancer treatments t
Read more →ARAYAccuray to Present at Lake Street Capital Markets
SUNNYVALE, Calif., Sept. 10, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Joshua H. Levine, president and chief executive officer and Shig Hamamatsu, chief financial officer will present at the fourth annual Lake Street Capital Markets Best Ideas
Read more →ARAYUniversity Hospital Città della Salute e della Scienza, Turin, Italy is First in EIMEA to Treat Cancer Patients Using the Accuray Radixact® System with Synchrony® Technology
SUNNYVALE, Calif., Sept. 1, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the medical care team at University Hospital Città della Salute e della Scienza, in Turin, Italy have treated the first cancer patients in the Europe, India, Middle East and
Read more →ARAYJoe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 889-9700 +1 (408) 789-4426 diaz@lythampartners.com bkaplan@accuray.com Accuray Reports Fourth Quarter and Fiscal 2020 F
Joe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 889-9700 +1 (408) 789-4426 diaz@lythampartners.com bkaplan@accuray.com Accuray Reports Fourth Quarter and Fiscal 2020 Financial Results SUNNYVALE, Calif., August 13, 2020 - Accu
Read more →ARAYAccuray Reports Fourth Quarter and Fiscal 2020 Financial Results
SUNNYVALE, Calif., Aug. 13, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2020. Q4 Fiscal 2020 and Recent Operating Highlights Gross orders of $94.3 million, including 8 orders fro
Read more →ARAYincluding new product offerings; the c ompany's ability to effectively integrate and execute its China joint venture strategy ; risks and uncertainties related to future Type A and B license announcements in China; risks
Anne B. Le Grand Joins Accuray Board of Directors SUNNYVALE, Calif., July 22, 2020 - Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Anne B. Le Grand to the company's Board of Directors, effective as of July 16, 2020. In addition, she will serve on the Boa
Read more →ARAYAnne B. Le Grand Joins Accuray Board of Directors
SUNNYVALE, Calif., July 22, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Anne B. Le Grand to the company's Board of Directors, effective as of July 16, 2020. In addition, she will serve on the Board's Nominating and Corporate Governa
Read more →ARAYAccuray To Report Fiscal Year-end 2020 Financial Results on August 13, 2020
SUNNYVALE, Calif., July 16, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and the 2020 fiscal year, ended June 30, 2020 after the market close on Thursday, August 13, 2020. Management will host a conference call to r
Read more →ARAYAccuray Launches New CyberKnife® S7™ System
SUNNYVALE, Calif., June 17, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has launched the CyberKnife® S7™ System, an innovative device combining speed, advanced precision, and real-time artificial intelligence (AI)-driven motion tracking an
Read more →ARAYAccuray Synchrony® Real-time Adaptive Technology for the Radixact® System Wins 2020 MedTech Breakthrough Award
SUNNYVALE, Calif., May 19, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology
Read more →ARAYJoe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 889-9700 +1 (408) 789-4426 diaz@lythampartners.com bkaplan@accuray.com Accuray Reports Fiscal 2020 Third Quarter Financ
Joe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 889-9700 +1 (408) 789-4426 diaz@lythampartners.com bkaplan@accuray.com Accuray Reports Fiscal 2020 Third Quarter Financial Results SUNNYVALE, Calif., April 28, 2020 - Accuray In
Read more →ARAYAccuray Reports Fiscal 2020 Third Quarter Financial Results
SUNNYVALE, Calif., April 28, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the third quarter of fiscal 2020 ended March 31, 2020. Recent Company Highlights Gross orders increased 27% year-over-year to $106.0 million, including
Read more →ARAYAccuray To Report Fiscal 2020 Third Quarter Financial Results on April 28, 2020
SUNNYVALE, Calif., April 16, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2020 on Tuesday, April 28, 2020 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:3
Read more →ARAYFirst Accuray CyberKnife® M6™ System Installed in Missouri at Mercy Hospital St. Louis
SUNNYVALE, Calif., Feb. 25, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife® M6™ System in Missouri at their
Read more →ARAYStudies Support Use of the Accuray TomoTherapy® System for Advanced Rectal Cancer to Improve Treatment Efficacy and Reduce Side Effects
SUNNYVALE, Calif., Feb. 5, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that two new studies demonstrate the benefits of the TomoTherapy® System in the treatment of advanced rectal cancer. Radiotherapy, with or without chemotherapy, followed by surgery
Read more →ARAYJoe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 889-9700 +1 (408) 789-4426 diaz@lythampartners.com bkaplan@accuray.com Accuray Reports Fiscal 2020 Second Quarter Finan
Joe Diaz Beth Kaplan Investor Relations, Lytham Partners Public Relations Director, Accuray +1 (602) 889-9700 +1 (408) 789-4426 diaz@lythampartners.com bkaplan@accuray.com Accuray Reports Fiscal 2020 Second Quarter Financial Results SUNNYVALE, Calif., January 28, 2020 - Accuray
Read more →ARAYAccuray Reports Fiscal 2020 Second Quarter Financial Results
SUNNYVALE, Calif., Jan. 28, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the second quarter of fiscal 2020 ended December 31, 2019. Recent Company Highlights Gross orders of $98.6 million, including 11 orders from China Net
Read more →ARAYAccuray To Report Fiscal 2020 Second Quarter Financial Results on January 28, 2020
SUNNYVALE, Calif., Jan. 16, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its second quarter ended December 31, 2019 on Tuesday, January 28, 2020 after the market close. Management will host a conference call to review the results at 1:30 p.m. P
Read more →ARAYAccuray To Discuss Revenue Growth Expectations for the Next Three Fiscal Years at the JP Morgan Healthcare Conference Company to present on Wednesday
Accuray To Discuss Revenue Growth Expectations for the Next Three Fiscal Years at the JP Morgan Healthcare Conference Company to present on Wednesday, January 15, 2020 at 10 am PT / 1 pm ET Sunnyvale, Calif. - January 13, 2020 - Accuray Incorporated (Nasdaq: ARAY) will be dis
Read more →ARAYAccuray To Discuss Revenue Growth Expectations for the Next Three Fiscal Years at the JP Morgan Healthcare Conference
SUNNYVALE, Calif., Jan. 13, 2020 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) will be discussing its business and revenue growth expectations for the next three fiscal years at the JP Morgan Healthcare Conference on Wednesday, January 15, 2020 at 10:00 am PACIFIC / 1:00 pm
Read more →ARAYAccuray CyberKnife® System Provides Excellent Disease Control for Men with Recurrent Prostate Cancer, a Medical Condition with Few Viable Treatment Options
SUNNYVALE, Calif., Jan. 8, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective study which showed that at five years, stereotactic body radiation therapy (SBRT) administered with the CyberKnife® System provided excellent disease contro
Read more →ARAYAccuray to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 15, 2020
SUNNYVALE, Calif., Jan. 6, 2020 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Joshua H. Levine, president and chief executive officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 10:00 a.m. PT. Th
Read more →ARAYTimpanogos Cancer Services First in Utah to Offer Precise and Accurate Radiation Treatments with the Accuray Radixact® System
SUNNYVALE, Calif., Dec. 12, 2019 /PRNewswire/ -- Timpanogos Cancer Services made history in Utah recently with the installation of the state's first Radixact® System, the next-generation TomoTherapy® platform. Accuray Incorporated's (NASDAQ: ARAY) Radixact System is one of the mo
Read more →ARAYStanford University Medical Center to Acquire Second Accuray CyberKnife® M6™ System
SUNNYVALE, Calif., Dec. 4, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Stanford University Medical Center has selected a second CyberKnife® M6™ System to expand access to precise radiosurgery treatments to more of their patients. With its install
Read more →ARAYAccuray Reports Fiscal 2020 First Quarter Financial Results
SUNNYVALE, Calif., Oct. 29, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2020 ended September 30, 2019. Recent Company Highlights Gross orders increased 28 percent year over year to $78.5 million
Read more →ARAYMichael Polyviou Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (732) 933-2754 +1 (408) 789-4426 mpolyviou@evcgroup.com bkaplan@accuray.com Accuray Reports Fiscal 2020 First Quarter Finan
Michael Polyviou Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (732) 933-2754 +1 (408) 789-4426 mpolyviou@evcgroup.com bkaplan@accuray.com Accuray Reports Fiscal 2020 First Quarter Financial Results SUNNYVALE, Calif., October 29, 2019 - Accuray
Read more →ARAYFirst Asia-Pacific hospital treats patients with RayStation and Radixact
SUNNYVALE, Calif., Oct. 28, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) – Thailand's Lopburi Cancer Hospital, a center of excellence for cancer treatment, is the first in the Asia-Pacific region to clinically use the combination of RaySearch's treatment planning syst
Read more →ARAYAccuray Appoints Medtech Veteran Suzanne Winter as Chief Commercial Officer
Accuray Appoints Medtech Veteran Suzanne Winter as Chief Commercial Officer SUNNYVALE, Calif., October 21, 2019 -- Accuray Incorporated (Nasdaq: ARAY) announced today that Suzanne Winter has joined the company as Senior Vice President, Chief Commercial Officer effective October
Read more →ARAYAccuray To Report Fiscal 2020 First Quarter Financial Results on October 29, 2019
SUNNYVALE, Calif., Oct. 10, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2019 on Tuesday, October 29, 2019 after the market close. Management will host a conference call to review the results at 1:30 p.m. P
Read more →ARAYAccuray Educates Radiation Oncology Practices on the Potential Impact of the Proposed Alternative Payment Model (RO-APM)
SUNNYVALE, Calif., Sept. 19, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today published an informational guide designed to help radiation oncology practices understand the complexities of the much-anticipated proposed Medicare & Medicaid reimbursement changes. The n
Read more →ARAYData Published in The Lancet Oncology Suggest CyberKnife® Prostate Patients Experienced Lower Levels of Acute Genitourinary Toxicity (Grade 2 or Higher) Than Patients Treated on a Conventional Linear Accelerator
SUNNYVALE, Calif., Sept. 17, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announces that The Lancet Oncology, a high impact and leading global peer-reviewed oncology journal, has published patient- and clinician-reported outcomes data from the PACE — Prostate Advances
Read more →ARAYChina Announces Tariff Exclusion for Medical Linear Accelerators
China Announces Tariff Exclusion for Medical Linear Accelerators SUNNYVALE, Calif., September 16, 2019 Accuray Incorporated (NASDAQ: ARAY) announced that, on September 11, 2019, China s Customs Tariff Commission of the State Council issued a tariff exemption for medical linear
Read more →ARAYAccuray Appoints Healthcare Veteran James M. Hindman to Board of Directors
SUNNYVALE, Calif., Sept. 12, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) strengthened its Board of Directors with the appointment of James (Jim) M. Hindman, effective as of September 6, 2019, and expanding the company's Board to nine members. Mr. Hindman, an experien
Read more →ARAYGeisinger Medical Center is First in Pennsylvania to Treat Cancer Patients with Accuray Radixact® System
SUNNYVALE, Calif., Sept. 10, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Geisinger Medical Center radiation oncology team is first in Pennsylvania to treat cancer patients with the innovative Radixact® System. The hospital, located in Danvill
Read more →ARAYAccuray to Set ASTRO 2019 in Motion with Patient-first Cancer Treatment Innovations
SUNNYVALE, Calif., Sept. 5, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that it will showcase its industry-leading motion-synchronization cancer treatment technologies at the upcoming American Society for Radiation Oncology (ASTRO) Annual Meeting taki
Read more →ARAYAccuray to Host ASTRO Investor Meeting on September 16, 2019
SUNNYVALE, Calif., Sept. 4, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will host an Investor Meeting during the American Society of Radiation Oncology (ASTRO) Annual Meeting, being held in Chicago, IL. The presentations will commence
Read more →ARAYsuch other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K , filed with the Securities and Exchange Commission (the "SEC") on
Accuray Appoints Healthcare Veteran James M. Hindman to Board of Directors SUNNYVALE, Calif., September 12, 2019 - Accuray Incorporated (NASDAQ: ARAY) strengthened its Board of Directors with the appointment of James (Jim) M. Hindman, effective as of September 6, 2019, and expan
Read more →ARAYFroedtert & the Medical College of Wisconsin Cancer Network is First in the World to Treat Cancer Patient Using the Accuray Radixact® System with Synchrony® Motion Tracking and Correction Technology
SUNNYVALE, Calif., Aug. 21, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that physicians at the Froedtert & the Medical College of Wisconsin ("MCW") Clinical Cancer Center at Froedtert Hospital in Milwaukee, Wisconsin have treated the first cancer pati
Read more →ARAYMichael Polyviou Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (732) 933-2755 +1 (408) 789-4426 mpolyviou@evcgroup.com bkaplan@accuray.com Accuray Reports Fourth Quarter and Fiscal 2019
Michael Polyviou Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (732) 933-2755 +1 (408) 789-4426 mpolyviou@evcgroup.com bkaplan@accuray.com Accuray Reports Fourth Quarter and Fiscal 2019 Financial Results SUNNYVALE, Calif., August 15, 2019 - Acc
Read more →ARAYAccuray Reports Fourth Quarter and Fiscal 2019 Financial Results
SUNNYVALE, Calif., Aug. 15, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2019. Q4 Fiscal 2019 and Recent Operating Highlights Revenue increased 3 percent to $117.4 million, the hi
Read more →ARAYNew Data Demonstrating Benefits of Accuray Software Solutions Presented at the Annual Meeting of the American Association of Physicists in Medicine
SUNNYVALE, Calif., July 24, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies validating the benefits of CyberKnife® and Radixact® System software innovations were shared by prominent physicists at the recent 61st annual meeting of the American
Read more →ARAYAccuray Provides Update on China Joint Venture Operational Progress
SUNNYVALE, Calif., July 23, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today provided an update on the operational progress of its China joint venture, CNNC Accuray (Tianjin) Medical Technology Co., Ltd (CNNC Accuray). CNNC Accuray has received the Radiation Safety
Read more →ARAYAccuray To Report Fiscal 2019 Fourth Quarter and Full Year Financial Results on August 15, 2019
SUNNYVALE, Calif., July 19, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2019 ended June 30, 2019 on Thursday, August 15, 2019 after the market close. Management will host a conference call to review the resul
Read more →ARAYSwiss Medical Network Advances Cancer Care in Switzerland with Multi-System Agreement for Accuray Radiation Therapy Systems and RaySearch Oncology Software Systems
SUNNYVALE, Calif., July 18, 2019 PRNewswire/ -- The Swiss Medical Network, one of Switzerland's two largest private hospital groups, has signed a multi-system, multi-clinic agreement to purchase Accuray Incorporated's radiation therapy delivery systems as well as RaySearch's trea
Read more →ARAYHong Kong Sanatorium & Hospital Signs Agreement at ESTRO to Acquire the Synchrony® Motion Tracking and Correction Technology for the Accuray Radixact® System
SUNNYVALE, Calif., May 1, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has signed an agreement with Hong Kong Sanatorium & Hospital (HKSH) for the acquisition of two Synchrony® motion tracking and correction technology[1] upgrades, to
Read more →ARAYAccuray Launches Synchrony® Motion Tracking and Correction Technology for the Radixact® System
SUNNYVALE, Calif., April 24, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the launch of its Synchrony® motion tracking and correction technology1 to be used with the Radixact® System. This new feature adds intrafraction motion synchronization capabilit
Read more →ARAYDoug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Reports Fiscal 2019 Third Quarter Results
Doug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Reports Fiscal 2019 Third Quarter Results SUNNYVALE, Calif., April 23, 2019 - Accuray Incorporated (NASDAQ
Read more →ARAYAccuray Reports Fiscal 2019 Third Quarter Results
SUNNYVALE, Calif., April 23, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the third quarter of fiscal 2019 ended March 31, 2019. Fiscal Third Quarter Highlights Gross orders increased 12 percent year over year to $83.6 millio
Read more →ARAYAccuray to Report Fiscal 2019 Third Quarter Financial Results on April 23, 2019
SUNNYVALE, Calif., April 2, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2019 on Tuesday, April 23, 2019 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30
Read more →ARAYPhase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
SUNNYVALE, Calif., Feb. 22, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from an international, randomized, 38-center trial (PACE - Prostate Advances in Comparative Evidence) show that treatment with stereotactic body radiation therapy (SBRT)
Read more →ARAYPrimer Sistema Radixact® de Accuray instalado en América Latina en la Clínica El Rosario de Medellín (Colombia)
SUNNYVALE, California, 7 de febrero de 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) anunció hoy que los pacientes colombianos con cáncer pronto tendrán acceso a un tratamiento de vanguardia con la instalación del Sistema Radixact® [c212.net] en la Clínica El Rosario d
Read more →ARAYACCURAY AND CHINA ISOTOPE AND RADIATION CORPORATION ENTER JOINT VENTURE CONTRACT TO MANUFACTURE AND SELL RADIATION ONCOLOGY SYSTEMS IN CHINA Joint Venture Uniquely Positioned to Serve World's Largest Growth Market for Ra
ACCURAY AND CHINA ISOTOPE AND RADIATION CORPORATION ENTER JOINT VENTURE CONTRACT TO MANUFACTURE AND SELL RADIATION ONCOLOGY SYSTEMS IN CHINA Joint Venture Uniquely Positioned to Serve World's Largest Growth Market for Radiation Oncology Systems Conference Call Today at 6:00 a.m
Read more →ARAYDoug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Reports Fiscal 2019 Second Quarter Results
Doug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Reports Fiscal 2019 Second Quarter Results SUNNYVALE, Calif., January 22, 2019 - Accuray Incorporated (NAS
Read more →ARAYAccuray Reports Fiscal 2019 Second Quarter Results
SUNNYVALE, Calif., Jan. 22, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the second quarter of fiscal 2019 ended December 31, 2018. Fiscal Second Quarter Highlights Gross orders increased 29 percent year over year to a record
Read more →ARAYThe Urology Group Surpasses 1,600 Prostate Cancer Patients Treated with the Accuray CyberKnife® M6™ System
SUNNYVALE, Calif., Jan. 17, 2019 /PRNewswire/ -- According to the American Cancer Society, prostate cancer is the most common cancer in American men other than skin cancer. Accuray Incorporated (NASDAQ: ARAY) and The Urology Group (TUG) are partnering to recognize TUG's commitmen
Read more →ARAYAccuray To Report Fiscal 2019 Second Quarter Financial Results on January 22, 2019
SUNNYVALE, Calif., Jan. 8, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its second quarter ended December 31, 2018 on Tuesday, January 22, 2019 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT
Read more →ARAYAccuray to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
SUNNYVALE, Calif., Jan. 2, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will present at the J.P. Morgan 37th Annual Healthcare Conference on Wednesday, January 9, 2019 at the Westin St. Francis Hotel in San Francisco. Attendance at the
Read more →ARAYAccuray CyberKnife® System Treatment Delivery Times Up to 50 Percent Faster With Software Upgrade
SUNNYVALE, Calif., Dec. 6, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the new release of its Accuray Precision® Treatment Planning System (TPS) with the CyberKnife® VOLO™ Optimizer will enable CyberKnife System customers to significantly improve
Read more →ARAYAccuray Appoints Shig Hamamatsu Chief Financial Officer
Accuray Appoints Shig Hamamatsu Chief Financial Officer SUNNYVALE, Calif., November 19, 2018 - Accuray Incorporated (NASDAQ: ARAY) announced today that its Board of Directors has named Shig Hamamatsu as senior vice president, chief financial officer effective immediately. Mr. Ha
Read more →ARAYTodd Kehrli Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (310) 625-4462 +1 (408) 789-4426 tkehrli@evcgroup.com bkaplan@accuray.com Accuray Reports Fiscal 2019 First Quarter Financial Re
Todd Kehrli Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (310) 625-4462 +1 (408) 789-4426 tkehrli@evcgroup.com bkaplan@accuray.com Accuray Reports Fiscal 2019 First Quarter Financial Results SUNNYVALE, Calif., October 30, 2018 - Accuray Incorp
Read more →ARAYAccuray Reports Fiscal 2019 First Quarter Financial Results
SUNNYVALE, Calif., Oct. 30, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2019 ended September 30, 2018. China Ministry of Health confirms Type A and B quota and licenses Gross orders increased 10 p
Read more →ARAYAccuray Showcases Radiation Therapy Innovations Designed to Improve What
SUNNYVALE, Calif., Oct. 17, 2018 /PRNewswire/ -- Building on its heritage of patient-first innovation, at this year's ASTRO (American Society for Radiation Oncology) Annual Meeting, Accuray Incorporated (NASDAQ: ARAY) will showcase radiation therapy solutions designed to enable c
Read more →ARAYAccuray To Report Fiscal 2019 First Quarter Financial Results On October 30, 2018
SUNNYVALE, Calif., Oct. 11, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2018 on Tuesday, October 30, 2018 after the market close. Management will host a conference call to review the first quarter results
Read more →ARAYTechnische Universität München Hospital is First in Germany to Treat Cancer Patients with Accuray Radixact® System
SUNNYVALE, Calif., Oct. 9, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Klinikum rechts der Isar der Technischen Universität München (TUM) clinical team has treated the first cancer patients in Germany with the innovative Radixact® System. Thi
Read more →ARAYHCG is First in India to Treat Cancer Patients Using the Accuray Radixact® System
SUNNYVALE, Calif., Oct. 4, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the clinical team at Healthcare Global Enterprises (HCG) EKO, Kolkata, has treated the first patient in India using the Radixact® System. HCG EKO is part of Healthcare Global
Read more →ARAYLargest Prostate SBRT Studies to Date Show Accuray CyberKnife® System Provides Excellent Prostate Cancer Survival Rates in Five or Fewer Sessions
SUNNYVALE, Calif., Sept. 25, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that published data from two prospective, multi-center studies using differing protocols provide consistent results and reinforce the use of the CyberKnife® System for the effect
Read more →ARAYTodd Kehrli Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (310) 625-4462 +1 (408) 789-4426 tkehrli@evcgroup.com bkaplan@accuray.com Accuray Reports Fourth Quarter and Fiscal 2018 Financi
Todd Kehrli Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (310) 625-4462 +1 (408) 789-4426 tkehrli@evcgroup.com bkaplan@accuray.com Accuray Reports Fourth Quarter and Fiscal 2018 Financial Results SUNNYVALE, Calif., August 16, 2018 - Accuray In
Read more →ARAYAccuray Reports Fourth Quarter and Fiscal 2018 Financial Results
SUNNYVALE, Calif., Aug. 16, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2018. Q4 Fiscal 2018 and Recent Operating Highlights Gross orders increased 12 percent to $96.4 million R
Read more →ARAYAddenbrooke
Internationally Renowned Centre in Cambridge, England is First NHS Hospital to Install the Innovative Radiation Therapy System SUNNYVALE, California, July 25, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Addenbrooke's Hospital clinical team h
Read more →ARAYJoseph E. Whitters Appointed to Accuray Board of Directors
Joseph E. Whitters Appointed to Accuray Board of Directors SUNNYVALE, Calif., July 19, 2018 Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Joseph E. Whitters to the company s Board of Directors, effective as of July 16, 2018. In addition, he will serve o
Read more →ARAYAccuray To Report Fiscal 2018 Fourth Quarter And Full Year Financial Results On August 16, 2018
SUNNYVALE, Calif., July 19, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2018 ended June 30, 2018 on Thursday, August 16, 2018 after the market close. Management will host a conference call to review the fourt
Read more →ARAYAccuray Receives AERB Approval for Sale and Supply of its Radixact® X9 System in India
SUNNYVALE, Calif., June 21, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company has received an Atomic Energy Regulatory Board (AERB) Type Approval for its Radixact® X9 System in India. The AERB Type Approval indicates the device conforms to
Read more →ARAYNew Studies Show the Accuray TomoTherapy® System Provides Greater Precision, Excellent Clinical Outcomes in Patients Undergoing Total Body Irradiation
SUNNYVALE, Calif., May 30, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy® System in the delivery of total body irradiation (TBI), a procedure commonly used to
Read more →ARAYAccuray CyberKnife® Customer Achieves Top Score in Multiple Brain Metastases TROG 2018 Treatment Plan Study
SUNNYVALE, Calif., May 22, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Daniela Schmitt, PhD, a medical physicist at Heidelberg University Hospital, took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery (SR
Read more →ARAYAccuray Unveils New Company Website Reflecting Industry-Leading Patient-First Cancer Treatment Innovation and Care
SUNNYVALE, California, May 15, 2018 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today the unveiling of a new corporate website that reflects the company's evolution and leadership in patient-first cancer treatment innovations. The fully redesigned, modern site
Read more →ARAYMercy Advances Cancer Care in Missouri with Multi-System, Multi-Hospital Agreement for Accuray Radiation Therapy Systems
SUNNYVALE, Calif., May 9, 2018 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the company has signed a multi-system, multi-hospital agreement with Mercy for the acquisition of Accuray Radixact® and CyberKnife® M6™ Systems, building on a 13-year relations
Read more →ARAYDoug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Reports Third Fiscal Quarter Results
Doug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Reports Third Fiscal Quarter Results SUNNYVALE, Calif., April 30, 2018 - Accuray Incorporated (NASDAQ: ARA
Read more →ARAYSouth Florida Radiation Oncology Treats First Cancer Patients Using Its New CyberKnife® M6™ System
SUNNYVALE, Calif., April 24, 2018 /PRNewswire/ -- Accuray Incorporated's (NASDAQ: ARAY) CyberKnife® M6™ System with the InCise™ Multileaf Collimator (MLC) is enabling clinicians at South Florida Radiation Oncology's cancer center in Stuart, Florida to treat more patients on a dai
Read more →ARAYAccuray to Bring Patient-First Cancer Treatment Innovations to ESTRO 37
SUNNYVALE, Calif., April 17, 2018 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today it will be showcasing the benefits of its radiotherapy systems and software solutions at the 37th annual European Society for Radiotherapy and Oncology (ESTRO) meeting in Barcelo
Read more →ARAYAccuray To Report Fiscal 2018 Third Quarter Financial Results On April 30, 2018
SUNNYVALE, Calif., April 9, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2018 on Monday, April 30, 2018 after the market close, following the annual European Society for Radiotherapy and Oncology (ESTRO) meetin
Read more →ARAYApollo Hospitals in India to Acquire Two Accuray Radixact® Systems
SUNNYVALE, Calif., March 28, 2018 /PRNewswire/ -- Personalized, precise, radiation treatments will soon be available to more cancer patients in India. Accuray Incorporated (NASDAQ: ARAY) announced today that the company has signed an agreement with the Apollo Hospitals Group in C
Read more →ARAYErasmus MC Completes First Step in the Evolution of Online Adaptive Radiation Therapy With the CyberKnife® System
SUNNYVALE, California and ROTTERDAM, Netherlands, March 27, 2018 /PRNewswire/ -- New Clinical Trial Evaluates Use of Online-Adaptive Stereotactic Body Radiation Therapy Approach in the Treatment of Oligometastases Accuray Incorporated (NASDAQ: ARAY) and Erasmus MC, the largest
Read more →ARAYConférence Européenne AERO Academy d
SUNNYVALE, Californie, February 20, 2018 /PRNewswire/ -- La conférence 2018 Accuray s'est concentrée sur les approches innovantes permettant de faire progresser les soins délivrés aux patients : des traitements curatifs aux oligométastases en passant par les soins palliatifs Ac
Read more →ARAYAccuray's European AERO Academy Meeting: Innovation and Safety in the Field of Advanced Radiotherapy - Patients Come First 2018 Accuray Conference Focused on Innovative Approaches for Advancing Patient Care, from Curative Treatment to Oligometastases and Palliation...
SUNNYVALE, Caliornia, February 20, 2018 /PRNewswire/ -- 2018 Accuray Conference Focused on Innovative Approaches for Advancing Patient Care, from Curative Treatment to Oligometastases and Palliation Accuray Incorporated (NASDAQ: ARAY) announced today highlights from its 2018 Eu
Read more →ARAYAccuray to Present at the 2018 RBC Capital Markets Global Healthcare Conference on February 22, 2018
SUNNYVALE, Calif., Feb. 15, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will present at the 2018 RBC Capital Markets Global Healthcare Conference at the Lotte New York Palace Hotel in New York on Thursday, February 22, 2018. Attendanc
Read more →ARAYAccuray Retires February 2018 Convertible Notes Company Continues to Execute Strategies to Reduce Total Debt While Minimizing Shareholder Dilution
Accuray Retires February 2018 Convertible Notes Company Continues to Execute Strategies to Reduce Total Debt While Minimizing Shareholder Dilution SUNNYVALE, Calif., Feb. 5, 2018 Accuray Incorporated (NASDAQ: ARAY) announced today it has retired all February 2018 convertible no
Read more →ARAYAccuray Retires February 2018 Convertible Notes
SUNNYVALE, Calif., Feb. 5, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has retired all February 2018 convertible notes, including $13 million aggregate principal amount of its 3.50% convertible senior notes and $27 million aggregate principal amoun
Read more →ARAYStudy Shows CyberKnife® System Provides Long-Lasting Pain Relief for Trigeminal Neuralgia Patients
SUNNYVALE, Calif., Jan. 29, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a study of 138 patients with trigeminal neuralgia (TN) showed stereotactic radiosurgery (SRS) delivered with the CyberKnife® System resulted in rapid and long-lasti
Read more →ARAYDoug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Fiscal Second Quarter Revenue Exceeds $100 Milli
Doug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Fiscal Second Quarter Revenue Exceeds $100 Million and Increases 15 Percent Year-over-Year; Gross Orders of
Read more →ARAYAccuray Fiscal Second Quarter Revenue Exceeds $100 Million and Increases 15 Percent Year-over-Year; Gross Orders of $77.9 Million; Backlog Up 10 Percent
SUNNYVALE, Calif., Jan. 23, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second fiscal quarter ended December 31, 2017. Fiscal Second Quarter Highlights Revenue increased 15 percent year-over-year to $100.3 million driven by
Read more →ARAYBeverly A. Huss Joins Accuray Board of Directors
Beverly A. Huss Joins Accuray Board of Directors SUNNYVALE, Calif., January 11, 2018 Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Beverly A. Huss to the company s Board of Directors, effective January 7, 2018. Ms. Huss also currently serves on the board
Read more →ARAYAccuray To Report Fiscal 2018 Second Quarter Financial Results On January 23, 2018
SUNNYVALE, Calif., Jan. 10, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its second quarter ended December 31, 2017 on Tuesday, January 23, 2018 after the market close. Management will host a conference call to review the results at 1:30 p.m. P
Read more →ARAYth Annual J.P. Morgan Healthcare Conference
36th Annual J.P. Morgan Healthcare Conference January 10, 2018 Joshua H. Levine President and CEO Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements a
Read more →ARAYAccuray Elects Net Share Settlement for 3.50% Series A Convertible Senior Notes Due 2018 Company will pay principal in cash and deliver shares for any excess conversion value
Accuray Elects Net Share Settlement for 3.50% Series A Convertible Senior Notes Due 2018 Company will pay principal in cash and deliver shares for any excess conversion value SUNNYVALE, Calif., January 3, 2018 Accuray Incorporated (NASDAQ: ARAY) has made an irrevocable Net Shar
Read more →ARAYAccuray to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 10, 2018
SUNNYVALE, Calif., Jan. 3, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will present at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, January 10, 2018 at the Westin St. Francis Hotel in San Francisco. Attendance at th
Read more →ARAYAccuray Enters into $40 Million Term Loan; Company Intends to Retire Principal Amount of February 2018 Convertible Notes with Cash at Maturity Company Also Modifies Revolving Loan Agreement
Accuray Enters into $40 Million Term Loan; Company Intends to Retire Principal Amount of February 2018 Convertible Notes with Cash at Maturity Company Also Modifies Revolving Loan Agreement SUNNYVALE, Calif., December 21, 2017 Accuray Incorporated (NASDAQ: ARAY) announced today
Read more →ARAYFirst Hospitals in the World Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
SUNNYVALE, Calif., Dec. 14, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Heidelberg University Hospital in Heidelberg, Germany and Oscar Lambret Cancer Center in Lille, France are the first in the world to connect both their Accuray CyberKnife
Read more →ARAYAccuray Military Veterans Support U.S. Veteran Community
SUNNYVALE, Calif., Nov. 8, 2017 /PRNewswire/ -- November 11, 2017 marks Veterans Day in the United States, a day to publicly recognize and honor those people who have served, or are serving, in the Armed Services. Accuray Incorporated (NASDAQ: ARAY) employees who have aided their
Read more →ARAYTreatment Planning for the CyberKnife® System Now Up to 40% Faster
SUNNYVALE, Calif., Oct. 26, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the CyberKnife® System with the new Accuray Precision™ Treatment Planning System (TPS) enables clinicians to reduce treatment times, while advanced TPS features enhance workf
Read more →ARAYAccuray Generated $55.6 Million in First Quarter Gross Orders; Revenue Increased 5 Percent Year over Year
SUNNYVALE, Calif., Oct. 24, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first fiscal quarter ended September 30, 2017. First Quarter Highlights Gross orders increased 11 percent to $55.6 million, net orders were $51.0 millio
Read more →ARAYDoug Sherk Investor Relations, EVC Group +1 (415) 652-9100 dsherk@evcgroup.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Generated $55.6 Million in First Quarter Gross O
Accuray Generated $55.6 Million in First Quarter Gross Orders; Revenue Increased 5 Percent Year over Year SUNNYVALE, Calif., October 24, 2017 Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first fiscal quarter ended September 30, 2017. First Quart
Read more →ARAYEuropean Court of Appeal Rejects Varian
SUNNYVALE, Calif., Oct. 19, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accuray TomoTherapy® System by University Hospital of Tours
Read more →ARAYAccuray To Report Fiscal 2018 First Quarter Financial Results On October 24, 2017
SUNNYVALE, Calif., Oct. 10, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2017 on Tuesday, October 24, 2017 after the market close. Management will host a conference call to review the results at 1:30 p.m. P
Read more →ARAYAccuray Incorporated Reports Inducement Grant Under NASDAQ Listing Rules
SUNNYVALE, Calif., Oct. 4, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, an equity inducement award to Shig Hamamatsu, the company's new VP, Finance & Chief Accounting Officer. As a material inducement to Mr. Ha
Read more →ARAY10-year Data Shows CyberKnife® System Provides Excellent Long-term Control of Low-Risk Prostate Cancer
SUNNYVALE, Calif., Sept. 26, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent had local disease control 10 years after receiving stereotactic body radiation the
Read more →ARAYAccuray Showcases CyberKnife® and Radixact™ Systems at ASTRO 2017
SUNNYVALE, Calif., Sept. 20, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data and first-hand experience with its advanced CyberKnife® and Radixact™ Systems, and unique software solutions, will be shared by leading radiation oncology practitioners
Read more →ARAYAccuray Reports Fourth Quarter and Fiscal 2017 Financial Results
SUNNYVALE, Calif., Aug. 22, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2017. Q4 Fiscal 2017 and Recent Highlights Gross orders of $85.7 million driven by strong demand from both
Read more →ARAYDoug Sherk Investor Relations, EVC Group +1 (415) 652-9100 dsherk@evcgroup.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Reports Fourth Quarter and Fiscal 2017 Financial
Accuray Reports Fourth Quarter and Fiscal 2017 Financial Results SUNNYVALE, Calif., August 22, 2017 Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2017. Q4 Fiscal 2017 and Recent Highlights Gross order
Read more →ARAYAccuray To Report Fiscal 2017 Fourth Quarter And Full Year Results On August 22, 2017
SUNNYVALE, Calif., Aug. 14, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2017 ended June 30, 2017 on Tuesday, August 22, 2017 after the market close. Management will host a conference call to review the result
Read more →ARAYFirst Radixact™ System Research Results Presented at the American Association of Physicists in Medicine Annual Meeting
SUNNYVALE, Calif., Aug. 4, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the first studies validating the benefits of the leading-edge Radixact™ System were presented at the 59th Annual Meeting of the American Association of Physicists in Medicine
Read more →ARAYAccuray Receives 510(k) Clearance for iDMS™ Data Management System Upgrade for the TomoTherapy® System
SUNNYVALE, Calif., July 31, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its iDMS™ Data Management System, enabling its use with the Company's TomoTherapy® platform.
Read more →ARAYCONFIDENTIAL 07.27.17 Accuray Enhances Capital Structure Through Convertible Debt Transactions Transactions Facilitate Reduction of Short-term Debt and Potential Dilution to Shareholders
Enhances Capital Structure Through Convertible Debt Transactions Facilitate Reduction of Short-term Debt and Potential Dilution to Shareholders Calif., July 28, 2017 - Accuray Incorporated (NASDAQ: ARAY) has entered into privately negotiated agreements with a limited number of
Read more →ARAYAccuray Enhances Capital Structure Through Convertible Debt Transactions
SUNNYVALE, Calif., July 28, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) has entered into privately negotiated agreements with a limited number of existing holders of the company's outstanding convertible notes to exchange an aggregate of approximately $47 million pri
Read more →ARAYNew Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
SUNNYVALE, Calif., July 20, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that a prospective study conducted at 14 French centers showed the clinical benefits of intensity-modulated radiation therapy (IMRT) delivered using the TomoTherapy® System over v
Read more →ARAYAccuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results Q4 Revenue Expected to be Approximately $111.5-$112 Million and Q4 Gross Orders Expected to be Approximately $86 Million; Accuray Expects to Finis
Accuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results Q4 Revenue Expected to be Approximately $111.5-$112 Million and Q4 Gross Orders Expected to be Approximately $86 Million; Accuray Expects to Finish Fiscal Year with Approximately $108 Million in Cash, Cas
Read more →ARAYNeuro Spinal Hospital in Dubai to Acquire Accuray CyberKnife® and Radixact™ Systems
SUNNYVALE, Calif., July 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding access to its products in the Middle East with the signing of an agreement with the Neuro Spinal Hospital (NSH) in Dubai, United Arab Emirates, for the ac
Read more →ARAYMontefiore is First in NY Metropolitan Area to Treat Cancer Patients with Accuray Radixact™ System
SUNNYVALE, Calif. and NEW YORK, June 27, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS), announced today that Montefiore doctors have treated the first cancer patients in
Read more →ARAYIUCT Oncopole Advances Cancer Care in France with the New Accuray Radixact™ System
SUNNYVALE, Calif., June 20, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) is providing advanced radiation treatments to cancer patients using the uniquely smart Radixact™ Treatmen
Read more →ARAYAnova Marks 1,500th Prostate Cancer Patient Treated with the Accuray CyberKnife® System
SUNNYVALE, Calif., June 16, 2017 /PRNewswire/ -- In honor of Father's Day, Accuray Incorporated (NASDAQ: ARAY) joins Anova Cancer Care in recognizing the center's commitment to providing the most advanced treatments available to men with prostate cancer, many of whom are fathers.
Read more →ARAYAccuray Enters into New Revolving Loan Agreement New Loan Expected to Reduce Interest Costs by Approximately $2.0 Million Annually
Accuray Enters into New Revolving Loan Agreement New Loan Expected to Reduce Interest Costs by Approximately $2.0 Million Annually SUNNYVALE, Calif., June 15, 2017 Accuray Incorporated (NASDAQ: ARAY) announced today it has closed a new $52 million senior secured revolving loan
Read more →ARAYAccuray Enters into New Revolving Loan Agreement
SUNNYVALE, Calif., June 15, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has closed a new $52 million senior secured revolving loan facility with MidCap Financial Trust. The net proceeds of the facility, in addition to cash on hand were used to reti
Read more →ARAYAccuray Appoints Stan Gee VP of Revenue Management
SUNNYVALE, Calif., May 24, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed, Stan Gee, who has been with Accuray for over eight years, to the newly created Vice President of Revenue Management position reporting to Kevin Waters, Chief Fina
Read more →ARAYNew Data Presented at ESTRO 36 Reinforce Unmatched Versatility and Precision of the CyberKnife® System
SUNNYVALE, Calif., May 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies on the clinical use of the leading-edge CyberKnife® System continue to demonstrate its benefits across a wide range of cancer indications and stages in the cancer trea
Read more →ARAYNew Data Reinforce Benefits of TomoTherapy® Platform for Mainstream Radiation Therapy Treatment Indications
SUNNYVALE, Calif., May 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies continue to demonstrate the unmatched flexibility of the cutting-edge TomoTherapy® System to treat, with precision and efficiency, a wide variety of indications of all
Read more →ARAYAccuray to Showcase CyberKnife® and Radixact™ Systems at ESTRO 2017
SUNNYVALE, Calif., May 3, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will highlight its portfolio of radiation therapy delivery systems and software solutions at the annual European Society for Radiotherapy and Oncology (ESTRO) meeti
Read more →ARAYCyberKnife® System Provides Effective Treatment Option with Minimal Side Effects and Excellent Cosmesis for Early Stage Breast Cancer Patients
SUNNYVALE, Calif., May 2, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today preliminary results from a prospective, phase I clinical trial evaluating adjuvant stereotactic partial breast irradiation (S-PBI) in early stage breast cancer patients treated with
Read more →ARAYAccuray Names Lionel Hadjadjeba Chief Commercial Officer
SUNNYVALE, Calif., April 27, 2017 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today reported the appointment of Lionel Hadjadjeba as senior vice president, chief commercial officer effective immediately. The chief commercial officer position will provide a high level of f
Read more →ARAYAccuray Third Quarter Gross Orders Increase 49% YoY; Backlog Up 21%
SUNNYVALE, Calif., April 27, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third fiscal quarter and nine months ended March 31, 2017. Fiscal Third Quarter Highlights Ending backlog increased 21 percent year-over-year to $450.0
Read more →ARAYDoug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Third Quarter Gross Orders Increase 49% YoY; Bac
Doug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Third Quarter Gross Orders Increase 49% YoY; Backlog Up 21% SUNNYVALE, Calif., April 27, 2017 Accuray Inco
Read more →ARAYAccuray To Report Fiscal 2017 Third Quarter Financial Results On April 27, 2017
SUNNYVALE, Calif., April 13, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fiscal third quarter ended March 31, 2017 on Thursday, April 27, 2017 after the market close. Management will host a conference call to review the results at 1:30 p.m
Read more →ARAYAccuray 2017 Regional AERO Summit Brings Together Leading Oncology Specialists to Advance Cancer Patient Care
SUNNYVALE, Calif., April 12, 2017 /PRNewswire/ -- Renowned radiation oncologists, physicists, therapists and administrators from around the world joined together at the Accuray Exchange in Radiation Oncology (AERO™) Users' Summit to discuss best practices and further collaboratio
Read more →ARAYFirst Cancer Patients in Africa Treated with the TomoTherapy® System
SUNNYVALE, Calif., April 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the newly built Radiotherapy and Medical Oncology Center of Sidi Abdellah, Algeria is now treating cancer patients with the first TomoTherapy® Systems installed in Africa. T
Read more →ARAYAccuray Launches New Cancer Patient Websites
SUNNYVALE, Calif., March 2, 2017 /PRNewswire/ -- The Internet is one of the first places patients turn to for healthcare information after receiving a cancer diagnosis, according to the American Cancer Society. Accuray Incorporated (NASDAQ: ARAY) is launching www.cyberknife.com a
Read more →ARAYAccuray to Present at Cowen and Company 37th Annual Healthcare Conference on March 6, 2017
SUNNYVALE, Calif., Feb. 21, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), announced today that the Company will present at Cowen and Company's 37th Annual Healthcare Conference in Boston on Monday, March 6, 2017. Accuray's fireside chat with analyst Joshua Jennings,
Read more →ARAYCyberKnife® System Provides Long-term Disease Control for Prostate Cancer Patients
SUNNYVALE, Calif., Feb. 16, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective, Phase II, 17-center study which showed that treatment with the CyberKnife® System for low- and intermediate-risk prostate cancer provides excellent long-t
Read more →ARAYAccuray to Participate in the 2017 RBC Capital Markets Healthcare Conference on February 22, 2017
SUNNYVALE, Calif., Feb. 13, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), announced today that Kevin Waters, Senior Vice President and Chief Financial Officer, is scheduled to meet with investors one-on-one at the 2017 RBC Capital Markets Healthcare Conference in New
Read more →ARAYThe Accuray Radixact™ System Receives Shonin Approval
SUNNYVALE, Calif., Feb. 8, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its Radixact™ Treatment Delivery System, Accuray Precision™ Treatment
Read more →ARAYAccuray Grows Second Quarter Gross Orders 17%; Backlog Up 16% YoY
SUNNYVALE, Calif., Jan. 31, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2016. Fiscal Second Quarter Highlights Ending backlog increased 16 percent year-over-year to $4
Read more →ARAYDoug Sherk Investor Relations, EVC Group +1 (415) 652-9100 dsherk@evcgroup.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Grows Second Quarter Gross Orders 17%; Backlog U
Accuray Grows Second Quarter Gross Orders 17%; Backlog Up 16% YoY SUNNYVALE, Calif., January 31, 2017 Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2016. Fiscal Second Quarter Highlights En
Read more →ARAYMiami Cancer Institute Treats First Cancer Patients with the Accuray Radixact™ System
SUNNYVALE, Calif., Jan. 26, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Miami Cancer Institute, a part of Baptist Health South Florida, is now treating patients using the new, uniquely "smart" Radixact™ Treatment Delivery System, fully integrated
Read more →ARAYAccuray Continues to Set the Industry Standard for Customer Satisfaction
SUNNYVALE, Calif., Jan. 19, 2017 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that its CyberKnife® and TomoTherapy® Systems continue to set the bar for excellence in customer satisfaction. The Accuray systems received the highest composite overall user sati
Read more →ARAYAccuray To Report Fiscal 2017 Second Quarter Financial Results On January 31, 2017
SUNNYVALE, Calif., Jan. 17, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fiscal second quarter ended December 31, 2016 on Tuesday, January 31, 2017 after the market close. Management will host a conference call to review the results at 1:30
Read more →ARAYth Annual JP Morgan Healthcare Conference
35th Annual JP Morgan Healthcare Conference January 11, 2017 Josh Levine President and Chief Executive Officer Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking
Read more →ARAYAccuray to Present at JP Morgan
SUNNYVALE, Calif., Jan. 10, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will present at JP Morgan's 35th Annual Healthcare Conference on Wednesday, January 11, 2017 at the Westin St. Francis Hotel in San Francisco. Accuray's presenta
Read more →ARAYHong Kong Sanatorium & Hospital to Acquire Three RadixactTM Systems
SUNNYVALE, Calif., Dec. 21, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) has signed an agreement with Hong Kong Sanatorium & Hospital (HKSH) for the acquisition of three RadixactTM Systems that will provide clinicians and their patients with access to the newest advan
Read more →ARAYFirst Cancer Patients in the World Treated with the Smart, New Accuray Radixact™ System
SUNNYVALE, Calif., Dec. 8, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that leading hospitals in Europe and the United States are now treating patients with the new Radixact™ Treatment Delivery System, fully integrated with the new Accuray Precision™
Read more →ARAYAccuray to Participate in the Citi 2016 Global Healthcare Conference
SUNNYVALE, Calif., Nov. 21, 2016 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that it will participate in the Citi 2016 Global Healthcare Conference on Thursday, December 8, 2016 in New York City. Kevin Waters, Senior Vice President and Chief Financial Off
Read more →ARAYAccuray Reports Financial Results for First Quarter and Affirms Full Year Fiscal 2017 Guidance
SUNNYVALE, Calif., Oct. 27, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the 2017 fiscal first quarter ended September 30, 2016. "With our first quarter results we remain well-positioned to drive growth for both orders and revenue
Read more →ARAYDoug Sherk Investor Relations, EVC Group +1 (415) 652-9100 dsherk@evcgroup.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Reports Financial Results for First Quarter and
Accuray Reports Financial Results for First Quarter and Affirms Full Year Fiscal 2017 Guidance SUNNYVALE, Calif., October 27, 2016 Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the 2017 fiscal first quarter ended September 30, 2016. With our first qua
Read more →ARAYAccuray To Report Fiscal 2017 First Quarter Financial Results On October 27, 2016
SUNNYVALE, Calif., Oct. 6, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fiscal first quarter ended September 30, 2016 on Thursday, October 27, 2016 after the market close. Management will host a conference call to review the results at 1:30
Read more →ARAYProspective, Multi-Institutional Study Shows Five Treatments with the CyberKnife® System Provide Excellent Disease Control for Prostate Cancer Patients
SUNNYVALE, Calif., Sept. 27, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, 21 center study showed 97 percent of low- and intermediate-risk prostate cancer patients had excellent cancer control five years after receiving ste
Read more →ARAYAccuray to Unveil New Technology at the ASTRO 2016 Annual Meeting
SUNNYVALE, Calif., Sept. 22, 2016 /PRNewswire/ -- New data on the Accuray (NASDAQ: ARAY) CyberKnife® and TomoTherapy® Systems will be shared by leading radiation oncology practitioners, and the Company's new, innovative radiation therapy treatment delivery system, the Radixact™ S
Read more →ARAYAccuray to Participate in the Morgan Stanley Global Healthcare Conference 2016
SUNNYVALE, Calif., Sept. 6, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), announced today that Joshua H. Levine, President and Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 14, 2
Read more →ARAYAccuray Reports Fourth Quarter and Fiscal 2016 Financial Results
SUNNYVALE, Calif., Aug. 17, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2016. Q4 Fiscal 2016 Highlights Gross orders increased 12 percent over the prior year period to $95.4 mill
Read more →ARAYDoug Sherk Investor Relations, EVC Group +1 (415) 652-9100 dsherk@evcgroup.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Reports Fourth Quarter and Fiscal 2016 Financial
Accuray Reports Fourth Quarter and Fiscal 2016 Financial Results Achieves Record Backlog of $405.9 Million as Q4 Gross Orders Increase 12 Percent Announces Fiscal 2017 Guidance SUNNYVALE, Calif., August 17, 2016 Accuray Incorporated (NASDAQ: ARAY) today reported financial resu
Read more →ARAYAccuray CE Marks its New Radixact™ System
SUNNYVALE, Calif., Aug. 9, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that it has CE marked its Radixact™ Treatment Delivery System, Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. The next generation hardware and softw
Read more →ARAYAccuray Retires Remaining 3.75% Convertible Debt
SUNNYVALE, Calif., Aug. 2, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the Company has settled the remaining principal amount and accrued interest thereon of the 3.75% Convertible Senior Notes (the "2016 Notes"). The 2016 Notes were settled on August
Read more →ARAYTomoTherapy® System Provides Favorable Cosmetic Outcomes Without Compromising Efficacy in Low-Risk Breast Cancer Patients
SUNNYVALE, Calif., July 21, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today preliminary results from a prospective, phase II trial evaluating once-daily accelerated partial breast irradiation (APBI) in patients treated with the TomoTherapy® System. The st
Read more →ARAYAccuray Products Continue to Receive Highest Composite User Satisfaction Ratings in Latest MD Buyline Report
SUNNYVALE, Calif., July 14, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its CyberKnife® and TomoTherapy® Systems continue to set the standard for overall user satisfaction. The Accuray systems received the highest composite overall user satisfact
Read more →ARAYAccuray To Report Fiscal 2016 Fourth Quarter And Full Year Results On August 17, 2016
SUNNYVALE, Calif., July 7, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fiscal fourth quarter and full year ended June 30, 2016 on Wednesday, August 17, 2016 after the market close. Management will host a conference call to review the resul
Read more →ARAYAccuray Receives 510(k) FDA Clearance for the Radixact™ Image-Guided Radiation Therapy Platform and Integrated Software
SUNNYVALE, Calif., June 27, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radixact™ Treatment Delivery Platform. Accuray also received 510(k) clearance for its new
Read more →ARAYFUCAM Treats 1,000 Breast Cancer Patients with the TomoTherapy® System
SUNNYVALE, Calif., June 21, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Fundación de Cancer de Mama in México City (FUCAM) has treated 1,000 breast cancer patients with the TomoTherapy® System. The milestone was achieved less than 18 months a
Read more →ARAYFUCAM trata 1.000 pacientes de câncer de mama com o Sistema TomoTherapy®
SUNNYVALE, Califórnia, 21 de junho de 2016 /PRNewswire/ -- A Accuray Incorporated (NASDAQ: ARAY) anunciou hoje que a Fundación de Cancer de Mama na Cidade do México (FUCAM) tratou 1.000 pacientes de câncer de mama com o Sistema TomoTherapy®. O marco foi atingido em menos de 18 me
Read more →ARAYFUCAM trata a 1000 pacientes con cáncer de mama con el Sistema TomoTherapy®
SUNNYVALE, California, 21 de junio de 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) anunció hoy que la Fundación del Cáncer de Mama de Ciudad de México (FUCAM) ha tratado a 1000 pacientes de cáncer de mama con el Sistema TomoTherapy®. Este importante suceso se alcanzó
Read more →ARAYUnited Kingdom
SUNNYVALE, Calif., June 16, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) has a signed deal with NHS Supply Chain for seven TomoTherapy® Systems in a new partnership designed to provide clinicians and their patients with additional access to advanced radiation therapy.
Read more →ARAYAccuray to Participate in the 2016 Jefferies Healthcare Conference
SUNNYVALE, Calif., May 25, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), announced today that Joshua H. Levine, President and Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference in New York, NY on Friday, June 10, 2016 at 8:00 a.m.
Read more →ARAYKevin Waters Senior Vice President, Chief Financial Officer 1
Kevin Waters Senior Vice President, Chief Financial Officer 1 May 20, 2016 3 $ millions +22% +18% Key Metrics Significant growth: fiscal year 2015 vs. fiscal year 2013 +22% growth FY 15/ 13 Gross orders drive backlog +18% growth FY 15/ 13 Backlog drives revenue $ millions $219 $
Read more →ARAYAccuray to Host Analyst and Investor Day on May 20, 2016
SUNNYVALE, Calif., May 19, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will host an Analyst and Investor Day on Friday, May 20, 2016 at the Lotte Palace Hotel in New York City. Presentations will begin at 8:30 a.m. ET and a webcast w
Read more →ARAYAccuray Signs Long-Term Strategic Development and Supply Agreement with medPhoton for Volumetric Image Guidance Solutions for the CyberKnife® System
SUNNYVALE, Calif., May 1, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has signed an agreement with medPhoton GmbH to collaborate on integration of its ImagingRing® system, a new technology for volumetric image guidance, with the Cyber
Read more →ARAYDoug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Generates $105.3 Million in Third Quarter Revenu
Doug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Generates $105.3 Million in Third Quarter Revenues Achieves 8% year-over-year revenue growth; Generate
Read more →ARAYAccuray Submits 510(k) Premarket Notification to FDA for Its Radixact™ Treatment Delivery System
SUNNYVALE, Calif., April 26, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the submission of its 510(k) premarket notification with the Food and Drug Administration (FDA) for the company's Radixact™ Treatment Delivery System. Accuray also submitted 510(
Read more →ARAYAccuray Generates $105.3 Million in Third Quarter Revenues
SUNNYVALE, Calif., April 26, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the third fiscal quarter and nine months ended March 31, 2016. Fiscal Third Quarter Highlights Gross orders were $56.4 million; 9% year-over-year growth;
Read more →ARAYAccuray Hosts Regional AERO Users
SUNNYVALE, Calif., April 22, 2016 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the Accuray Exchange in Radiation Oncology (AERO™) Users' Meeting was held April 10 – 11, 2016 at the Palace Hotel in San Francisco, California. The two day summit, coordina
Read more →ARAYPrimer Sistema TomoTherapy® en Colombia instalado en Clínica FOSCAL
SUNNYVALE, California, 12 de abril de 2016 /PRNewswire/ --Accuray Incorporated (NASDAQ: ARAY) anunció hoy que el primer Sistema TomoTherapy® de Colombia se encuentra ahora instalado en Clínica FOSCAL en Bucaramanga, Colombia. El centro eligió TomoHD™, el Sistema TomoTherapy® de ú
Read more →ARAYPrimeiro sistema TomoTherapy® da Colômbia é instalado na Clinica FOSCAL
SUNNYVALE, Califórnia, 12 de abril de 2016 /PRNewswire/ -- A Accuray Incorporated (NASDAQ: ARAY) anunciou hoje que o primeiro sistema TomoTherapy® da Colômbia foi instalado na Clinica FOSCAL em Bucaramanga, Colômbia. A clínica escolheu o TomoHD™, a última geração do sistema TomoT
Read more →ARAYAccuray To Report Results For Third Quarter Fiscal 2016 On April 26, 2016
SUNNYVALE, Calif., April 6, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2016 on April 26, 2016 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET
Read more →ARAYMedStar Georgetown University Hospital Treats 1,000 Prostate Cancer Patients with the CyberKnife® System
SUNNYVALE, Calif., March 31, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that MedStar Georgetown University Hospital in Washington, D.C. treated its 1,000th prostate cancer patient with the leading-edge CyberKnife® System. The System was designed to d
Read more →ARAYAccuray to Participate in the 36th Annual Cowen and Company Health Care Conference
Accuray Incorporated SUNNYVALE, Calif., Feb. 24, 2016 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Joshua H. Levine, President and Chief Executive Officer, is scheduled to present at the 36th Annual Cowen and Company Health Care Conference in Boston,
Read more →ARAYDoug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Generates $108.9 Million in Second Quarter Reven
Doug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Generates $108.9 Million in Second Quarter Revenues Record Revenues Achieved as Commercial Execution Conti
Read more →ARAYAccuray Generates $108.9 Million in Second Quarter Revenues
Accuray Incorporated SUNNYVALE, Calif., Jan. 28, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2015. Fiscal Second Quarter Highlights Gross orders were $67.1 million; s
Read more →ARAYAccuray Announces Repurchases of Convertible Debt
Accuray Announces Repurchases of Convertible Debt SUNNYVALE, Calif., January 19, 2016 Accuray Incorporated (NASDAQ: ARAY) today announced that between January 11 and January 15, 2016, the company, in privately-negotiated transactions, had repurchased approximately $63.4 million
Read more →ARAYAccuray Announces First Radiation Therapy Systems Installed in Qatar, Latvia and Bulgaria
Accuray Incorporated SUNNYVALE, Calif., Jan. 14, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the first centers in Qatar, Latvia, and Bulgaria are now equipped with its radiation therapy technology, demonstrating continued momentum in adoption of
Read more →ARAYAccuray Closes $70 Million Straight Debt Financing
Accuray Incorporated SUNNYVALE, Calif., Jan. 12, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has closed a $70 million straight debt financing agreement with Cerberus Business Finance, LLC, an affiliate of Cerberus Capital Management, L.P. The net
Read more →ARAYAccuray Announces Preliminary Second Quarter Financial Results
Accuray Incorporated SUNNYVALE, Calif., Jan. 11, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today preliminary product orders and revenues for the second quarter of fiscal 2016, which ended on December 31, 2015. As a result of the expected second quarter r
Read more →ARAYJ.P. Morgan Healthcare Conference January 2016 Accuray and/or its affiliates. All rights reserved. Safe Harbor Statement Forward Looking Statements Safe Harbor Statement Statements in this presentation (including the ora
Safe Harbor Statement Forward Looking Statements Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor provisions of t
Read more →ARAYDoug Sherk Investor Relations, EVC Group +1 (415) 652-9100 dsherk@evcgroup.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Announces Preliminary Second Quarter Financial R
Accuray Announces Preliminary Second Quarter Financial Results Revenue Expected to be Approximately $107.5 Million; Gross Orders Expected to be Approximately $67 Million Management Reiterates Guidance for FY2016 SUNNYVALE, Calif., January 11, 2016 Accuray Incorporated (NASDAQ:
Read more →ARAYAccuray To Report Results For Second Quarter Fiscal 2016 On January 28, 2016
SUNNYVALE, Calif., Jan. 7, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its second quarter ended December 31, 2015 on January 28, 2016 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m
Read more →ARAYAccuray Hosts First Regional Users
SUNNYVALE, Calif., Dec. 17, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Accuray Exchange in Radiation Oncology (AERO™) Users' Meeting was held November 13-14, 2015 at the University of North Carolina at Chapel Hill Friday Center for Continuin
Read more →ARAYPrimeiros sistemas CyberKnife® M6™ e TomoTherapy® no Chile instalados no Instituto do Câncer da Fundación Arturo López Pérez
SUNNYVALE, Califórnia, 5 de novembro de 2015 /PRNewswire/ -- A Accuray Incorporated (NASDAQ: ARAY) anunciou hoje que os primeiros sistemas CyberKnife® M6™ e TomoTherapy® no Chile foram instalados no Instituto do Câncer da Fundación Arturo López Pérez (FALP), em Santiago. A FALP t
Read more →ARAYFirst CyberKnife® M6™ and TomoTherapy® Systems in Chile Installed at Fundacion Arturo Lopez Perez Cancer Institute
SUNNYVALE, Calif., Nov. 5, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the first CyberKnife® M6™ and TomoTherapy® Systems in Chile are now installed at Fundacion Arturo Lopez Perez (FALP) Cancer Institute in Santiago, Chile. FALP is also the firs
Read more →ARAYPrimeros Sistemas CyberKnife® M6™ y TomoTherapy® en Chile instalados en Centro Clínico Oncológico Fundación Arturo López Pérez
SUNNYVALE, California, 5 de noviembre de 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) anunció hoy que los primeros Sistemas CyberKnife® M6™ y TomoTherapy® en Chile están instalados en el Instituto Oncológico Fundación Arturo López Pérez (FALP) en la ciudad de Santiago
Read more →ARAYAccuray - Cowealth Arbitration Ruling Delivered
SUNNYVALE, Calif., Nov. 4, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the International Chamber of Commerce International Court of Arbitration (ICC) issued an interim award in an arbitration filed by Cowealth Medical Holding Co., Ltd., Accuray's
Read more →ARAYAccuray to Participate in the 24th Annual Credit Suisse Healthcare Conference
SUNNYVALE, Calif., Nov. 3, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that a member of its management team is scheduled to present at the 24th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona on Tuesday, November 10, 2015 at 1:30pm
Read more →ARAYNew CyberKnife® and TomoTherapy® System Data Presented at Leading Scientific Industry Meeting
SUNNYVALE, Calif., Nov. 2, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies on the clinical use of the leading-edge CyberKnife® and TomoTherapy® Systems continue to reinforce the devices' broad-based radiation treatment capabilities. More than
Read more →ARAYDoug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Generates 10% Year-Over-Year Gross Order Growth
Doug Sherk Beth Kaplan Investor Relations, EVC Group Public Relations Director, Accuray +1 (415) 652-9100 +1 (408) 789-4426 dsherk@evcgroup.com bkaplan@accuray.com Accuray Generates 10% Year-Over-Year Gross Order Growth in First Quarter Commercial Momentum Continues; Management
Read more →ARAYKelly Londy Named Chief Operating Officer Of Accuray
SUNNYVALE, Calif., Oct. 15, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that Kelly Londy, formerly chief commercial officer has been named chief operating officer of the Company effective immediately. Ms. Londy will also remain an executive vice presi
Read more →ARAYAnova Cancer Care Treats 1,000th Prostate Cancer Patient with the CyberKnife® System
SUNNYVALE, Calif., Oct. 13, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Anova Cancer Care in Denver, Colorado, has treated its 1,000th prostate cancer patient with the leading-edge CyberKnife® System. This non-invasive treatment for cancerous and
Read more →ARAYAccuray To Report Fiscal 2016 First Quarter Financial Results On October 29, 2015
SUNNYVALE, Calif., Oct. 8, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fiscal first quarter ended September 30, 2015 on October 29, 2015 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4
Read more →ARAYAccuray and RaySearch Announce Second Long-Term Collaboration Agreement
SUNNYVALE, Calif., and STOCKHOLM, Oct. 5, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) and RaySearch Laboratories AB (publ) (NASDAQ OMX Stockholm: RAY B) announced today that they have expanded on their existing relationship with the signing of a new long-term collabo
Read more →ARAYACCURAY INCORPORATED 2007 INCENTIVE AWARD PLAN 2016 MARKET STOCK UNIT GRANT NOTICE Accuray Incorporated, a Delaware corporation (the Company ), pursuant to its 2007 Incentive Award Plan (the Plan ), hereby grants to the
ACCURAY INCORPORATED 2007 INCENTIVE AWARD PLAN 2016 MARKET STOCK UNIT GRANT NOTICE Accuray Incorporated, a Delaware corporation (the Company ), pursuant to its 2007 Incentive Award Plan (the Plan ), hereby grants to the individual listed below ( Participant ), the following Per
Read more →ARAYKEVIN WATERS NAMED CHIEF FINANCIAL OFFICER OF ACCURAY Succeeds Retiring CFO Greg Lichtwardt
KEVIN WATERS NAMED CHIEF FINANCIAL OFFICER OF ACCURAY Succeeds Retiring CFO Greg Lichtwardt SUNNYVALE, Calif., September 15, 2015 Accuray Incorporated (Nasdaq: ARAY) announced today that Kevin Waters, formerly Senior Vice President, Finance, has been promoted to Chief Financial
Read more →ARAYAccuray to Participate in the Morgan Stanley Global Healthcare Conference 2015
SUNNYVALE, Calif., Sept. 1, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), announced today that its management team is scheduled to present at the Morgan Stanley Global Healthcare Conference 2015 in New York, NY on Thursday, September 17, 2015 at 12:55pm ET. A live we
Read more →ARAYAccuray Incorporated Josh levine president and ceo Morgan Stanley Healthcare Conference september 2015 NASDAQ: ARAY Safe Harbor Statement Forward Looking Statements Safe Harbor Statement Statements in this presentation (
Accuray Incorporated Reconciliation of GAAP net loss to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) (In thousands) (Unaudited) Three Months Ended June 30, Years Ended June 30, 2015 2014 2015 2014 GAAP net los
Read more →ARAYAccuray Awarded Multi-System Order by 21st Century Oncology
SUNNYVALE, Calif., Aug. 21, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has received a multi-system order from 21st Century Oncology for one CyberKnife® M6™ and four TomoHDA™ Systems. These are the latest generation CyberKnife and TomoTherapy Syste
Read more →ARAYAccuray Generates 14% Year-Over-Year Gross Order Growth During Fourth Quarter
SUNNYVALE, Calif., Aug. 20, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the fiscal fourth quarter and fiscal year ended June 30, 2015. Fiscal Fourth Quarter Highlights Gross orders were $84.9 million, representing 14 percent ye
Read more →ARAYDoug Sherk Investor Relations, EVC Group +1 (415) 652-9100 dsherk@evcgroup.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Generates 14% Year-Over-Year Gross Order Growth
Accuray Generates 14% Year-Over-Year Gross Order Growth During Fourth Quarter Reports Financial Results for Fourth Quarter and Fiscal 2015, Introduces Fiscal 2016 Guidance SUNNYVALE, Calif., August 20, 2015 Accuray Incorporated (NASDAQ: ARAY) announced today financial results f
Read more →ARAYAccuray Products Received Highest Composite User Satisfaction Ratings in Latest MD Buyline Report
SUNNYVALE, Calif., July 27, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that its CyberKnife® and TomoTherapy® Systems have received the highest composite overall user satisfaction rating among radiation treatment delivery systems in the U.S., accordin
Read more →ARAYNew CyberKnife® System Data Presented at Leading Scientific Industry Meeting
SUNNYVALE, Calif., July 14, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that studies on the clinical use of the CyberKnife® System, the only robotic SBRT system capable of tracking and automatically correcting for target motion, continue to demonstrat
Read more →ARAYNew TomoTherapy® System Data Presented at Leading Scientific Industry Meeting
SUNNYVALE, Calif., July 14, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that studies on the clinical use of the TomoTherapy® System continue to demonstrate its mainstream use and the benefits of its gold-standard treatment planning and delivery capabi
Read more →ARAYAccuray and RaySearch Announce Long-Term Collaboration Agreement Regarding the RayCare® Oncology Information System
SUNNYVALE, Calif. and STOCKHOLM, July 13, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) and RaySearch Laboratories AB (publ) (NASDAQ OMX Stockholm: RAY B) announced today they have signed a long-term collaboration agreement which will allow Accuray to co-market and off
Read more →ARAYTotal Marrow Irradiation Provides Greater Precision, Fewer Side Effects
SUNNYVALE, Calif., June 9, 2015 /PRNewswire/ -- This month marks the 10-year anniversary of the first successful total marrow irradiation (TMI) using the TomoTherapy® System. This procedure was performed at City of Hope in Duarte, California. As a result of continuing research an
Read more →ARAYAccuray to Participate in the Goldman Sachs 36th Annual Global Healthcare Conference
SUNNYVALE, Calif., June 2, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that its management team is scheduled to present at the Goldman Sachs 36th Annual Global Healthcare Conference in Rancho Palos Verdes, California on Wednesday, June 10, 2015 at 4:
Read more →ARAYAccuray to Participate in the Jefferies 2015 Healthcare Conference
SUNNYVALE, Calif., May 26, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that its management team is scheduled to present at the Jefferies 2015 Healthcare Conference in New York on Wednesday, June 3, 2015 at 2:30pm ET. A live webcast of the presentati
Read more →ARAYAccuray to Participate in the Bank of America Merrill Lynch 2015 Healthcare Conference
SUNNYVALE, Calif., May 5, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that management is scheduled to present at the Bank of America Merrill Lynch 2015 Healthcare Conference in Las Vegas on Tuesday, May 12, 2015 at 2:20pm PT. A live webcast of the p
Read more →ARAYAccuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software
SUNNYVALE, Calif., April 30, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that it has signed an agreement with MIM Software Inc. to further develop adaptive therapy software for the TomoTherapy® and CyberKnife® product portfolios. The new software solu
Read more →ARAYAccuray Reports Financial Results for Third Quarter of Fiscal Year 2015
SUNNYVALE, Calif., April 30, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the third fiscal quarter and nine months ended March 31, 2015. Third Quarter Highlights Gross orders grew 15 percent year-over-year or 21 percent on a con
Read more →ARAYDoug Sherk Investor Relations, EVC Group +1 (415) 652-9100 dsherk@evcgroup.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Reports Financial Results for Third Quarter of F
Accuray Reports Financial Results for Third Quarter of Fiscal Year 2015 SUNNYVALE, Calif., April 30, 2015 Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the third fiscal quarter and nine months ended March 31, 2015. Third Quarter Highlights Gross ord
Read more →ARAYAccuray realiza el lanzamiento comercial internacional del InCise™ Multileaf Collimator para el sistema CyberKnife® M6™
- La evaluación del sistema InCise™ Multileaf Collimator se completa con éxito SUNNYVALE, California, 21 de abril de 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) anunció hoy que el InCise™ Multileaf Collimator (MLC) para el sistema CyberKnife® M6™ ya estará disponibl
Read more →ARAYAccuray entame la commercialisation à l
- Evaluation favorable du collimateur multi-lame InCise™ SUNNYVALE, Californie, 21 avril 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY) a annoncé aujourd'hui que le collimateur multi-lame InCise™ (MLC) du Système CyberKnife® M6™ sera désormais commercialisé en dehors
Read more →ARAYAccuray Initiates International Commercial Launch of the InCise™ Multileaf Collimator for the CyberKnife® M6™ System
SUNNYVALE, Calif., April 21, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the InCise™ Multileaf Collimator (MLC) for the CyberKnife® M6™ System will now be available outside the United States in markets where it is approved for sale, in addition t
Read more →ARAYAccuray startet die internationale Markteinführung des InCise™ Multileaf-Kollimators für das CyberKnife® M6™-System
-- Erfolgreicher Abschluss der Evaluierung des InCise™ Multileaf-Kollimator-Systems SUNNYVALE, Kalifornien, 21. April 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) gab heute bekannt, dass der InCise™ Multileaf-Kollimator (MLC) für das CyberKnife® M6™-System jetzt auße
Read more →ARAYAccuray To Report Results For Third Quarter Fiscal 2015 On April 30, 2015
SUNNYVALE, Calif., April 9, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2015 on April 30, 2015 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET
Read more →ARAYFirst Patient Treatment with the CyberKnife® M6™ System and the InCise™ Multileaf Collimator Has Been Completed
SUNNYVALE, Calif., March 2, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the first patient treatment has been completed using the CyberKnife® M6™ System with the InCise™ Multileaf Collimator (MLC). The treatment was administered as a multidiscipli
Read more →ARAYLe premier traitement d
- Un patient atteint d'une tumeur cérébrale a reçu un traitement extrêmement précis en un temps réduit SUNNYVALE, Californie, 2 mars 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY) a annoncé aujourd'hui que le premier traitement d'un patient a été mené à terme à l'aide
Read more →ARAYErste Patientenbehandlung mit dem CyberKnife® M6™-System und dem InCise™ Multileaf-Kollimator ist abgeschlossen
- Patient mit Gehirntumor erhielt extrem präzise und zeitsparende Behandlung SUNNYVALE, Kalifornien, 2. März 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) meldete heute die erste unter Einsatz des CyberKnife® M6™-Systems mit dem InCise™ Multileaf-Kollimator (MLC) abge
Read more →ARAYFoi concluído o tratamento do primeiro paciente com o sistema CyberKnife® M6™ e o colimador multifolhas InCise™
SUNNYVALE, Califórnia, 2 de março de 2015 /PRNewswire/ -- A Accuray Incorporated (Nasdaq: ARAY) anunciou hoje a conclusão do tratamento do primeiro paciente utilizando o sistema CyberKnife® M6™ com o colimador multifolhas InCise™(MLC). O tratamento foi administrado através da ini
Read more →ARAYCompletan primer tratamiento de paciente con Sistema CyberKnife® M6™ y el colimador multihojas InCise™
SUNNYVALE, California, 2 de marzo de 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) anunció hoy que se completó el primer tratamiento de paciente usando el Sistema CyberKnife® M6™ System con el Colimador Multihoja InCise™ (MLC). El tratamiento fue administrado como un e
Read more →ARAYLancaster General Health Receives First Commercial InCise™ Multileaf Collimator for the CyberKnife® M6™ System
SUNNYVALE, Calif. and LANCASTER, Pa., Feb. 24, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) and Lancaster General Health announced today that the first commercially available InCise™ Multileaf Collimator (MLC) for the CyberKnife® M6™ System has been received by Lancas
Read more →ARAYClass A User Licenses for Accuray Products Awarded to 16 Hospitals in China
SUNNYVALE, Calif., Feb. 17, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced that class A user licenses for Accuray products were awarded to 16 hospitals during February by the Chinese National Health and Family Planning Commission (NHFPC). TomoTherapy® System l
Read more →ARAYAccuray to Participate in the Cowen 35th Annual Healthcare Conference
SUNNYVALE, Calif., Feb. 9, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that its management is scheduled to present at the Cowen 35th Annual Healthcare Conference in Boston on Monday, March 2, 2015 at 2:10pm ET. A live webcast of the presentation will
Read more →ARAYPrimeiro sistema TomoTherapy® da América Latina dedicado exclusivamente aos cuidados do câncer de mama agora é utilizado para tratar pacientes
SUNNYVALE, Califórnia, 5 de fevereiro de 2015 /PRNewswire/ -- A Accuray Incorporated (Nasdaq: ARAY) anunciou hoje que o primeiro sistema TomoTherapy® da América Latina dedicado exclusivamente ao tratamento do câncer de mama agora está em operação na FUCAM (Fundacion de Cancer de
Read more →ARAYFirst TomoTherapy® System in Latin America Dedicated Solely to Breast Cancer Care Now Treating Patients
SUNNYVALE, Calif., Feb. 4, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the first TomoTherapy® System in Latin America dedicated solely to the treatment of breast cancer is now operational at FUCAM (Fundacion de Cancer de Mama) in Mexico City. Mor
Read more →ARAYEl primer sistema TomoTherapy® en América Latina dedicado exclusivamente a la atención del cáncer de mama ya está tratando pacientes
-- Sistema avanzado de radioterapia ideal para el tratamiento eficaz y efectivo de una gama de casos de cáncer de mama SUNNYVALE, California, 4 de febrero de 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) anunció hoy que el primer sistema TomoTherapy® en América Latina
Read more →ARAYSelon la nouvelle enquête Accuray/IFOP, 60%[1] de la population française s
-- Soixante pour cent pensent ne pas disposer de suffisamment d'informations pour avoir un avis personnel sur les traitements SUNNYVALE, Californie, 28 janvier 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY) a annoncé les résultats d'une enquête menée auprès de 1 000 c
Read more →ARAYAccuray Reports Financial Results for Second Quarter of Fiscal Year 2015
SUNNYVALE, Calif., Jan. 27, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2014. Second Quarter Highlights Generates improved order volume with gross orders of $72.3 mill
Read more →ARAYDoug Sherk Investor Relations, EVC Group +1 (415) 652-9100 dsherk@evcgroup.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Reports Financial Results for Second Quarter of
Accuray Reports Financial Results for Second Quarter of Fiscal Year 2015 SUNNYVALE, Calif., January 27, 2015 Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2014. Second Quarter Highlights Ge
Read more →ARAYAccuray To Report Results For Second Quarter Fiscal 2015 On January 27, 2015
SUNNYVALE, Calif., Jan. 12, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its second quarter ended December 31, 2014 on January 27, 2015 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.
Read more →ARAYAccuray Incorporated j.p. morgan healthcare conference January 2015 NASDAQ: ARAY Safe Harbor Statement Forward Looking Statements Safe Harbor Statement Statements in this presentation (including the oral commentary that
Accuray Incorporated Reconciliation of Projected GAAP Net Loss to Forward-Looking Guidance for Non-GAAP Financial Measures (In thousands) (Unaudited) Twelve Months Ending June 30, 2015 From To GAAP net loss $(36,700) $(28,000) Amortization of intangibles (a) 8,000 8,000 Depreciat
Read more →ARAYLe Centre Hospitalier Universitaire (CHRU) de Tours prend en charge ses premiers patients avec le système TomoTherapy®
PARIS, 9 janvier 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY) a annoncé que le CHRU de Tours a traité les premiers patients atteints de cancer avec le système TomoTherapy®. Combinant à la fois un système de guidage par imagerie 3D au quotidien (IG-IMRT) et un collima
Read more →ARAYAccuray to Present at JP Morgan 33rd Annual Healthcare Conference
Accuray Incorporated announced its participation in the JP Morgan 33rd Annual Healthcare Conference, scheduled for January 12, 2015. The presentation will be available via a live webcast on the company's Investor Relations page. Accuray specializes in developing innovative tumor treatment solutions in radiation oncology.
Read more →ARAYFirst CyberKnife® Full-Body Radiosurgery System in Manhattan Now Treating Patients
SUNNYVALE, Calif., Nov. 18, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the first CyberKnife® System in Manhattan is now treating patients at Winthrop University Hospital's NYCyberKnife Center. Winthrop's decision to install the latest generation
Read more →ARAYAccuray to Participate in Brean Capital's 2014 Life Science Conference
Accuray Incorporated will participate in the Brean Capital 2014 Life Science Conference in New York City on November 24, 2014. The company is known for its advanced radiation oncology solutions aimed at improving patient outcomes. This event presents an opportunity for Accuray to showcase its innovations and connect with industry leaders.
Read more →ARAYLos estudios apoyan el uso del sistema CyberKnife® para tratar las enfermedades neurológicas
-- Los estudios apoyan el uso del sistema CyberKnife® como una opción segura y efectiva para tratar las enfermedades neurológicas -- Estudios de seguimiento de cinco años demuestran resultados excelentes para los meningiomas periópticos SUNNYVALE, California, 3 de noviembre de
Read more →ARAYDes études appuient l
-- Des études de suivi à cinq ans démontrent d'excellents résultats s'agissant des méningiomes péri-optiques SUNNYVALE, Californie, le 3 novembre 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY) a annoncé que les études présentées lors du 15e Congrès européen des sociét
Read more →ARAYStudie unterstützt die Verwendung des CyberKnife® Systems als eine sichere und effektive Option bei der Behandlung von neurologischen Erkrankungen
-- Folgestudie zeigt nach fünf Jahren hervorragende Ergebnisse bei perioptischen Meningeomen SUNNYVALE, Kalifornien, 3. November 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) gab heute bekannt, dass verschiedene, auf dem 15. European Congress of Neurosurgical Societie
Read more →ARAYAccuray y Lausanne University Hospital ofrecerán tratamientos de radiación personalizados
- Accuray y Lausanne University Hospital se unen para ofrecer a los pacientes tratamientos de radiación personalizados - La colaboración aumenta el acceso del paciente a los sistemas CyberKnife® y TomoTherapy® SUNNYVALE, California, 31 de octubre de 2014 /PRNewswire/ -- Accuray
Read more →ARAYAccuray und Universitätsklinik in Lausanne bündeln ihre Kräfte, um Patienten personalisierte Strahlentherapien anbieten zu können
-- Kollaboration ermöglicht Patientenbehandlung mit den CyberKnife® und TomoTherapy® Systemen SUNNYVALE, Kalifornien, 31. Oktober 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) hat heute eine langfristige Zusammenarbeit mit der Universitätsklinik im schweizerischen Lau
Read more →ARAYAccuray et le Centre hospitalier universitaire vaudois de Lausanne conjuguent leurs forces pour offrir des traitements personnalisés de radiothérapie aux patients
- La collaboration favorise l'accès des patients aux systèmes CyberKnife® et TomoTherapy® SUNNYVALE, Californie, 31 octobre 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY) a annoncé aujourd'hui le début d'une collaboration à long terme avec le Centre hospitalier univer
Read more →ARAYAccuray Reports Financial Results for First Quarter of Fiscal Year 2015
Accuray Incorporated reported its financial results for the first quarter of fiscal year 2015, with total revenue of $82.4 million, a 7% increase year-over-year. However, gross product orders were disappointing at $58.8 million. The company anticipates stronger order growth in the latter half of the fiscal year, driven by new product releases. Despite revenue growth, the net loss widened to $21.7 million compared to the previous year.
Read more →ARAYLynn Pieper Investor Relations, Westwicke Partners +1 (415) 202-5678 lynn.pieper@westwicke.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Reports Financial Results for Fi
Accuray Reports Financial Results for First Quarter of Fiscal Year 2015 SUNNYVALE, Calif., October 29, 2014 Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the first fiscal quarter ended September 30, 2014. First Quarter Highlights Gross orders of $58
Read more →ARAYAccuray to Report Financial Results for First Quarter Fiscal 2015
Accuray Incorporated will announce its financial results for the first quarter of fiscal 2015 on October 29, 2014. A conference call will be held to discuss these results, with details provided for both dial-in and webcast options. The company continues to emphasize its role in radiation oncology and innovative treatment solutions.
Read more →ARAYDes études soutiennent l
-- Les nouvelles données démontrent que les systèmes TomoTherapy et CyberKnife® d'Accuray permettent une administration de dose et une gestion des tumeurs avec précision SUNNYVALE, Californie, 19 septembre 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY) a annoncé aujou
Read more →ARAYStudien stützen zunehmende Verwendung des TomoTherapy®-Systems von Accuray bei Brustkrebs für eine bessere Tumorkontrolle bei verminderter Toxizität
- Zusätzliche Daten belegen, dass die Systeme TomoTherapy und CyberKnife® von Accuray präzise Dosierungen und Tumormanagement ermöglichen SUNNYVALE, Kalifornien, 19. September 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) gab heute bekannt, dass auf der 56. jährlichen
Read more →ARAYStudies Support Growing Use of the Accuray TomoTherapy® System for Breast Cancer to Improve Tumor Control with Reduced Toxicities
SUNNYVALE, Calif., Sept. 18, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that studies presented at the 56th Annual American Society for Radiation Oncology (ASTRO) Meeting in San Francisco, September 14 – 17, 2014 continue to reinforce broad-based heal
Read more →ARAYAccuray Signs Exclusive Radiation Therapy Solutions Contract With Premier, Inc.
Accuray Incorporated has entered into a three-year exclusive agreement with Premier, Inc. to provide its CyberKnife and TomoTherapy product lines to Premier's extensive network of hospitals and providers. This partnership aims to enhance patient care through innovative radiation therapy solutions and increase Accuray's market visibility. The contract commenced on September 1, 2014.
Read more →ARAYACCURAY INCORPORATED 2007 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE The Participant must notify the Company by [insert date] if he or she wishes to reject this RSU award. Otherwise, the Participant will be
ACCURAY INCORPORATED 2007 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE The Participant must notify the Company by [insert date] if he or she wishes to reject this RSU award. Otherwise, the Participant will be deemed to have accepted the award on the terms and conditi
Read more →ARAYAccuray Reports Financial Results for Fourth Quarter of Fiscal Year 2014 and Introduces Fiscal 2015 Guidance
Accuray Incorporated reported strong financial results for the fourth quarter and fiscal year 2014, with a 20% increase in total revenue and significant growth in gross and net orders. The company achieved a positive adjusted EBITDA of $2.5 million, marking an improvement from the previous year. However, it also reported a net loss of $9.8 million for the quarter, despite overall positive trends.
Read more →ARAYJamar Ismail Investor Relations, Westwicke Partners +1 (415) 202-5678 Jamar.Ismail@westwicke.com Beth Kaplan Public Relations Director, Accuray +1 (408) 789-4426 bkaplan@accuray.com Accuray Reports Financial Results for
Accuray Reports Financial Results for Fourth Quarter of Fiscal Year 2014 and Introduces Fiscal 2015 Guidance Achieves Full Year Net Order Guidance Strong Revenue, Margin Expansion and adjusted EBITDA Growth SUNNYVALE, Calif., August 21, 2014 Accuray Incorporated (Nasdaq: ARAY)
Read more →ARAYAccuray Incorporated to Present at 2014 Morgan Stanley Global Healthcare Conference
Accuray Incorporated will present at the 2014 Morgan Stanley Global Healthcare Conference on September 8, 2014. The presentation will be available via a live webcast, which will be accessible for 30 days after the event. The company specializes in radiation oncology and aims to improve patient outcomes through its advanced technologies.
Read more →ARAYAccuray to Report Financial Results for Fourth Quarter and Year End Fiscal 2014
Accuray Incorporated will announce its financial results for the fourth quarter and fiscal year ending June 30, 2014, on August 21, 2014. A conference call hosted by CEO Joshua H. Levine and CFO Gregory Lichtwardt will take place at 1:30 p.m. PT. The call will also be available via a live webcast and replay on the company's website.
Read more →ARAYLatest MD Buyline Report Shows Highest User Satisfaction Composite Ratings for Accuray Incorporated
SUNNYVALE, Calif., July 17, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that its CyberKnife® and TomoTherapy® Systems have received the highest composite overall user satisfaction rating among radiation treatment delivery systems in the U.S., accordin
Read more →ARAYAccuray Incorporated Announces Updated Time of Presentation at Goldman Sachs 35th Annual Healthcare Conference 2014
Accuray Incorporated has announced an updated time for its presentation at the Goldman Sachs 35th Annual Healthcare Conference. The presentation is scheduled for June 12, 2014, at 11:00 a.m. ET. A live webcast will be available on the company's Investor Relations page, with a replay accessible for 30 days post-event.
Read more →ARAYAccuray Incorporated to Present at Goldman Sachs 35th Annual Healthcare Conference 2014
Accuray Incorporated announced its participation in the Goldman Sachs 35th Annual Healthcare Conference, scheduled for June 12, 2014. The presentation will be accessible via a live webcast, which will also be available for replay afterward. This event highlights Accuray's focus on innovative treatment solutions in radiation oncology.
Read more →ARAYAccuray Incorporated to Present at 2014 Jefferies Global Healthcare Conference
SUNNYVALE, Calif., May 19, 2014 (GLOBE NEWSWIRE) -- Accuray Incorporated (Nasdaq:ARAY), announced today that its management is scheduled to present at the 2014 Jefferies Global Healthcare Conference in New York City on Tuesday, June 3, 2014 at 3 p.m. ET/ 12 p.m. PT. A live webca
Read more →ARAYAccuray Signs Three-Year Contract With Novation
SUNNYVALE, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- Accuray Incorporated (Nasdaq:ARAY) announced today that it has signed a new three-year contract with Novation on the CyberKnife M6 and TomoTherapy H product portfolio. Novation is the largest health care supply chain expertise
Read more →ARAYAccuray Reports Financial Results for Third Quarter of Fiscal Year 2014
Achieves Positive Cash Flow on Strong Revenue Growth Updates Financial Guidance SUNNYVALE, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- Accuray Incorporated (Nasdaq:ARAY) announced today financial results for the third fiscal quarter and nine months ended March 31, 2014. Third Q
Read more →ARAYLynn Pieper Investor Relations +1 (415) 202-5678 Lynn.pieper@westwicke.com Madelyn Homick Manager Communications +1 (408) 789-4335 mhomick@accuray.com Accuray Reports Financial Results for Third Quarter of Fiscal Year 20
Accuray Reports Financial Results for Third Quarter of Fiscal Year 2014 Achieves Positive Cash Flow on Strong Revenue Growth Updates Financial Guidance SUNNYVALE, Calif., April 30, 2014 Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the third fiscal
Read more →ARAYAccuray to Report Financial Results for Third Quarter Fiscal 2014
SUNNYVALE, Calif., April 10, 2014 (GLOBE NEWSWIRE) -- Accuray Incorporated (Nasdaq:ARAY) announced today that it will report results for its third quarter of fiscal 2014, ended March 31, 2014 on Wednesday, April 30, 2014 after the market closes. A conference call to review the r
Read more →ARAYThe European CyberKnife Center Munich is celebrating its 5,000th patient treatment using the CyberKnife® System
SUNNYVALE, Calif., April 7, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the European CyberKnife Center Munich-Grosshadern (ECZM) has performed 5,000 CyberKnife® treatments since June 2005. The center uses a CyberKnife M6™ System from the latest g
Read more →ARAYAccuray Identifies EIMEA Region as Growth Territory
SUNNYVALE, Calif., April 3, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in adoption of its CyberKnife® and TomoTherapy® Systems in Europe, India, the Middle East and Africa (EIMEA). Accuray has expanded its installed base in the EI
Read more →ARAYAccuray Incorporated
SUNNYVALE, Calif., March 27, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the CyberKnife® M6™ System to treat radiation therapy patients. The system, w
Read more →ARAYAccuray to Participate in Upcoming Investor Conferences
SUNNYVALE, Calif., Feb. 12, 2014 (GLOBE NEWSWIRE) -- Accuray Incorporated (Nasdaq:ARAY), announced today that its management is scheduled to participate in three upcoming investor conferences. Accuray management is scheduled to present at the Citi 2014 Global Healthcare Conferen
Read more →ARAYLatest MD Buyline Ratings Show Significant, Sustained Increase in User Satisfaction for Accuray Incorporated
SUNNYVALE, Calif., Feb. 11, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that overall user satisfaction for its TomoTherapy® System has increased for the fifth consecutive quarter, according to the Q4 2013 MD Buyline Market Intelligence Briefing™. In a
Read more →ARAYLynn Pieper Investor Relations +1 (415) 202-5678 Lynn.pieper@westwicke.com Rebecca Phillips Public Relations Manager +1 (408) 716-4773 rphillips@accuray.com Accuray Reports Financial Results for Second Quarter of Fiscal
Accuray Reports Financial Results for Second Quarter of Fiscal Year 2014 Achieves Adjusted EBITDA Profit on Revenue Growth and Margin Expansion Updates Financial Guidance SUNNYVALE, Calif., January 30, 2014 Accuray Incorporated (Nasdaq: ARAY) announced today financial results
Read more →ARAYAccuray Reports Financial Results for Second Quarter of Fiscal Year 2014
SUNNYVALE, Calif., Jan. 30, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2013. Second Quarter Highlights Strong order momentum with gross orders of $80.3 million Total
Read more →ARAYAccuray to Present at JP Morgan 32nd Annual Healthcare Conference
SUNNYVALE, Calif., Jan. 6, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that its management is scheduled to present at the JP Morgan 32nd Annual Healthcare Conference in San Francisco on Monday, January 13, 2014 at 4:00 p.m. PST/7:00 p.m. EST/. A liv
Read more →ARAYWidespread Acceptance and Use of Accuray
SUNNYVALE, Calif., Nov. 25, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in global adoption of its CyberKnife® and TomoTherapy® Systems. Accuray has expanded its installed base to more than 700 systems worldwide which have been used
Read more →ARAYAccuray to Present at Piper Jaffray 25th Annual Healthcare Conference
SUNNYVALE, Calif., Nov. 18, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that its management is scheduled to present at the Piper Jaffray 25th Annual Healthcare Conference in New York on Wednesday, December 4, 2013 at 1:00 p.m. EST/10:00 a.m. PST. A
Read more →ARAYLynn Pieper Rebecca Phillips Investor Relations Public Relations Manager +1 (415) 202-5678 +1 (408) 716-4773 Lynn.pieper@westwicke.com rphillips@accuray.com Accuray Reports Financial Results for First Quarter of Fiscal Y
Lynn Pieper Rebecca Phillips Investor Relations Public Relations Manager +1 (415) 202-5678 +1 (408) 716-4773 Lynn.pieper@westwicke.com rphillips@accuray.com Accuray Reports Financial Results for First Quarter of Fiscal Year 2014 Gross Orders Increase 17% Year over Year SUN
Read more →ARAYAccuray Reports Financial Results for First Quarter of Fiscal Year 2014
SUNNYVALE, Calif., Nov. 7, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the first fiscal quarter ended September 30, 2013. Results are presented on a GAAP basis, unless otherwise indicated, as the magnitude of purchase accounting
Read more →ARAYTwo Papers From a Large Multi-site Study Further Demonstrate Efficacy and Quality of Life Benefits for Prostate Cancer Patients Treated with Accuray
SUNNYVALE, Calif., Nov. 7, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the publication of two papers stemming from a large multi-center study of CyberKnife® stereotactic body radiotherapy (SBRT) led by investigators at the University of California, L
Read more →ARAYMore than 100 Presentations at Leading Radiation Oncology Meeting Demonstrate High Value and Broad Utilization of Accuray
SUNNYVALE, Calif., Oct. 3, 2013 /PRNewswire/ -- ASTRO 2013 (Atlanta) – Accuray Incorporated (Nasdaq: ARAY) announced today that studies presented at the 55th Annual American Society for Radiation Oncology (ASTRO) Meeting in Atlanta, September 22 – 25, 2013 continue to reinforce e
Read more →ARAYPage 1 of 19 ACCURAY INCORPORATED 2007 INCENTIVE AWARD PLAN 2014 MARKET STOCK UNIT GRANT NOTICE Accuray Incorporated, a Delaware corporation (the Company ), pursuant to its 2007 Incentive Award Plan (the Plan ), hereby g
ACCURAY INCORPORATED 2007 INCENTIVE AWARD PLAN 2014 MARKET STOCK UNIT GRANT NOTICE Accuray Incorporated, a Delaware corporation (the Company ), pursuant to its 2007 Incentive Award Plan (the Plan ), hereby grants to the individual listed below ( Participant ), the following Per
Read more →ARAYAccuray to Showcase Clinical Utilization and Adoption of its Latest Advanced Product Platforms at ASTRO 2013
SUNNYVALE, Calif. and ATLANTA, Sept. 22, 2013 /PRNewswire/ -- ASTRO 2013 -- Accuray Incorporated (Nasdaq: ARAY) announced today its momentum in gaining adoption for both the new CyberKnife® M6™ Series and TomoTherapy® H™ Series Systems at the 55th Annual American Society for Radi
Read more →ARAYLynn Pieper Investor Relations +1 (415) 202-5678 Lynn.pieper@westwicke.com Rebecca Phillips Public Relations Manager +1 (408) 716-4773 rphillips@accuray.com Accuray Incorporated CFO Resigns Accuray Appoints Successor
Accuray Incorporated CFO Resigns Accuray Appoints Successor SUNNYVALE, Calif., September 3, 2013 Accuray Incorporated (Nasdaq: ARAY), announced today that Derek Bertocci has resigned as Senior Vice President and Chief Financial Officer of the company effective September 2, 2013
Read more →ARAYAccuray Incorporated CFO Resigns
SUNNYVALE, Calif., Sept. 3, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Derek Bertocci has resigned as Senior Vice President and Chief Financial Officer of the company effective September 2, 2013. Today, Accuray has appointed Gregory Lichtwardt,
Read more →ARAYAccuray Announces Results for Fourth Quarter and Fiscal Year 2013
SUNNYVALE, Calif., Aug. 27, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the fourth quarter and fiscal year ended June 30, 2013. Non-GAAP results are provided to enhance understanding of Accuray's ongoing core results of operation
Read more →ARAYLynn Pieper Investor Relations +1 (415) 202-5678 Lynn.pieper@westwicke.com Rebecca Phillips Public Relations Manager +1 (408) 716-4773 rphillips@accuray.com Accuray Announces Results for Fourth Quarter and Fiscal Year 20
Accuray Announces Results for Fourth Quarter and Fiscal Year 2013 Continued Momentum in New Order Activity and Backlog Provides Guidance for Fiscal 2014 SUNNYVALE, Calif., August 27, 2013 Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the fourth quar
Read more →ARAYAccuray to Host Investor Meeting at ASTRO 2013
SUNNYVALE, Calif., Aug. 26, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced that its management will host an investor meeting on Monday, September 23, 2013 at the annual meeting of the American Society for Radiation Oncology (ASTRO) being held in Atlanta.
Read more →ARAYAccuray to Present at Upcoming Investor Conferences
SUNNYVALE, Calif., Aug. 22, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that its management is scheduled to present at two upcoming investor conferences. Accuray Incorporated management is scheduled to present at the 2013 Goldman Sachs European Medte
Read more →ARAYAccuray will showcase its CyberKnife® and TomoTherapy® Systems at CHINA-HOSPEQ 2013
SUNNYVALE, Calif., Aug. 16, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today its participation in the 22nd China International Medical Instruments and Equipment Exhibition and Seminar (CHINA-HOSPEQ), taking place from Friday, August 16 to Sunday, August 1
Read more →ARAYAccuray to Report Financial Results for Fourth Quarter and Year End Fiscal 2013
SUNNYVALE, Calif., Aug. 7, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced that it will report results for its fourth quarter and fiscal year ended June 30, 2013 on Tuesday, August 27, 2013 after the market closes. A conference call to review the results
Read more →ARAYPremier patient au monde traité avec le nouveau système TomoHDA™ d
- Une radiothérapie de pointe aujourd'hui disponible pour les patients atteints de cancer en France SUNNYVALE, Californie, 25 juin 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY) a annoncé aujourd'hui que le premier patient a été traité avec son nouveau système TomoHDA
Read more →ARAYFirst U.S. Center Treats Patient with the New TomoHDA™ System
SUNNYVALE, Calif., June 25, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that the Tulsa Cancer Institute is the first U.S. center to treat a patient with Accuray's TomoHDA™ System, the latest and most advanced innovation in the TomoTherapy® product li
Read more →ARAYFirst U.S. Center to Treat a Patient with the new CyberKnife® M6™ System
SUNNYVALE, Calif., June 13, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that Lancaster General Health in Pennsylvania is the first U.S. center to treat a patient with the CyberKnife® M6™ System, the most advanced robotic radiosurgery system in the wor
Read more →ARAYWeltweit erste Patientin mit dem neuen TomoHDA™ System von Accuray behandelt
- Modernste Strahlentherapie jetzt für Krebspatienten in Frankreich verfügbar SUNNYVALE, Kalifornien, 6. Juni 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) gab heute bekannt, dass die erste Patientin im Centre Oscar Lambret im französischen Lille mit dem neuen TomoHDA
Read more →ARAYFirst Patient Treated Worldwide with Accuray
SUNNYVALE, Calif., June 5, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the first patient has been treated with its new TomoHDA™ System at Centre Oscar Lambret in Lille, France. Building upon the proven TomoTherapy® Hi-Art® and TomoHD™ technologies, t
Read more →ARAYAccuray is Honored for Delivering
SUNNYVALE, Calif., May 29, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today it has received the NorthFace ScoreBoard AwardSM from Omega Management Group Corp. in recognition of achieving excellence in customer service and support in 2012. Since 2000, the
Read more →ARAYAccuray Incorporated to Present at 2013 Jefferies Global Healthcare Conference
SUNNYVALE, Calif., May 22, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that its management is scheduled to present at the 2013 Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2013 at 1:30 p.m. EDT/10:30 a.m. PDT. A live webca
Read more →ARAYNew Data Validates CyberKnife SBRT for Prostate Cancer Treatment
SUNNYVALE, Calif., May 21, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the publication of study results involving hundreds of prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System, the most widely used form of prostate ste
Read more →ARAYAccuray Announces Results for Third Quarter Fiscal 2013
SUNNYVALE, Calif., May 7, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced financial results for the third quarter of fiscal 2013 that ended March 31, 2013. Non-GAAP results are provided to enhance understanding of Accuray's ongoing core results of operati
Read more →ARAYLynn Pieper Investor Relations +1 (415) 202-5678 Lynn.pieper@westwicke.com Rebecca Phillips Public Relations Manager +1 (408) 716-4773 rphillips@accuray.com Accuray Announces Results for Third Quarter Fiscal 2013 New Ord
Accuray Announces Results for Third Quarter Fiscal 2013 New Order Activity Improves - First Installations of New Models Guidance Updated SUNNYVALE, Calif., May 7, 2013 Accuray Incorporated (Nasdaq: ARAY) today announced financial results for the third quarter of fiscal 2013 tha
Read more →ARAYAccuray Provides Clarification on Recently Initiated Voluntary Recalls
SUNNYVALE, Calif., April 18, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today clarification on two voluntary recalls that the company initiated on March 19, 2013. In keeping with its commitment to patient safety and total quality management, Accuray has v
Read more →ARAYAccuray Incorporated to Report Financial Results for Third Quarter Fiscal 2013
SUNNYVALE, Calif., April 18, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a radiation oncology company, today announced that it will report results for its third quarter of fiscal 2013, ended March 31, 2013 on Tuesday, May 7, 2013 after the market closes. A conferen
Read more →ARAYFirst Patient Treated Worldwide with the new TomoEDGE™ Dynamic Jaws Technology
SUNNYVALE, Calif., April 4, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Heidelberg University Hospital, Germany, has treated the world's first patients with the new TomoEDGE™ Dynamic Jaws technology combined with VoLO™ Planning as part of its To
Read more →ARAYDr. Emad Rizk Joins Accuray Board of Directors
SUNNYVALE, Calif., March 28, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the appointment of Emad Rizk, M.D. to the company's Board of Directors, effective March 15, 2013. Dr. Rizk is a renowned healthcare industry expert who brings more than 25 year
Read more →ARAYFirst Center in Hong Kong Treats Patients with CyberKnife® and TomoTherapy® Systems
SUNNYVALE, Calif., March 11, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Hong Kong Adventist Oncology Center, the first center locally to offer both the CyberKnife® Robotic Radiosurgery and TomoTherapy® Systems, hosted its official opening cerem
Read more →ARAYFirst European Conference on SRS/SBRT and IG-IMRT Held in Milan
SUNNYVALE, California, March 4, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), today announced highlights from the First European Conference on stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) and image-guided intensity-modulated radiation ther
Read more →ARAYAccuray Incorporated to Speak at Cowen and Company 33rd Annual Healthcare Conference
SUNNYVALE, Calif., Feb. 26, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that its management is scheduled to present at the Cowen and Company Annual Healthcare Conference in Boston on Tuesday, March 5, 2013 at 9:20 a.m. EST/6:20 a.m. PST. A live webc
Read more →ARAYAccuray Prices Offering Of $100 Million Of 3.50% Convertible Senior Notes
SUNNYVALE, Calif., Feb. 8, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) ("Accuray") today announced the pricing of its offering of $100 million aggregate principal amount of 3.50% convertible senior notes due 2018 (the "notes"). The notes are being offered and sold to
Read more →ARAYAccuray Company Overview About Accuray Accuray is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping pati
Services cost of revenue included the following adjustments to expenses arising from the acquisition of TomoTherapy; charges due to the write up of service related inventory on hand at the time of the acquisition from cost basis to fair value, charges for property, plant and equi
Read more →ARAYAccuray Announces Results for Second Quarter Fiscal 2013
SUNNYVALE, Calif., Feb. 6, 2013 /PRNewswire/ -- Accuray Incorporated, a radiation oncology company, (Nasdaq: ARAY) today announced financial results for the second quarter of fiscal 2013 that ended December 31, 2012. Non-GAAP results are provided to enhance understanding of Accur
Read more →ARAYAccuray Announces Proposed Offering Of $75 Million Of Convertible Senior Notes
SUNNYVALE, Calif., Feb. 6, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) ("Accuray") today announced its intention to commence an offering, subject to market and other conditions, of $75 million aggregate principal amount of convertible senior notes due 2018 (the "note
Read more →ARAYTom Rathjen Vice President, Investor Relations +1 (408) 789-4458 trathjen@accuray.com Rebecca Phillips Public Relations Manager +1 (408) 716-4773 rphillips@accuray.com Accuray Announces Results for Second Quarter Fiscal
Accuray Announces Results for Second Quarter Fiscal 2013 Decline in Product Revenue Partly Offset by Strong Service Revenue and Profitability SUNNYVALE, Calif., February 6, 2013 Accuray Incorporated, a radiation oncology company, (Nasdaq: ARAY) today announced financial results
Read more →ARAYFirst Patient Treated Worldwide with the new CyberKnife® M6™ System
SUNNYVALE, Calif., Feb. 4, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a radiation oncology company, announced today that the European CyberKnife Center Munich-Grosshadern (ECZM) has treated the world's first patient with the new CyberKnife® M6™ System. With the ins
Read more →ARAYWeltweit erster Patient mit dem neuen CyberKnife® M6™ System behandelt
- Europäisches CyberKnife Zentrum bietet Patienten erweiterte radiochirurgische Behandlungen in München SUNNYVALE, Kalifornien, 4. Februar 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), ein Radiologie-Onkologie-Unternehmen, gab heute bekannt, dass das Europäische Cybe
Read more →ARAYPremière mondiale du traitement d
- L'European CyberKnife Center (centre européen de radiochirurgie robotisée CyberKnife) de Munich propose des traitements de radiochirurgie avancés aux patients SUNNYVALE, Californie, 4 février 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY), une société de radio-oncol
Read more →ARAYAccuray Incorporated to Report Financial Results for Second Quarter Fiscal 2013
SUNNYVALE, Calif., Jan. 17, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its second quarter of fiscal 2013, ended December 31, 2012 on Wednesday, February 6, 2013 after the market
Read more →ARAYAccuray Incorporated to Speak at Needham
SUNNYVALE, Calif., Jan. 8, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Needham Growth Conference in New York on Wednesday, January 16, 2013 at 8:00 a.m. EST/5:
Read more →ARAYTom Rathjen Stephanie Tomei Vice President, Investor Relations Director, Corporate Communications +1 (408) 789-4458 +1 (408) 789-4234 trathjen@accuray.com stomei@accuray.com Accuray Announces Preliminary Results for Seco
Tom Rathjen Stephanie Tomei Vice President, Investor Relations Director, Corporate Communications +1 (408) 789-4458 +1 (408) 789-4234 trathjen@accuray.com stomei@accuray.com Accuray Announces Preliminary Results for Second Quarter Fiscal 2013 and Updated Guidance for Fiscal
Read more →ARAYAccuray Announces Preliminary Results for Second Quarter Fiscal 2013 and Updated Guidance for Fiscal 2013; Announces Restructuring
SUNNYVALE, Calif., Jan. 3, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today preliminary results for the second quarter of fiscal 2013 that ended December 31, 2012 and updated guidance for fiscal 2013. Non-GAAP results are provided to enhance understanding
Read more →ARAYPrimeros pacientes tratados con el sistema de radiocirugía robótica CyberKnife® en Venezuela
SUNNYVALE, California, 17 de diciembre del 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) anunció hoy que los médicos del Hospital Dr. Domingo Luciani de Venezuela están aplicando a los pacientes el sistema de radiocirugía robótica CyberKnife®, primer y único sistema de
Read more →ARAYPrimeiros Pacientes Tratados com o Sistema Robótico de Radio Cirurgia CyberKnife® na Venezuela
SUNNYVALE, Califórnia, 17 de dezembro de 2012 /PRNewswire/ -- A Accuray Incorporated (Nasdaq: ARAY) anunciou hoje que médicos do Hospital Dr. Domingo Luciani da Venezuela estão agora tratando pacientes com o Sistema de Radio Cirurgia Robótica CyberKnife®, o primeiro e único siste
Read more →ARAYFirst Patients Treated with the CyberKnife® Robotic Radiosurgery System in Venezuela
SUNNYVALE, Calif., Dec. 17, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that doctors at Hospital Dr Domingo Luciani in Venezuela are now treating patients with the CyberKnife® Robotic Radiosurgery System, the first and only robotic radiosurgery system
Read more →ARAYAccuray Incorporated to Speak at 23rd Annual Oppenheimer Healthcare Conference
SUNNYVALE, Calif., Dec. 6, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Oppenheimer Healthcare Conference in New York on Thursday, December 13, 2012 at 11:10 a.
Read more →ARAYAccuray Incorporated to Speak at 24th Annual Piper Jaffray Healthcare Conference
SUNNYVALE, Calif., Nov. 20, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2012 at 8:30
Read more →ARAYAccuray Incorporated to Speak at Lazard Capital Markets Healthcare Conference
SUNNYVALE, Calif., Nov. 9, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Lazard Capital Markets Healthcare Conference in New York on Tuesday, November 13, 2012 a
Read more →ARAYPresentations at Leading Radiation Oncology Meeting Demonstrate the Breadth and Depth of Clinical Evidence for Accuray Technologies
SUNNYVALE, Calif., Nov. 8, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that studies presented at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting in Boston, October 28-31, 2012 continue t
Read more →ARAYAccuray Announces Results for First Quarter Fiscal 2013
SUNNYVALE, Calif., Nov. 7, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today financial results for the first quarter of fiscal 2013 that ended September 30, 2012. Non-GAAP results are provided to enhance understandin
Read more →ARAYTom Rathjen Vice President, Investor Relations +1 (408) 789-4458 trathjen@accuray.com Stephanie Tomei Director, Corporate Communications +1 (408) 789-4234 stomei@accuray.com Accuray Announces Results for First Quarter Fi
Accuray Announces Results for First Quarter Fiscal 2013 Transformative Technology Launch at Leading Radiation Oncology Meeting Sets Stage for Future Growth SUNNYVALE, Calif., November 7, 2012 Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announce
Read more →ARAYPresentations at Leading Radiation Oncology Meeting Highlight CyberKnife Prostate Outcomes from Patients at More Than 40 Centers
SUNNYVALE, Calif., Nov. 5, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today clinical findings using non-invasive CyberKnife® stereotactic body radiation therapy (SBRT) for the treatment of prostate cancer. Two studi
Read more →ARAYAccuray Receives FDA 510(k) Clearance for New CyberKnife® M6™ Series, Merging Multileaf Collimation with Non-Isocentric Robotic Delivery
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new CyberKnife® M6™ Series. The CyberKn
Read more →ARAYAccuray Launches New TomoTherapy® H™ Series Featuring TomoEDGE™
SUNNYVALE, Calif. and BOSTON, Oct. 28, 2012 /PRNewswire/ -- ASTRO 2012 -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today launched its new TomoTherapy® H™ Series, featuring the TomoHDA™ System, with faster planning, faster delivery and increased
Read more →ARAYSubstantial Clinical Evidence and Adoption Presented at Accuray
SUNNYVALE, Calif., Oct. 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, showcased new clinical research on its TomoTherapy® System at the 2012 TomoTherapy Asia Pacific Users' Meeting, which was held in conjunction with the Hon
Read more →ARAYAccuray Incorporated to Report Financial Results for First Quarter Fiscal 2013
SUNNYVALE, Calif., Oct. 19, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its first quarter of fiscal 2013, ended September 30, 2012 on Wednesday, November 7, 2012 after the market
Read more →ARAYAccuray to Announce Significant Product News at ASTRO
SUNNYVALE, Calif., Oct. 18, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, will announce significant product news at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting taking place at the Boston Convention Ce
Read more →ARAYACCURAY INCORPORATED 2007 INCENTIVE AWARD PLAN MARKET STOCK UNIT GRANT NOTICE Accuray Incorporated, a Delaware corporation (the Company ), pursuant to its 2007 Incentive Award Plan (the Plan ), hereby grants to the indiv
ACCURAY INCORPORATED 2007 INCENTIVE AWARD PLAN MARKET STOCK UNIT GRANT NOTICE Accuray Incorporated, a Delaware corporation (the Company ), pursuant to its 2007 Incentive Award Plan (the Plan ), hereby grants to the individual listed below ( Participant ), the following Performa
Read more →ARAYInvestor Contact: Tom Rathjen Vice President, Investor Relations +1 (408) 789-4458 trathjen@accuray.com Media Contact : Stephanie Tomei Director, Corporate Communications +1 (408) 789-4234 stomei@accuray.com Ac
Accuray Incorporated CEO Resigns Board Appoints Successor for Next Phase of Growth SUNNYVALE, Calif., October 12, 2012 Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that Euan S. Thomson has resigned as President and Chief Executive
Read more →ARAYAccuray Incorporated CEO Resigns, Board Appoints Successor for Next Phase of Growth
SUNNYVALE, Calif., Oct. 12, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that Euan S. Thomson has resigned as President and Chief Executive Officer and Director of the Board. Accuray's Board has appointed Joshua
Read more →ARAYAccuray Incorporated to Host Investor Meeting at ASTRO 2012
SUNNYVALE, Calif., Oct. 1, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that it will host an investor meeting on Monday, October 29, 2012 at the annual meeting of the American Society for Radiation Oncology (AST
Read more →ARAYTom Rathjen Vice President, Investor Relations +1 (408) 789-4458 trathjen@accuray.com Stephanie Tomei Director, Corporate Communications +1 (408) 789-4234 stomei@accuray.com Accuray Announces Results for Fourth Quarter a
Accuray Announces Results for Fourth Quarter and Fiscal Year 2012 Integration of TomoTherapy on Track; Company Preparing for Major Technology Releases SUNNYVALE, Calif., September 6, 2012 Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced tod
Read more →ARAYAccuray Announces First CyberKnife System in South America
SUNNYVALE, Calif., Aug. 2, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that doctors at Instituto Neurologico de Colombia (INDEC) in Medellin, Colombia are now treating patients using the first and only robotic
Read more →ARAYAccuray anuncia el primer Sistema CyberKnife en Sudamérica
SUNNYVALE, California, 2 de agosto del 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), la compañía líder en radiación oncológica, anunció hoy que los médicos del Instituto Neurológico de Colombia (INDEC) de Medellín, Colombia, están tratando ahora a los pacientes utiliz
Read more →ARAYAccuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2012
SUNNYVALE, Calif., July 31, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its fourth quarter and fiscal year 2012, ended June 30, 2012 on Thursday, September 6, 2012 after the mark
Read more →ARAYClinical Research on Accuray
SUNNYVALE, Calif., July 29, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that more than 70 studies on the clinical use of the CyberKnife Robotic Radiosurgery® System and the TomoTherapy® System will be presented
Read more →ARAYAccuray to Acquire Morphormics, Inc.
SUNNYVALE, Calif., July 16, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that they have signed a definitive agreement to acquire Morphormics, Inc., a privately held company founded by University of North Carolin
Read more →ARAYAccuray Announces Installation of TomoTherapy® System at University of California, San Francisco
SUNNYVALE, Calif., June 27, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that doctors at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center in San Francisco, Calif
Read more →ARAYAccuray and Erasmus Medical Center Sign Master Research and Collaboration Agreement
SUNNYVALE, Calif., June 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with Erasmus Medical Center (MC), a leading research center in Rot
Read more →ARAYOne Year After TomoTherapy Acquisition, Accuray on Track to Meet or Exceed Integration Success Metrics And Expecting Near-term Return to Profitability
SUNNYVALE, Calif., June 21, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the company's successes since its acquisition of TomoTherapy Incorporated one year ago and its vision for growth and profitability in the
Read more →ARAYAccuray Rolls Out Comprehensive Customer Service Program in Japan
SUNNYVALE, Calif., June 20, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the extension of its industry-leading Emerald Service Program for the TomoTherapy® System, which provides equipment protection and product
Read more →ARAYAccuray Incorporated to Speak at Wells Fargo Healthcare Conference
SUNNYVALE, Calif., June 13, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Wells Fargo Healthcare Conference in Boston on Wednesday June 20, 2012 at 9:00 a.m. EDT
Read more →ARAYCyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
SUNNYVALE, Calif., June 7, 2012 /PRNewswire/-- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that outcome data on intermediate risk prostate cancer patients treated with CyberKnife® Prostate SBRT was presented at the American Urologi
Read more →ARAYAccuray Incorporated to Speak at Jefferies Global Healthcare Conference
SUNNYVALE, Calif., May 30, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Jefferies Global Healthcare Conference in New York on Thursday, June 7, 2012 at 11:30 a.
Read more →ARAYAccuray und das Deutsche Krebsforschungszentrum unterschreiben eine Forschungs-und Kooperationsvereinbarung
- Die jüngste Zusammenarbeit mit führenden Forschungseinrichtungen setzt die Partnerschaft in der Entwicklung neuer Technologien fort SUNNYVALE, California, 23. Mai, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), das wichtigste Radioonkolgie-Unternehmen gab heute die
Read more →ARAYAccuray et le Centre allemand de recherche sur le cancer ont signé un accord cadre de recherche et collaboration
- La toute récente collaboration avec un organisme de recherche de pointe perpétue le partenariat dans le domaine du développement des nouvelles technologies SUNNYVALE, Californie, 22 mai 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY), la société leader en matière de
Read more →ARAYAccuray y el German Cancer Research Center firman un acuerdo maestro de investigación y colaboración
- La última colaboración con la principal institución de investigación continúa con su asociación en el desarrollo de nuevas tecnologías SUNNYVALE, California, 22 de mayo de 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), la principal compañía de oncología de radiación
Read more →ARAYAccuray and the German Cancer Research Center Sign Master Research and Collaboration Agreement
SUNNYVALE, Calif., May 22, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with the German Cancer Research Center (Deutsches Krebsforschungsze
Read more →ARAYRebecca Phillips Helen Shik Public Relations Manager, Accuray Schwartz MSL +1 (408) 716-4773 +1 (781) 684-0770 rphillips@accuray.com Accuray@schwartzmsl.com Accuray Appoints Richard Pettingill, LFACHE to Board
Contacts: Rebecca Phillips Helen Shik Public Relations Manager, Accuray Schwartz MSL +1 (408) 716-4773 +1 (781) 684-0770 rphillips@accuray.com Accuray@schwartzmsl.com Accuray Appoints Richard Pettingill, LFACHE to Board of Directors SUNNYVALE, Calif., May 17, 2012 Accuray In
Read more →ARAYAccuray Appoints Richard Pettingill, LFACHE to Board of Directors
SUNNYVALE, Calif., May 17, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the appointment of Richard Pettingill, LFACHE as a member of the company's Board of Directors effective May 11, 2012. Richard Pettingill's
Read more →ARAYAccuray dévoile un système de planification amélioré du traitement TomoTherapy, à l
- La nouvelle technologie VoLO™ offre une plus grande efficacité et flexibilité lors de la planification du traitement complexe ; démontre l'engagement continu d'Accuray de réaliser des progrès en matière de radio-oncologie. SUNNYVALE, Californie, 10 mai 2012 /PRNewswire/ -- Acc
Read more →ARAYAccuray presenta el sistema de planificación de tratamiento TomoTherapy mejorado en ESTRO 31
- La nueva tecnología VoLO™ ofrece una mayor eficiencia y flexibilidad en la planificación de tratamientos complejos; demuestra el compromiso actual de Accuray de avanzar la oncología de radiación SUNNYVALE, California, 9 de mayo de 2012 /PRNewswire/ -- Accuray Incorporated (Nas
Read more →ARAYAccuray stellt erweitertes TomoTherapy-System zur Behandlungsplanung auf der ESTRO 31 vor
- Neue VoLO™-Technologie bietet größere Effizienz und Flexibilität bei komplexer Behandlungsplanung; Beleg für Accurays gezieltes Engagement für Fortschritte im Bereich der Radioonkologie SUNNYVALE, Kalifornien, 9. Mai 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), da
Read more →ARAYAccuray Unveils Enhanced TomoTherapy Treatment Planning System at ESTRO 31
SUNNYVALE, Calif., May 9, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the availability of VoLO™ Technology for the TomoTherapy® System, a new treatment planning system that leverages advanced graphics processin
Read more →ARAYTom Rathjen Stephanie Tomei Vice President, Investor Relations Director, Corporate Communications +1 (408) 789-4458 +1 (408) 789-4234 trathjen@accuray.com stomei@accuray.com Accuray Announces Results for Third Quarter Fi
Tom Rathjen Stephanie Tomei Vice President, Investor Relations Director, Corporate Communications +1 (408) 789-4458 +1 (408) 789-4234 trathjen@accuray.com stomei@accuray.com Accuray Announces Results for Third Quarter Fiscal 2012 Continued Service Margin Improvement Highlig
Read more →ARAYAccuray Announces Results for Third Quarter Fiscal 2012
SUNNYVALE, Calif., May 8, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today financial results for the third quarter of fiscal 2012 that ended March 31, 2012. The fiscal 2012 financial data presented below reflects Ac
Read more →ARAYAccuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
SUNNYVALE, Calif., April 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the launch of the Prostate Advances in Comparative Evidence (PACE) Study, an international, multi-center, randomized study to compare Cyb
Read more →ARAYAccuray lisää potilaiden hoitovaihtoehtoja Suomessa
SUNNYVALE, Kalifornia, April 2, 2012 /PRNewswire/ -- - CyberKnife-sädeleikkaus on tehokas, kajoamaton ja vaivaton hoitovaihto potilaille Johtava säteilyonkologian alan yhtiö Accuray Incorporated (Nasdaq: ARAY) ilmoitti tänään, että Kuopion yliopistollinen sairaala on alkanut ho
Read more →ARAYAccuray Signs Master Research and Collaboration Agreement With University of Heidelberg
SUNNYVALE, Calif., March 30, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research institutio
Read more →ARAYAccuray Rolls Out PlanTouch for the CyberKnife System
SUNNYVALE, Calif., March 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the release of PlanTouch™, the first commercially available, fully integrated software application in radiation oncology that allows phys
Read more →ARAYAccuray Receives Microsoft Dynamics® Customer Excellence Award
SUNNYVALE, Calif., March 19, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that it has been awarded the 2012 Industry Excellence Award by Microsoft® as part of the Microsoft Dynamics Customer Excellence Awards pr
Read more →ARAYAccuray Recognized for Delivering
SUNNYVALE, Calif., Feb. 29, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that it has received the NorthFace ScoreBoard Award(SM) (NFSB Award) from Omega Management Group Corp. (Omega) in recognition of achieving
Read more →ARAYAccuray Incorporated to Speak at Citi 2012 Global Health Care Conference
SUNNYVALE, Calif., Feb. 15, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Citi 2012 Global Health Care Conference in New York City on Tuesday, February 28, 2012
Read more →ARAYFinal Contacts: Tom Rathjen Stephanie Tomei Vice President, Investor Relations Director, Corporate Communications +1 (408) 789-4458 +1 (408) 789-4234 trathjen@accuray.com stomei@accuray.com Accuray Announces Results for
Contacts: Tom Rathjen Stephanie Tomei Vice President, Investor Relations Director, Corporate Communications +1 (408) 789-4458 +1 (408) 789-4234 trathjen@accuray.com stomei@accuray.com Accuray Announces Results for Second Quarter Fiscal 2012 Achieves Solid Revenue, Positive S
Read more →ARAYAccuray Announces Results for Second Quarter Fiscal 2012
SUNNYVALE, Calif., Feb. 8, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today financial results for the second quarter of fiscal 2012 that ended December 31, 2011. The fiscal 2012 financial data presented below reflec
Read more →ARAYStudy Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors
SUNNYVALE, Calif., Jan. 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today publication of a study demonstrating the benefits of the CyberKnife® Robotic Radiosurgery System in treating central lung tumors. Historic
Read more →ARAYAccuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2012
SUNNYVALE, Calif., Jan. 18, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its second quarter of fiscal year 2012, ended December 31, 2011 on Wednesday, February 8, 2012 after the m
Read more →ARAYPrimer Sistema de Radiocirugía Robótica CyberKnife se implementa en México
SUNNYVALE, California, 17 de enero del 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), compañía líder en radiación oncológica, anunció hoy que CHRISTUS MUGUERZA Hospital Alta Especialidad en Monterrey, México ha comenzado a tratar a los pacientes con el Sistema de Radio
Read more →ARAYFirst CyberKnife Robotic Radiosurgery System Goes Live in Mexico
SUNNYVALE, Calif., Jan. 17, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that CHRISTUS MUGUERZA Hospital Alta Especialidad in Monterrey, Mexico has starting treating patients with the CyberKnife® Robotic Radiosu
Read more →ARAYAccuray Surpasses 600 Installations Globally
SUNNYVALE, Calif., Jan. 10, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today significant momentum in global adoption of its CyberKnife® Robotic Radiosurgery System and TomoTherapy® System, solidifying the company's
Read more →ARAYStudy Highlights CyberKnife Stereotactic Body Radiotherapy (SBRT): Noninvasive Brachytherapy-like Treatment for Prostate Cancer
SUNNYVALE, Calif., Jan. 9, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced publication of a study describing the clinical outcomes of prostate cancer patients treated with stereotactic body radiotherapy (SBRT) usin
Read more →ARAYAccuray Incorporated to Speak at 14th Annual Needham Growth Conference
SUNNYVALE, Calif., Jan. 5, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Needham Growth Conference in New York City on Thursday, January 12, 2012 at 8:40 a.m. ES
Read more →ARAYMedical Centers Worldwide Adopt Both Accuray
SUNNYVALE, Calif., Dec. 19, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that 23 leading medical centers globally have installed both a CyberKnife® Robotic Radiosurgery System and a TomoTherapy® System enabling
Read more →ARAYAccuray Incorporated to Speak at 22nd Annual Oppenheimer Healthcare Conference
SUNNYVALE, Calif., Dec. 5, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Oppenheimer Healthcare Conference in New York City on Tuesday, December 13, 2011 at 1:00
Read more →ARAYACCURAY INCORPORATED 2007 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT GRANT NOTICE The Participant must notify the Company by [insert date] if he or she wishes to reject this PSU award. Otherwise, the Participant will be
ACCURAY INCORPORATED 2007 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT GRANT NOTICE The Participant must notify the Company by [insert date] if he or she wishes to reject this PSU award. Otherwise, the Participant will be deemed to have accepted the award on the terms and condit
Read more →ARAYAccuray Incorporated to Speak at 23rd Annual Piper Jaffray Healthcare Conference
SUNNYVALE, Calif., Nov. 22, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the 23rd Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 30,
Read more →ARAYAccuray Announces Results for First Quarter Fiscal 2012
SUNNYVALE, Calif., Nov. 8, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today financial results for the first quarter of fiscal 2012 that ended September 30, 2011. On June 10, 2011, Accuray completed the acquisition o
Read more →ARAYAccuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode
SUNNYVALE, Calif., Oct. 26, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today significant momentum in global adoption of its TomoDirect treatment modality. More than 100 systems are now in use at leading cancer cente
Read more →ARAYAccuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System
SUNNYVALE, Calif., Oct. 25, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market the Dose Control System (DCS), a new f
Read more →ARAYAccuray Incorporated to Report Financial Results for First Quarter of Fiscal 2012
SUNNYVALE, Calif., Oct. 24, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its first quarter of fiscal year 2012, ended September 30, 2011 on Tuesday, November 8, 2011 after the mar
Read more →ARAYAccuray Ranked 274th Fastest Growing Company in North America on Deloitte
SUNNYVALE, Calif., Oct. 19, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that it ranked 274th on Deloitte's Technology Fast 500™ ranking of the 500 fastest growing technology, media, telecommunications, life sci
Read more →ARAYAccuray Unveils CyberKnife and TomoTherapy Product Enhancements and Service Offerings at ASTRO 2011
MIAMI and SUNNYVALE, Calif., Oct. 3, 2011 /PRNewswire/ -- American Society for Radiation Oncology (ASTRO) 53rd Annual Meeting --Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that the company is unveiling several enhancements to its C
Read more →ARAYAccuray Incorporated to Speak at JMP Securities Healthcare Conference
SUNNYVALE, Calif., Sept. 26, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the JMP Securities Healthcare Conference in New York on Wednesday, September 28, 2011 at 9
Read more →ARAY2011 International Conference on TomoTherapy (ICT) Highlights Widespread Acceptance of the Benefits of Daily Image-Guided IMRT
SUNNYVALE, Calif., Sept. 23, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced details of the 2011 International Conference on TomoTherapy (ICT), which took place September 16-17, 2011 hosted by the University of Hei
Read more →ARAYAccuray Hires Chief Commercial Officer
SUNNYVALE, Calif., Sept. 21, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that Kelly Londy has joined Accuray as Senior Vice President and Chief Commercial Officer, effective October 1, 2011. Londy has spent he
Read more →ARAYAccuray Announces Results for Fourth Quarter and Fiscal Year 2011
SUNNYVALE, Calif., Sept. 19, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today financial results for the fourth quarter and fiscal year ended June 30, 2011. It should be noted that the acquisition of TomoTherapy was
Read more →ARAYAccuray Incorporated to Speak at UBS Global Life Sciences Conference
SUNNYVALE, Calif., Sept. 16, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 2011 at 4:30
Read more →ARAYAccuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2011
SUNNYVALE, Calif., Sept. 13, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), today announced that it will report results for its fourth quarter and fiscal year 2011, ended June 30, 2011 on Monday, September 19, 2011 after the market closes. The Company filed with the U
Read more →ARAYGrowing Clinical Evidence the Focus of Accuray
SUNNYVALE, Calif., Sept. 9, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, showcased new clinical research on its TomoTherapy® Radiation Therapy System at the 2011 Asia User Education Symposium, held September 2-4, 2011, in Singa
Read more →ARAYAccuray Extends Industry-Leading Customer Service Program to TomoTherapy Systems
SUNNYVALE, Calif., Sept. 6, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the extension of its Emerald Service Program to the TomoTherapy® Radiation Therapy System, building on the company's legacy as an industry
Read more →ARAYAccuray Launches New Organization for CyberKnife® and TomoTherapy® System Users
SUNNYVALE, Calif., Aug. 31, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the launch of Accuray Exchange in Radiation Oncology (AERO), a global organization for CyberKnife® Robotic Radiosurgery System and TomoThe
Read more →ARAYAccuray Drives Growth in Radiosurgery for Early-Stage Prostate Cancer
SUNNYVALE, Calif., Aug. 30, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today a significant increase in use of the CyberKnife® Robotic Radiosurgery System for prostate SBRT (stereotactic body radiotherapy). In Q4 201
Read more →ARAYBeth Israel Deaconess Medical Center Treats 2,000th Patient with the CyberKnife System
SUNNYVALE, Calif., Aug. 16, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that the Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard Medical School and a leader in pioneering innovative
Read more →ARAYAccuray Incorporated to Speak at 2011 Wedbush Life Sciences: Management Access Conference
SUNNYVALE, Calif., Aug. 9, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Wedbush Life Sciences: Management Access Conference in New York on Wednesday, August 17,
Read more →ARAYAccuray Prices Offering of $100 Million 3.75% Convertible Senior Notes
SUNNYVALE, Calif., July 27, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) ("Accuray") today announced the pricing of its offering of $100 million aggregate principal amount of 3.75% convertible senior notes due 2016 (the "notes"). The size of the offering was upsized f
Read more →ARAYAccuray Announces Proposed Offering of $75 Million Convertible Senior Notes
SUNNYVALE, Calif., July 26, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) ("Accuray") today announced its intention to commence an offering, subject to market and other conditions, of $75 million aggregate principal amount of convertible senior notes due 2016 (the "not
Read more →ARAYFive Leading Academic Hospitals Install the CyberKnife System for Dedicated Radiosurgery
SUNNYVALE, Calif., July 25, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today installation of the CyberKnife® Robotic Radiosurgery System at five renowned academic oncology centers in Europe and the United States, in
Read more →ARAYAccuray Hosts Symposium on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting
SUNNYVALE, Calif., July 20, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, will host a symposium examining best practices for quality assurance in radiation oncology at the 2011 Joint American Association of Physicists in Medicin
Read more →ARAYAccuray's CyberKnife and TomoTherapy Systems Highlighted at World Conference on Lung Cancer Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced new clinical data highlighting the ability of its CyberKnife®...
SUNNYVALE, Calif., July 7, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced new clinical data highlighting the ability of its CyberKnife® Robotic Radiosurgery System and its TomoTherapy® Radiation Therapy System to treat
Read more →ARAYAccuray Hosts Korean Embassy
SUNNYVALE, Calif., June 24, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiation oncology, today hosted a roundtable discussion on the U.S.-Korea Free Trade Agreement (KORUS FTA), which is currently pending Congressional ratification
Read more →ARAYAccuray Incorporated to Speak at Wells Fargo 2011 Healthcare Conference
SUNNYVALE, Calif., June 16, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, offering best-in-class technologies to fight cancer, announced today that its management is scheduled to present at the Wells Fargo 2011 Healthcare Confer
Read more →ARAYAccuray Successfully Completes Acquisition of TomoTherapy
SUNNYVALE, Calif., June 13, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that it has completed its previously announced acquisition of TomoTherapy Incorporated (Nasdaq: TOMO). The combination creates the premier radiation oncology company, offering bes
Read more →ARAYTomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy
SUNNYVALE, Calif., June 9, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that TomoTherapy shareholders have approved the proposed acquisition of TomoTherapy Incorporated (Nasdaq: TOMO) by Accuray. More tha
Read more →ARAYEl 85% de los centros CyberKnife(R) en Europa realiza tratamientos de radioterapia estereotáxica de próstata (SBRT)
SUNNYVALE, California, May 17, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), líder mundial dentro del campo de la radiocirugía, ha anunciado hoy que el 85% de los centros de Europa con CyberKnife(R) realizan SBRT para tratar los tipos de cáncer de próstata localizados
Read more →ARAYAccuray Showcases CyberKnife Robotic Radiosurgery System at American Urological Association Meeting
SUNNYVALE, Calif. and WASHINGTON, May 16, 2011 /PRNewswire/ -- The American Urological Association (AUA) Meeting, May 16, 2011 -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that it will showcase the CyberKnife® Robotic Radio
Read more →ARAYProzent der CyberKnife(R)-Zentren in Europa führen Körperstereotaxie (SBRT) der Prostata durch
SUNNYVALE, Kalifornien, May 13, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), ein weltweit führender Anbieter auf dem Gebiet der Radiochirurgie, gab heute bekannt, dass 85 Prozent der europäischen CyberKnife(R)-Zentren eine Körperstereotaxie (Stereotactic Body Radiati
Read more →ARAYQuatre-vingt-cinq pourcent des sites européens utilisant le CyberKnife(R) traitent des cancers de la prostate par radiothérapie en conditions stéréotaxiques (SBRT)
SUNNYVALE, Californie, May 12, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), leader mondial dans le domaine de la radiochirurgie, a annoncé aujourd'hui que 85 % des centres européens équipés avec le CyberKnife(R) traitent des cancers localisés de la prostate par radio
Read more →ARAYPercent of CyberKnife® Sites Within Europe Performing Prostate Stereotactic Body Radiation Therapy (SBRT)
SUNNYVALE, Calif., May 11, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that 85 percent of European CyberKnife® centers are performing prostate SBRT to treat localized prostate cancer. There is an increasi
Read more →ARAYSEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy
SUNNYVALE, Calif., May 9, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the U.S. Securities and Exchange Commission has declared effective the company's Form S-4 Registration Statement relating to the
Read more →ARAYAccuray Announces Results for Third Quarter of Fiscal 2011
SUNNYVALE, Calif., May 5, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today financial results for the third quarter of fiscal year 2011, ended March 31, 2011. For the third quarter of fiscal 2011, Accuray repo
Read more →ARAYAccuray Incorporated Announces HSR Clearance in Acquisition of TomoTherapy
SUNNYVALE, Calif., April 26, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced the expiration of the mandatory, pre-merger waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, in
Read more →ARAYAccuray Incorporated to Report Financial Results for Third Quarter of Fiscal 2011
SUNNYVALE, Calif., April 14, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that it will report results for its third quarter of fiscal 2011, ended March 31, 2011 on Thursday, May 5, 2011 after the market cl
Read more →ARAYAccuray Incorporated to Speak at 10th Annual Needham Healthcare Conference
SUNNYVALE, Calif., March 28, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its management is scheduled to present at the 10th Annual Needham Healthcare Conference in New York City on Tuesday, April 5,
Read more →ARAYAccuray's General Counsel Wins Best Bay Area Corporate Counsel Award Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its Senior Vice President, General Counsel...
SUNNYVALE, Calif., Feb. 25, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its Senior Vice President, General Counsel and Corporate Secretary, Darren Milliken, was named "Best General Counsel, Small Pub
Read more →ARAYCyberKnife® Robotic Radiosurgery Summit Provides Forum for Clinicians to Share Knowledge and Experience
SUNNYVALE, Calif., Feb. 14, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today the completion of the annual CyberKnife Scientific Meeting held February 10-12, 2011, in San Francisco, Calif. The global event host
Read more →ARAYAccuray Incorporated to Speak at 2011 Citi Global Healthcare Conference
SUNNYVALE, Calif., Feb. 9, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its management is scheduled to present at the 2011 Citi Global Healthcare Conference in New York City on Tuesday, March 1, 2011
Read more →ARAYCyberKnife Radiosurgery to be Highlighted by Leading Thoracic Surgeons at 2011 STS Annual Meeting
SUNNYVALE, Calif., and SAN DIEGO, Jan. 31, 2011 /PRNewswire/ -- The Society of Thoracic Surgeons (STS) Annual Meeting – Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its CyberKnife technology will be featured at the Societ
Read more →ARAYAccuray Announces Results for Second Quarter of Fiscal 2011
SUNNYVALE, Calif., Jan. 27, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today financial results for the second quarter of fiscal year 2011, ended December 31, 2010. For the second quarter of fiscal 2011, Accur
Read more →ARAYAccuray Hires Chief Marketing Officer
SUNNYVALE, Calif., Jan. 18, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Eric Pauwels has joined Accuray as Senior Vice President and Chief Marketing Officer, effective January 17, 2011. Pauwels is a
Read more →ARAYAccuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011
SUNNYVALE, Calif., Jan. 14, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that it will report results for its second quarter of fiscal 2011, ended December 31, 2010 on Thursday, January 27, 2011 after the m
Read more →ARAYFirst Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer
SUNNYVALE, Calif., Jan. 11, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today the first published five-year outcomes on low risk prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System
Read more →ARAYAccuray Elevated to NASDAQ Global Select Market
SUNNYVALE, Calif., Jan. 3, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that it has been named to the NASDAQ Global Select Market, the premier listing tier for NASDAQ companies. The NASDAQ Global Select Ma
Read more →ARAYAccuray Establishes Medical Affairs Function
SUNNYVALE, Calif., Dec. 17, 2010 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company has established a Medical Affairs function to accelerate CyberKnife data collection, utilization and referral patte
Read more →ARAYAccuray Receives FDA Clearance for the CyberKnife® System
SUNNYVALE, Calif., Dec. 15, 2010 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market Lung Optimized Treatme
Read more →ARAYAccuray's CyberKnife VSI System Named Best New Radiology Device Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company's CyberKnife® VSI™ System...
SUNNYVALE, Calif., Nov. 29, 2010 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company's CyberKnife® VSI™ System received the 2010 Minnie for Best New Radiology Device from AuntMinnie.com, the largest a
Read more →ARAYAccuray Incorporated to Speak at Seventh Annual Lazard Capital Markets
SUNNYVALE, Calif., Nov. 10, 2010 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its management is scheduled to present at the Lazard Capital Markets' Healthcare Conference in New York City on Wednesday, Nove
Read more →ARAYAccuray Announces Results for First Quarter of Fiscal 2011
SUNNYVALE, Calif., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today financial results for the first quarter of fiscal year 2011, ended September 30, 2010. For the first quarter of fiscal 201
Read more →ARAYInstallation of a Second CyberKnife® Robotic Radiosurgery System in Vicenza Hospital
SUNNYVALE, Calif., Nov. 1, 2010 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Vicenza Hospital, Ospedale Civile San Bortolo in Italy, has become the first European hospital to be equipped with two CyberKnif
Read more →ARAYCyberKnife Radiosurgery for Early-Stage Breast Cancer
SUNNYVALE, Calif., Oct. 31 /PRNewswire/ -- Accuray Incorporated, (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today studies underway at two leading academic institutions using CyberKnife radiosurgery in breast cancer treatment. These two studies, from t
Read more →ARAYAccuray Announces Expanded Service Program
SUNNYVALE, Calif., Oct. 29 /PRNewswire/ -- Accuray Incorporated, a global leader in the field of radiosurgery, announced today expansion of its Diamond service program to address the unique technical, business and operational needs of its customers. The Diamond service program ha
Read more →ARAYCyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times
SUNNYVALE, Calif., Oct. 29 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today feedback from Creekside Cancer Care on their use of the CyberKnife VSI System. Creekside Cancer Care was the first facility in the world t
Read more →ARAYAccuray's CyberKnife VSI System Featured at 2010 American Society for Radiation Oncology (ASTRO) Annual Meeting Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that 40 accepted abstracts highlighting the use of ...
SUNNYVALE, Calif., Oct. 29 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that 40 accepted abstracts highlighting the use of the CyberKnife Robotic Radiosurgery System will be presented as posters and presentatio
Read more →ARAYAccuray Hires General Manager for the Asia Pacific Region
SUNNYVALE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Bob Wong has returned to Accuray as General Manager of the APAC (Asia Pacific, including Australia but excluding India and
Read more →ARAYEighth CyberKnife System in South Korea Installed and Treating Patients
SUNNYVALE, Calif., Oct. 27 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that the Korea Cancer Care Hospital (KCCH) in Seoul, South Korea has installed its second CyberKnife® Robotic Radiosurgery System, marking
Read more →ARAYAccuray Incorporated to Speak at Oppenheimer
SUNNYVALE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its management is scheduled to present at the Oppenheimer Healthcare Conference in New York City on Wednesday, November 3,
Read more →ARAYAccuray Incorporated to Report Financial Results for First Quarter of Fiscal 2011
SUNNYVALE, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that it will report results for its first quarter of fiscal 2011, ending September 30, 2010 on Monday, November 8, 2010 after th
Read more →ARAYAccuray Ranked Number 113 Fastest Growing Company in North America on Deloitte
SUNNYVALE, Calif., Oct. 20 /PRNewswire/ -- Accuray, Inc., (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that it ranked number 113 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life
Read more →ARAYFirst CyberKnife® System in Clinical Use in Czech Republic
SUNNYVALE, Calif., Oct. 14 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that the first CyberKnife Robotic Radiosurgery System in Czech Republic is now treating cancer patients at the University Hospital of Ostr
Read more →ARAYAccuray Incorporated to Host Analyst Meeting at ASTRO 2010
SUNNYVALE, Calif., Oct. 13 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, will host an Analyst Meeting in San Diego, Calif., on Monday, November 1, 2010 at 3:30 p.m. PT/ 6:30 p.m. ET. This meeting coincides with the 52nd Annual
Read more →ARAY100,000th Patient Treated With Accuray
SUNNYVALE, Calif., Oct. 6 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the 100,000th patient has been treated with the CyberKnife® Robotic Radiosurgery System, a non-invasive alternative to surgery for the
Read more →ARAYAccuray Awarded $1 Million Grant by U.S. Government
SUNNYVALE, Calif., Oct. 5 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company was awarded a $1 million Small Business Innovation Research (SBIR) grant by the U.S. Government to be used toward further
Read more →ARAYBenefits of CyberKnife® Lung Radiosurgery Treatments Emphasized During Europe
SUNNYVALE, Calif., Sept. 17 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that for the first time in Europe the company showcased its latest offering, the CyberKnife VSI System, at ESTRO 29; the Annual Congress
Read more →ARAYLe Système CyberKnife VSI, la dernière génération du Système CyberKnife, a été le premier à être installé en Europe dans un centre de cancérologie
SUNNYVALE, Californie, September 2, 2010 /PRNewswire/ -- - Le Centre Léon-Bérard à Lyon, France, offre désormais à ses patients atteints du cancer les avantages d'une radiochirurgie partout dans le corps Accuray Incorporated (Nasdaq : ARAY), leader mondial dans le domaine de la
Read more →ARAYCancer Center to be the First in Europe to Install a CyberKnife VSI System, the Latest Generation of the CyberKnife System
SUNNYVALE, Calif., Sept. 1 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that the first CyberKnife VSI System to be installed in Europe was placed at the Leon-Berard Cancer Multidisciplinary Center (CLB) in Lyon
Read more →ARAYAccuray Announces Results for Fourth Quarter and Fiscal Year 2010
SUNNYVALE, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today financial results for the fourth quarter and fiscal year 2010, ended June 30, 2010. For the fourth quarter of fiscal 2010, Accu
Read more →ARAYPresentaciones de la tercera terapia europea de radiación estereotáctica y de los talleres de radioterapia corporal completa
SUNNYVALE, California, July 6, 2010 /PRNewswire/ -- - Las presentaciones de la tercera terapia europea de radiación estereotáctica y de los talleres de radioterapia corporal completa destacan los resultados clínicos y las tendencias emergentes - Los resultados presentados en el
Read more →Competitive Position
How ARAY ranks across every disease it competes inCompetitive Position is a premium feature
See how ARAY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial